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Abstract
The devastation caused by HIV is driving the development of new point-of-care diagnostics.
The work presented in this thesis aims to help develop a new generation of smartphone-
connected HIV tests designed to address the very high levels of undiagnosed HIV-infected
individuals, by widening access to HIV testing to doctors surgeries, pharmacies and de-
veloping countries. The biosensor is based on mass manufacturable surface acoustic wave
(SAW) devices, and uses piezoelectricity to transduce the binding of biomarkers on the
surface of the device into a measurable electric signal, making the test low cost, easy to
use and reliable. In addition, the SAW biosensor presented here has the ability to wire-
lessly and securely transmit results to healthcare providers to potentially offer follow-up
appointments at local clinics, or virtually. This thesis begins with the theory behind SAW
biosensors. A more focussed characterisation of the specific device developed is then presen-
ted, followed by the details of the work done to optimise the biosensor in order to make it
a good candidate for a point-of-care test for HIV. Key results include the proof of concept
detection of different biomarkers of HIV infection, as well as a demonstration of the ability
of the SAW biosensor to deliver a fast response. Different pilot studies are then presen-
ted, demonstrating the performance of the device as a diagnostic test, highlighting 100%
sensitivity and 100% specificity. These were conducted with more than 30 confirmed HIV
positive patient samples and more than 100 healthy volunteers. The following chapter then
examines the fundamental mechanisms underpinning the SAW biosensor output and an
empirical method to ultimately design more sensitive devices in future antigen detection.
This thesis concludes with a summary of the main results and future work, including the
potential for larger clinical studies, and field trials in developing countries.
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Chapter 1
Introduction
Since it was first identified in 1981, one of the most important challenges to public health has
been the human immunodeficiency virus (HIV) and acquired immune deficiency syndrome
(AIDS) pandemic. In 30 years, more than 60 million people have been infected, causing
nearly 30 million deaths. [1] A significant minority of HIV infected persons (about a quarter
in the UK [2]) are unaware of their infection. These people are not only at risk for their
own health - people diagnosed at a late stage have a tenfold increased risk of dying within
a year of diagnosis [2]- but it also represents a risk for society, as a person unaware of their
infection is more likely to transmit it. [3] These alarming statistics, and more generally the
devastation caused by HIV, are driving the development of new diagnostics, which are an
effective path to both treatment and prevention. In addition, the potential for significant
savings associated with widening access to HIV testing outside of hospital settings [4] has
led to notable policy drivers to support HIV testing in hospital emergency services, doctors
surgeries, community outreach centres [5] and most recently, the legalisation of HIV self-
testing at home in the UK. [6]
This thesis aims at describing a prototype of a biosensor for HIV infection based on sur-
face acoustic wave (SAW) devices. The prototype is designed to work with a smartphone,
providing the test with the connectivity needed to analyse, record and send test data se-
curely to health care providers. The principle is first discussed from a theoretical point of
view. A characterisation of the SAW biosensor is then presented, along with a description
of proof-of-concept studies to illustrate the biosensor’s ability to detect key biomarkers of
23
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HIV infection. The results of a series of clinical pilot studies are then discussed, highlight-
ing the capacity for the test to deliver results under 5 minutes with high sensitivity and
specificity. A method used to characterise the biosensor’s response and help optimise its
design parameters is then presented.
1.1 HIV diagnostic needs
Different methods can be used to diagnose a patient with HIV, the gold standard tests being
based on enzyme linked immunosorbent assays (ELISA) and polymerase chain reaction
(PCR). Significant advances have been made recently in the field of bacterial and viral
nucleic acid sequencing applied to diagnostics. Analysis of the genome leads to an accurate
identification of the infection, and provides a crucial tool to prescribe the most effective
drugs against a particular strain, as well as revealing a possible resistance to a particular
drug. This can be achieved in approximately a week, and avoids lengthy periods of trial
and failure in the process of drug prescription. Sequencing is already routinely used to help
prescribe the best drugs to HIV patients. [7]
However, these diagnostic techniques are confined to centralised laboratories which require
large, sophisticated and costly instrumentation, as well as highly trained staff. Patients
have to experience unavoidable delays between sample collection, sample delivery to the dia-
gnostic laboratory and receiving results before follow-up appointments. [8–10] These delays
in correct diagnosis of the infection, and the fact patients have to visit their clinic multiple
times before receiving treatment, also contribute to increasing the risk that the patient
does not return.
Access to testing has recently been improved through policies aimed at widening the usage
of point of care tests (PoCT), which are affordable, simple tests designed to reduce testing
time down to a few minutes. This followed several cost effectiveness studies related to
the implementation of PoCT on a large scale. As an example, the National Institute
for Health and Clinical Excellence (NICE) estimate that despite the high costs involved
in implementing a program to increase the uptake of HIV testing among black Africans
and men who have sex with men in England (around £15.8 million), the balanced savings
generated by reducing treatment costs would increase annually. [11,12] In addition, modelling
suggests that in the UK, changes in clinical practice towards achieving earlier diagnosis of
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HIV would lead to significant savings: a discounted cost per life-year gain of £11,146 and
a discounted cost per quality-adjusted life years (QALY) gain of £7,504. [13] In 2014, the
WHO started to investigate the legal, ethical, gender, human rights and public health
implications of HIV self-testing (HIVST). [14] A recent review mentioned the need for clear
policies and regulations to be put in place before the implementation of HIVST, but that
pilot studies conducted globally documented a high acceptability towards HIVST. [15] In
addition, a study conducted in 2015 in South Africa suggests that the implementation of
HIVST in the country would have positive effects on HIV testing uptake, particularly on
hard to reach groups such as men. [16]
However, the performance of PoCT sometimes referred to as rapid PoCT and their imple-
mentation still remain a challenge. [17] The World Health Organisation (WHO) recommends
that newly designed PoCT meet the ASSURED criteria: [18]
• Affordable by those at risk of infection
• Sensitive, with very few false-negatives
• Specific, with very few false-positives
• User-friendly: tests that are simple to perform and require minimal training
• Rapid, to enable treatment at first visit, and Robust, for example not requiring refri-
gerated storage
• Equipment-free
• Delivered to those who need it
Currently, the most common PoCT are based on lateral flow technology. They are relatively
slow, requiring a 10-20 minutes waiting time for results, [19] which exceeds a typical doctors
appointment (8-10 mins in the UK [20]). It is also notoriously difficult to interpret a faint
lateral flow test line by eye, particularly for non-experts (e.g. self-testers) [8]. These tests
are insensitive to recently acquired infections [21] and lack the ability to automatically record
the test results electronically. This increases the risk of an incorrect reading and data loss,
and leaves missed opportunities to link patients to care efficiently.
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Recent advances in smartphone-connected diagnostic tests include nanophotonic-devices
which interface with smartphone cameras to read out current commercial lateral flow
tests, [22] overcoming the need to visually read tests by eye. Microfluidic technologies such
as the mChip and a dongle reported by Sia et al. recreate all the functions of an ELISA to
diagnose HIV and syphilis within 15 minutes, using nanoparticle signal enhancements. [23]
However, this rapid test requires the user to perform 7 steps, making it insufficiently simple
to use by untrained staff. A recent study conducted in Kenya, Malawi and South Africa
illustrated the importance of simplicity of use of PoCT, as a panel of untrained participants
were asked to use several prototypes and commercially available HIV self-tests, and less
than 25% performed all the tests steps correctly. [24]
This thesis aims at addressing the need for a better, high performance, simple-to-use, fast
and connected PoCT for early HIV infection. A new approach was adopted by investigating
the technology of surface acoustic wave (SAW) sensors. The promising potential offered
by SAW sensors to rapidly detect biomarkers of early HIV infection, as an element of a
simple-to-use and smartphone-connected PoCT, constituted the basis of this thesis.
1.2 Brief introduction to SAW biosensors
SAW sensors rely on piezoelectricity to sense perturbations occurring on their surface. An
electromagnetic wave is transformed into an acoustic wave, which propagates along the sur-
face of a piezoelectric crystal, before being transformed back into an electromagnetic wave.
The effects of the perturbation on the acoustic wave are monitored via the electromagnetic
wave. Different types of acoustic waves can be made to propagate through a piezoelectric
crystal, depending on the nature and cut of the crystal. Lord Rayleigh first predicted the
existence of surface acoustic waves in 1885 [25] and since then different modes of acoustic
wave propagation have been used and reported, the most recent and most sensitive being
the shear-horizontal SAW (SH-SAW) [26] and Love wave modes. [27]
As SAW sensors are commonly used as frequency filters in the telecommunications industry,
they can be mass manufactured easily and are inherently low cost. When used in liquid,
acoustic wave sensors can be used to detect variations in sample viscosity, pH or temperat-
ure. They can also be engineered into biosensors able to detect the binding of proteins to
their surface. SAW sensors have been reported to rapidly detect Salmonella typhimurium
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in food products with a high sensitivity, [28] as well as viral agents such as the Sin Nombre
virus (SNV), which causes serious pulmonary disease. [29] Detection of biomarkers of HIV
infection have also been reported, but so far the sensitivity has not been improved enough
to detect biomarkers at clinically relevant levels. [30]
Unlike lateral flow tests, which are commonly read by eye, the readout provided by SAW
sensors is entirely electronic, therefore avoiding the risk of incorrect interpretation of the
test result. The absence of need for interpretation of the test result, simplicity of use, low
cost and self-explanatory presentation of the test result are key points that form part of the
target product profile for HIV self-tests set out by the Program for Appropriate Technology
in Health (PATH). [31] With their low cost, small size and ease of use, they meet most of the
criteria of the ASSURED criteria for PoCT. The potential of SAW sensors to rapidly detect
biomarkers of HIV infection at clinically relevant levels has, however, not been achieved
yet, and constitutes the main challenge of the work presented here.
1.3 Aims and objectives of the thesis
The different objectives of this thesis, represented in Figure 1.1, merged towards contrib-
uting to the development of a new, higher performance and connected PoCT for HIV.
Successfully developing such a test would benefit millions of people in various ways. The
patients, first and foremost, by directing them to appropriate care quicker and increasing
their life expectancy. Then, society in general, by providing effective tools to monitor the
spread of the infection as well as potential outbreaks, and up to date crucial information
to inform adequate policies aiming at protecting the general public. Finally, the costs
associated with HIV treatment are considerable, and savings made by public health care
providers would be significant. In the UK, treatment provided to 100,000 patients costs
the NHS about £1 billion annually. [32]
The work presented in this thesis focused on the development, optimization and character-
isation of a biosensor with the capacity to diagnose early HIV infection. This key element
of the biosensor is a SAW device optimised to sense the presence of biomarkers of HIV
infection in a patient sample.
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The biosensor presented in this thesis is designed to be used with a smartphone, thereby
harnessing its mobile computing power. It can also take advantage of other sensors found
within smartphones such as Global Positioning System (GPS). The connectivity aspect,
which gives the test operator the option to record and send the test data to healthcare
providers, is a key objective of this work and distinguishes the new test from currently
available lateral flow PoCT. Avoiding the loss of data -and therefore patients- is crucial
in the eventuality of home testing, or non-traditional testing locations. [33,34] It brings the
benefit of facilitating linkage of the patient into the care cascade, from the point of diagnosis
through to care and treatment. A recent study using a mathematical model and focusing
on a high risk group of men who have sex with men in Seattle showed that replacing clinic-
based tests by home-based tests could indeed increase HIV testing, but at the same time
may increase the rate of false-negative tests and therefore decrease linkage to HIV care.
This study was performed using the commercially available OraQuick In-Home HIV Test
(OraSure Technologies, Inc, Bethlehem, USA), which is not a connected test. An online
study in South Africa is currently looking into whether a smartphone app can increase
linkage to care amongst newly diagnosed HIV patients in South Africa. [35] In addition, the
test connectivity helps healthcare organisations to build a dataset comprising the necessary
information to monitor the spread of the infection. Such information is also crucial in the
process of designing more efficient public healthcare policies aiming at addressing the fight
against the pandemic.
There are now more mobile device subscriptions than people on the planet and their number
is estimated to be growing five times faster than the human population. [36] The number
of smartphone users in the world is predicted to rise to 6.4 billion by 2021, meaning that
roughly 70% of the world population will have access to a smartphone in five years time [36]
and consequently there is potential for a long-term sustainable platform for diagnostic
testing worldwide. Emerging markets are expected to play a key part in this spectacular
growth, with regions like Asia Pacific, the Middle East and Africa predicted to account for
80% of all new subscriptions in the next five years. [36] These billions of phones can be used
to improve access to rapid tests and public surveillance efforts everywhere. Aside from the
use of the smartphone as a diagnostic tool, it has been shown that the use of specific apps
can increase HIV testing uptake among high risk groups such as men who have sex with
men. [37]
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This thesis focusses on the use of a SAW device as a key element of a biosensor for HIV. The
aims of this work were to investigate and improve the performance of the biosensor from
different angles. First, the intrinsic sensitivity of the SAW device to a given perturbation,
which is dependent on the design of some elements of the device, such as the length of
the delay line, the operating frequency, and the strategy used to cancel out the noise in
the signal. The objective was to show, using the theoretical definition of the SAW device
sensitivity, that the device used had the optimal sensitivity to the range of perturbations
it would have to sense.
Second, the biosensors ability to rapidly detect key biomarkers of HIV at clinically relev-
ant concentrations. The optimisation of the surface chemistry used to functionalise the
surface of the device with appropriate capture proteins was a central step in the biosensor
optimization. The aims here were to (i) investigate the response of different antibodies and
specificity testing using a non-specific antibody (negative control), (ii) test the reproducib-
ility of measurements on a single SAW biochip, (iii) demonstrate the detection of clinically
relevant concentrations of anti-HIV antibodies; (iv) reduce the time to result for ultra-
rapid testing, in order to achieve a time to result of less than 5 minutes, as recommended
by PATH in their target product profile for HIV self-tests, [31]; (v) show the proof of concept
detection of the HIV p24 antigen, key marker of early infection; and (vi) investigate signal
amplification strategies using gold nanoparticles.
Third, the biosensors clinical performance. An essential stage of development of a new
biosensor is to test its clinical sensitivity and specificity to biomarkers of HIV using a panel
of patient samples. The target product profile set out by PATH for HIV self-tests recom-
mends a clinical sensitivity and specificity both larger than 99% (optimistic requirements,
the minimum requirements are: clinical sensitivity >99%, clinical specificity >98%). [31]
Conducting pilot studies with a panel of patient samples and achieving these requirements
was a key objective of this work.
Finally, a last objective was to characterise the fundamental physical parameters contribut-
ing to the signal output measured with the biosensor. Using a method developed by Saha
and Gizeli, [38] the aim was to try and disentangle the contributions of different physical
parameters contributing to the signal, in the hope that a better understanding of the trans-
duction mechanisms would provide additional tools to improve the device performance.
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1.4 Industrial partners and funding
This work was supported by a studentship funded via the UCL Impact award in collabora-
tion with industrial partners OJ-Bio Ltd., a Newcastle-based SME. OJ-Bio Ltd. is a leading
telecommunications company developing biosensors for real time point-of-care diagnostic
tools. It was created in 2009 by Orla Proteins Technologies and Japan Radio Company
Ltd. (JRC). JRC is a multinational company with 100 years of electronics and wireless
communications expertise based in Saitama, Japan. Orla is a biotechnology company with
expertise in protein engineering, manufacture and surface technologies. In addition, grants
from the NIHR i4i program (II-LA-1111-20004) and EPSRC i-sense Early Warning Sensing
Systems in Infectious Diseases (EP/K031953/1) also supported the work presented here.
i-sense is a five year, £11m EPSRC-funded programme that was launched in October 2013.
Its vision is to engineer a new generation of early-warning sensing systems to identify dis-
ease outbreaks much earlier than before, using self-reported symptoms on the web and
mobile phone-connected diagnostic tests.
1.5 Outline of thesis structure
This thesis was articulated into the following 8 Chapters in order to assess the different
objectives, introduce the materials and methods used and present the various results ob-
tained:
• Chapter 2 gives an overview of AIDS, from its origin in the 1980s to the status of
the pandemic today. A brief presentation of the structure and mechanism of action
of HIV is given, leading to the identification of the key biomarkers of infection. A
timeline representing the order of appearance and temporal dynamics of different
biomarkers over time is then explained. Finally, an overview of the key requirements
for the design, characteristics and performance of PoCT for HIV is given, as well as
a review of the state of the art in this field.
• Chapter 3 presents the theory of shear-horizontal SAW (SH-SAW) devices, and out-
lines their potential as a good candidate for developing the biosensor. After presenting
the concept of piezoelectricity, a brief history of acoustic wave sensors is given. An
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introduction to the perturbation theory applied to SH-SAW follows, and how it can
be used to justify the choice of certain parameters to monitor perturbations detected
by the sensor.
• Chapter 4 is a detailed description of all materials and methods involved in the
process of obtaining the results presented in this thesis. In particular, this includes a
presentation of the prototype of the SH-SAW device and associated control box used
to obtain the results.
• Chapter 5 presents a characterisation of the SH-SAW device used throughout this
thesis. Different aspects are studied, to investigate the intrinsic sensitivity of the
device as well as its performance as a disposable, easy to use test.
• Chapter 6 reports a systematic study to demonstrate the ability of the biosensor to
detect key biomarkers of HIV at clinically relevant concentrations. Highlights include
ultrafast detection within 10 seconds after sample injection, and detection of a key
biomarker of early infection. Methods to amplify the SAW signal down to pg/ml
sensitivity are reported.
• Chapter 7 demonstrates the very good performance of the biosensor by assessing its
clinical sensitivity and specificity using a panel of 30 HIV patient samples and more
than 100 healthy volunteers. An investigation is presented to look into the speed at
which the result can be delivered without compromising the test performance.
• Chapter 8 presents a method to characterise the SH-SAW device, some of the liquid
sample properties, as well as some physical parameters associated with the proteins
detected by the biosensor. This work, which relies on a method described by Gizeli et
al., opens up new ways of improving the SH-SAW devices performance in the future.
• Chapter 9 aims at summarising the main conclusions presented throughout the thesis.
It brings together the different results obtained and their contribution towards the
initial objectives, before opening up the exciting opportunities created by this work
to advance towards future new objectives.
Chapter 2
HIV Diagnostic Needs
In this chapter, an introduction to the history and the impact caused by the HIV/AIDS
pandemic is given. The structure of the HIV-1 virus is presented, along with the key
biological markers of infection and their temporal dynamics. The benefits of early detection
are discussed, and, in the light of recommendations and guidelines provided by the WHO
and PATH, a portrait of the ideal PoCT for HIV infection is given. Finally, an overview of
the current HIV diagnostics is given, highlighting the current limitations in the field.
2.1 The HIV/AIDS pandemic
2.1.1 History
Nascent awareness of acquired immunodeficiency syndrome (AIDS) arose in 1981. In Los
Angeles and New York, incidences of homosexual men with unusual symptoms such as a
rare type of lung infection or rare skin tumours were reported. [39] More importantly, the
patients were found to have a severe reduction in CD4 cells, or T cells. [40,41] These cells play
an important role in the immune system as they are involved in, amongst other functions,
killing virus-infected cells, activating macrophages and driving inflammation. [41]
In the following months, this disease was recognized across the United States, Western
Europe, and Africa. In 1983, the etiological agent, the human immunodeficiency virus
(HIV), was identified by researchers in France and the United States who classified the
virus that causes AIDS as a member of the group of viruses called retroviruses. [42,43] It is
33
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generally accepted that the virus had spread throughout most of the world by the end of
the 1980s. [40,41] There are two species of the virus, called HIV-1 and HIV-2. Both evolved
from a simian immunodeficiency virus (SIV). The original SIV was found in chimpanzees
in the case of HIV-1 while HIV-2 evolved from an SIV in a type of monkey called the sooty
mangabey. [40,44–46]
HIV-1, which is responsible for the vast majority of AIDS cases worldwide, is divided into
three groups, depending on mutations and the general evolutionary path the virus has
followed: [41,47] group M (for Major), group O (for Outlier) and group N (for Non M, Non
O). Group M is the dominant group, as it represents 90 percent of all infections worldwide,
while groups N and O are rarer. Within the M group there are at least nine strains (or
subtypes) of HIV-1. Those different strains undergo continuous mutations, and often end
up recombining with each other, resulting, in combination with historical migration and
trade routes, in more associated recombinant strains of the virus. HIV-2 is not as virulent
and is restricted mainly to West Africa, where it originated. [41,48]
HIV infection causes AIDS, but the definition of AIDS given by the World Health Organ-
ization (WHO) is the development of a low CD4 cell count (lower than 350 cells/mm3 [32]).
The HIV/AIDS pandemic consists of many separate epidemics. Each epidemic has its own
distinct origin, both in terms of geography and specific populations affected, and involve dif-
ferent types of risky behaviours and practices, for example, unprotected sexual intercourse
with multiple partners or sharing drug injection equipment.
2.1.2 The situation today (2016)
The HIV/AIDS pandemic has spread over the world and now ranks among the most dev-
astating infectious diseases in human history, infecting more than 78 million people and 39
million deaths [49] with tremendous burden of illness in Sub-Saharan Africa, as illustrated
by the latest UNAIDS prevalence map in Figure 2.1.
UNAIDS indicates in its latest report that in 2015, approximately 2.1 million people ac-
quired HIV infection, and approximately 36.7 million people were estimated to be living
with HIV globally. [51] Antiretroviral therapy (ART) has been shown to reduce rate of HIV-
related mortality [52,53] and to increase life expectancy. [54,55] Some efforts to implement
access to ART have been successful. Since 2000, the percentage of HIV patients on ART
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Figure 2.1: HIV prevalence globally, 2015. The HIV/AIDS pandemic has spread
over the world since the late 1980s. Sub-saharan Africa is particulary impacted, with
prevalence as high as 7% and more in some countries. Adapted from [50]
increased from approximately 3% to more than 45% in 15 years. [51] As a consequence,
the number of AIDS-related deaths has been decreasing annually since 2005. [51] This is
illustrated in Figure 2.2.
2.1.3 Benefits of early detection
As mentioned in Chapter 1, strategies based on the use of antiretroviral drugs exist to
prevent transmission of the infection, and are recommended by the WHO. [56,57] In a press
release in 2014, the US Centre for Disease Control and prevention (CDC) recommended
the use of PrEP to those at high risk of contracting the infection, as it has been shown to
reduce the risk of infection by 92%. [58] The UK public health care system (National Health
Service NHS) has recently been made legally responsible to fund and implement PrEP
nationally. [59]
In parallel to these recent developments, and in the absence of a vaccine, a major aspect of
the fight against the HIV/AIDS pandemic remains the detection of the infection. In 2014,
UNAIDS set out the challenging 90-90-90 target: aiming for 90% of people living with HIV
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Figure 2.2: Global evolution of antiretroviral therapy coverage, and AIDS-
related deaths, since 2000. Adapted from: UNAIDS global AIDS update 2016 [51]
know their HIV status, 90% of people who know their HIV-positive status access ART
and 90% of people on treatment have suppressed viral loads. [60] At a recent International
AIDS conference in Durban, South Africa, UNAIDS announced significant progress has
been made towards this ambitious target. [61] One of the reasons to explain the increase
observed in the antiretroviral therapy coverage, as well as the decrease in AIDS-related
deaths since 2005 (see Figure 2.2), is the increase in access to testing. [1] However, the need
for better diagnostic tools remains, highlighted by the very high number of HIV-infected
individuals who are unaware of their infection. In 2015, it was estimated that around 17%
of the individuals living with HIV in the UK were unaware of their infection. [62] That
proportion is 12.5% in the USA [63], 55% in South Africa [64] and probably more in less
developed countries. In 2014, UNAIDS estimated that globally, this figure could be as high
as 54%. [64]
Individuals who are unaware of their infection are at risk for their own health, as they
are likely to start their treatment too late. It is estimated that people diagnosed late
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(CD4 cell count fewer than 350 cell/mm3) have a tenfold increased risk of dying within
a year of diagnosis. [32,62] Early diagnosis and access to antiretroviral treatment increases
life-expectancy by 10 years. [65] It also represents a public health problem, as individuals
unaware of their infection are likely to transmit it, particularly during the early acute stage
of infection. [66] A study has shown that pregnant women reduce the risk of transmitting
the virus to their babies to less than 1% when diagnosed early and treated. [67]
In addition to the human benefits associated with early diagnosis, the economic benefits are
potentially significant. According to the CDC, every case of HIV that is prevented saves
$380,000 in lifetime treatment costs. [67] In the UK, Public Health England (PHE) estimates
the annual cost for treatment and care in the UK to be in the region of £858 million, and
that if the estimated 4,000 UK-acquired infections diagnosed in 2011 had been prevented,
£1.9 billion in lifetime treatment and clinical care costs would have been saved. [32] In 2013,
another study in the UK modelled the cost effectiveness of HIV care and concluded that
the lifetime costs associated with 3,000 new HIV infections was likely to be in excess of 1
billion. [68]
Early detection of HIV benefits patients by triggering faster access to care with better health
outcomes, the public by contributing to stop the spread of the infection, and it generates
significant public savings. Early diagnosis relies on the identification and detection of
specific biomarkers of infection. The following section gives an insight into the common
biomarkers of early HIV infection.
2.2 Biomarkers of HIV infection
2.2.1 HIV-1 structure
HIV-1 is a retrovirus; more specifically a lentivirus. Lentiviruses are characterised by a long
latency period between infection and the start of the disease (8 to 12 years), and can infect
non-dividing cells. [47] Retroviruses are characterised by a capsid core protecting the genetic
information they carry (two single-stranded RNA molecules). The replication cycle begins
even before the virus gets in contact with the cell, as reverse transcription (transcribing
RNA into double stranded DNA by reverse transcriptase) begins in the virion. Infection
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triggers a series of processes that lead to the DNA being integrated into the hosts genome,
and a new infectious virion being created. [69]
p24
gp41
gp120
Genomic RNA
HIV enzymes
Lipid membrane
Matrix
(capsid protein)
(envelope protein)
Figure 2.3: HIV-1 structure. Schematic to illustrate the main elements forming the
structure of HIV-1. The two proteins that were key to this work are highlighted in orange
(p24) and purple (gp41). Adapted from [70]
The general structure of HIV-1 is schematised in Figure 2.3. The genome, which consists of
two copies of single-stranded RNA, is protected by a capsid composed of p24 proteins, also
known as capsid protein (CA). The capsid is itself surrounded by the virus envelope, which
is composed of an inner matrix of proteins and interacts directly with the environment
through spikes of trimers of envelope proteins which will be described further. [69]
The viral RNA is about 10 kilobases (9719 nucleotides) long and contains 9 different genes
coding for 15 different proteins. Those proteins are classified in three categories: structural
proteins, regulatory proteins and accessory proteins. [71] Two of the structural proteins were
essential to this work: the capsid protein (CA) p24 and the transmembrane protein (TM)
gp41. As will be discussed further on, the antibodies raised against these two proteins
(anti-p24 and anti-gp41) as well as p24 itself, are essential biomarkers of HIV infection.
The structural, regulatory and accessory proteins as well as the enzymes the virus needs to
replicate, are all derived from the cleavage of polyproteins that are encoded by three genes:
env, gag and pol. [69,72,73]
The env gene codes for a precursor protein, the glycoprotein gp160. This protein is then
cleaved by cellular protease into two smaller proteins, gp41 and the external surface protein
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(SU) gp120. Those two products of the cleavage of gp160 remain bound together but only by
non-covalent bonds: they form a non-covalently bound heterodimer. Those heterodimers
are grouped into trimers to form spikes on the surface of the virus. The gp41 protein
is embedded into the virus envelope while the gp120 protein in exposed to the external
environment and contains the recognition site for the cell surface receptor protein. The
gp120 protein is therefore directly involved in the first step of the process where the virus
attaches to and enters the cell. [69,72,74]
The gag gene also codes for a precursor polyprotein called Pr55. This polyprotein is cleaved
by viral proteases. It is cleaved by viral proteases - instead of cellular proteases like in the
case of gp160 - because the cleavage happens after the virus has budded out from the cell (or
during the budding process), in a step called the maturation process. The products of the
cleavage of Pr55 by virus proteases are four smaller proteins: p17, p24, p9 and p6. The p17
protein, also known as matrix protein (MA) forms the inner layer of the virus envelope.
As mentioned earlier, p24 constitutes the capsid core protecting the viral RNA. The p9
protein, also called nucleocapsid (NC), is associated with the RNA genome in the capsid
core and plays a role in the early stages of reverse transcription. The p6 protein plays a
role in the assembly process by helping incorporate accessory proteins into the virion. [73,75]
Finally, the pol gene codes for the polyprotein Pr160. The cleavage products of Pr160 are
the enzymatic components of the virus: protease, reverse transcriptase and integrase. As
mentioned before, the protease is responsible for the cleavage of Pr55, as well as for matura-
tion and hence production of an infectious virion (an immature virion is non-infectious [76]).
Reverse transcriptase produces the complementary DNA from the viral RNA template.
Integrase is necessary to insert the transcribed double-stranded DNA into the cells gen-
ome. [69,75]
The role of regulatory proteins is to help help control the synthesis of other proteins ne-
cessary to the replication cycle. Finally, HIV-1 accessory proteins help replicative cycles
to be productive. They modify the local environment within infected cells to ensure viral
persistence, replication, dissemination, and transmission. [69,72,75]
As mentioned earlier, p24 is a key marker of early HIV infection. As it constitutes the core
capsid of the virus, its sequence is highly conserved compared to envelope proteins, making
it easier to design capture protein against it. Despite being a core structural protein, p24
Chapter 2. HIV Diagnostic Needs 40
gets released continuously in the blood stream following the virus replication cycle, cell
lysis or host attack of the virus. [70,73,74,77,78]
2.2.2 Temporal dynamics of key biomarkers of HIV infection
There are several biomarkers of HIV infection in blood or saliva. They can be directly
related to the virus itself (viral RNA or actual virus proteins such as p24 or envelope
proteins), or antibodies raised against the different HIV proteins. [79] The graph in Figure
2.4, adapted from references, [80–82] shows the temporal dynamics of key HIV markers, in
blood, starting from transmission (day 0). The markers of interest here are viral RNA, p24,
anti-gp41 IgM, anti-p24 IgG and anti-gp120 IgG (IgM antibodies are produced first and
only during a short period of time, until the antibody response matures and the production
of IgG antibodies takes over). On this plot, it is important to note that the units on the
two y axes are different, and that the levels of RNA in blood are significantly lower than
the levels of the different HIV proteins or associated antibodies (for instance, for two copies
of viral RNA, approximately 1400 copies of p24 are produced [83]). In addition, as the left
axis shows signal over cut-off values, it is important to point at that while a peak of p24
might be lower than 400pg/ml, antibody levels reach values higher than a few micrograms
per millilitre.
The virus needs some time to replicate enough and spread from local to systemic infection.
As a consequence, the different markers of infection have a distinct order of appearance
and for some there is a defined window of detection. While this may differ in individuals,
this is true for a population level.
Viral RNA and p24 arise first, as they are part of the virus, before the host mounts a
detectable response. RNA can be detected after approximately 7 days, while the window
period for the detection of p24 is from approximately 2 to 5 weeks after transmission. The
host needs time to produce the antibodies that are raised against different HIV proteins,
which explains why there is a delay between the viral markers and the antibody response.
What looks like a slight delay between the appearance of viral RNA and p24 in the body is
probably an artefact of the difference in detection method used for the two markers. The
conventional method to detect RNA is to lyse the virus (by adding detergent to the sample,
which bursts open the envelope and the capsid), purify the RNA, use reverse transcriptase
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Figure 2.4: Evolution of HIV markers over time. Left axis shows viral RNA levels
in copies/ml. Right axis (not to scale) shows protein or antibody level as signal over cut-off
(s/co). Minimum level of detection represents a s/co of 1 for the proteins/antibodies and
50 copies of viral RNA per millilitre of blood, using standard current techniques. Adapted
from. [80–82] The different windows of detection corresponding to different generations of
laboratory tests for HIV are indicated. EIA stands for enzyme Immunoassay. NAAT refers
to nucleic acid amplification tests.
enzymes to reverse transcribe the RNA into DNA and run a qPCR (quantitative Poly-
merase Chain Reaction) to evaluate the amount of DNA, which therefore directly relates to
the viral load of the starting sample. Amplification of nucleic acid is easy and signal amp-
lifications of 109 are not uncommon for RNA/DNA. The conventional methods to detect
the presence of protein markers (antibody or antigen) can not compare with these levels of
signal amplification and are therefore less sensitive.
The first HIV antibody to appear is generally anti-gp41 IgM, and unlike IgG, there is
only a short window to detect it (approximately 3 to 6 weeks after transmission). This
is because it is an IgM, which, by nature, is only produced during a few weeks before
the antibody responses matures and IgG antibodies are produced. Then comes anti-p24
antibodies, which can be detected from around 4 weeks after transmission, and anti-gp120
IgG, detectable approximately 5 weeks after transmission. [84]
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The differences observed in terms of timing of the different antibodies can be explained by
the nature of the protein they are raised against. When a foreign protein is introduced in
the organism, it gets complexed by macrophages and various antigen presenting cells who
chop it up into peptides (short chains of amino acids, usually no longer than 10 amino
acids). The peptides are then presented to T cells. Recognition of the peptide antigen
by the T cell receptor leads to activation of the T cell, which in turn will activate B cells
which, in turn, produce the antibody against this sequence of amino acids. [69] The more
conserved the original foreign protein (i.e. the more its structure does not tend to evolve a
lot following mutations), the easier it is for the organism to raise antibodies against it. It
is more likely to be difficult for the organism to raise antibodies against a highly mutating
protein such as gp120 (envelope protein, interacts directly with the outside environment)
than against conserved proteins such as gp41 (which is embedded in the envelope) and p24
(capsid, inside the virus). This explains why anti-p24 comes second, and anti-gp120 comes
last. Furthermore, gp120 is a highly glycosylated protein, making it more difficult for the
macrophages and antigen presenting cells to present peptides properly.
The windows of detection of the different generations of laboratory-based tests are indicated
on the graph in Figure 2.4. Nucleic acid tests can reliably be used to diagnose HIV infection
from 7 days after infection, while the most recent generation of ELISA can be used from
14 days after infection (it detects p24). Detecting HIV infection in the acute stage is still
challenging in point-of-care settings. Rapid antibody tests are highly accessible but they
cannot detect HIV during the very acute stage, [21] and therefore highlight the need for
antigen/antibody combination assays. [85] The need for detecting both anti-p24 and anti-
gp41 has been discussed, as cases have been observed when a patient could be wrongly
diagnosed because one antibody was undetectable. [86]
2.2.3 Clinical range of key biomarkers of HIV infection
The clinical range of the three main proteins biomarkers of HIV infection can be found in
Table 2.1.
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Biomarker Clinical range
p24
0.1 - 1000pg/ml
4.2× 10−3 - 41.7pM
Anti-p24
82 - 1900µg/ml
0.5 - 12.7µM
Anti-gp41
5.4 - 5194µg/ml
0.03-34.7µM
Table 2.1: Clinical range of the three main proteins biomarkers of HIV infec-
tion. [82,87–89]
2.3 The ideal PoCT for HIV
2.3.1 Benefits of PoCT implementation
As mentioned in Chapter 1, a range of methods can be used in hospital settings to accur-
ately diagnose HIV infection. These include ELISA and PCR. However, these diagnostic
techniques are associated with high costs (staff training, instrumentation) and delays for
the patients, who need to return to the clinic or hospital to obtain their results or attend
a follow-up appointment. [8–10] These delays increase the risk transmission of the infection.
The common procedure to test for HIV in hospitals differs from country to country. The
UK guidelines state that a positive HIV antibody test should be confirmed by three inde-
pendent assays and at least one of them should distinguish between HIV-1 and HIV-2, [90]
whereas in the US a positive screening test and one positive confirmatory test should be
performed to make a diagnosis. [91] Both the WHO and the BHIVA recommend that all
individuals diagnosed with HIV should be offered treatment as soon as possible following
diagnosis, in an effort to prevent onward transmission of the infection. [56,92]
In addition, several cost-effectiveness studies were conducted; their conclusions all point
towards the potential for significant public savings associated with the implementation
of PoCT or HIVST. [11–13] These economic benefits, and the constraints and flows associ-
ated with traditional gold standard diagnostic techniques, are driving a push towards the
implementation of PoCT outside of hospitals or clinics, [4,5] as well as the legalisation of
self-testing in several countries like the UK [6], France [93] or the USA. [94] HIVST is also
recommended by the WHO. [14] HIVST has been widely shown to be well accepted by pa-
tients, [15] is believed to increase HIV testing uptake in general, [16] and to play an important
role in the near future to facilitate both treatment and prevention. [95]
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The general trend of the increase in the use of PoCT to diagnose HIV is illustrated by the
proportion of PoCT procured by the WHO globally, compared to ELISA or confirmatory
tests. Figure ?? shows that PoCT have largely dominated the WHO HIV test kit procure-
ment program since 2003, and the latest data indicate that more than 80% of the HIV tests
kit provided by the WHO around the world were PoCT in 2009. [96]
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Figure 2.5: Procurement of HIV diagnostics by the WHO. HIV test kits procured
by WHO, by assay type, 1999-2009. [96] Simple/Rapid refers to PoCT.
2.4 PoCT design criteria
As mentioned in Chapter 1, the WHO issued some general guidelines about the design of
PoCT in general, illustrated by the acronym ASSURED. [18] The recommendation is that
every PoCT needs to be low cost, exhibit good performance indicators (sensitivity and
specificity), be simple to use, rapid and robust, equipment-free and it should be possible
to deliver the test to regions where it is needed, taking into account shipping and changing
conditions of temperature and pressure. These guidelines are general and apply to PoCT
to any infection. PATH has issued more specific criteria that apply to HIVST. [31] As it
is assumed that a self-test could be purchased and performed anywhere in the world, the
requirements are stricter and therefore constitute a good set of criteria when developing
the ideal PoCT for HIV infection.
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PATH identified 51 variables, grouped into 6 requirement categories: Context (use case),
Performance requirements, User requirements, Operational requirements, Kit Requirements
and Commercialisation requirements. The variables belonging to the last two categories
would have to be improved at the scaling up stage of the manufacturing process, as they
range from the packaging to the waste management and quality control.
As some of the variables are met by most of the PoCT currently available, Table 2.2 lists
the requirements that are not yet fully met, and will be discussed further on. These targets
were the motivation of the work presented here.
2.4.1 Overview of current PoCT for HIV infection
There are dozens of HIV PoCT and HIVST on the market, some reliable, some less. As of
2016, the US Food and Drug Administration (FDA) has officially approved no fewer than
41 PoCT for HIV. [97] The two most common types of commercially available PoCT for HIV
are lateral flow tests, and flow-through tests. An example of each is show in Figure 2.6.
a b
Figure 2.6: Example of commercially available PoCT for HIV infection. a)
Lateral flow test Alere Determine HIV-1/2 (Alere, USA) [98] b) Flow-through test Insti
HIV-1/HIV-2 Antibody test (bioLytical Laboratories, Canada) [99]
Initial field testing has shown promising results. A 2007 study in 11 African countries found
that 15 FDA-approved commercially available PoCT for HIV gave accurate and comparable
results whether they were used in laboratory settings or in the field. Furthermore, the
conclusions of the study were positive about the potential to scale up the implementation
of these tests to national level. [100] However, inferior performances have also been reported
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when using commercially available PoCT in the field. A recent study performed in Cape
Town, South Africa, highlighted how one commercially available PoCT (brand not specified)
was unreliable compared to standards and to another similar commercially available PoCT
(also not specified). The levels of sensitivity to HIV infection observed in the clinic increased
from 68.7% to 93.5% simply by using a different brand of PoCT for HIV. Both tests claimed
a sensitivity of at least 99%. [17]
The most common PoCT for HIV on the market are lateral flow tests. The operating
principle is schematised in Figure 2.7. They are cheap, as paper-based, and relatively easy
to use. In a similar way to pregnancy tests, a drop of sample is applied at one end of the
paper strip and flows through the strip using capillary effect. The presence or absence of
a coloured line in the middle of the strip a few minutes after sample addition reveals the
presence or absence of the target protein.
The vast majority of the tests on the market meet the requirements of the ideal PoCT in
terms of cost, storage conditions and portability. However, some aspects are yet to be fully
optimised - or absent, e.g. antigen detection - as is discussed in the following paragraphs.
2.4.2 The interpretation of the test result needs to be easy
One of the main disadvantages of lateral flow tests is the subjectivity involved in interpreting
the test. It can be difficult to judge on the presence (or absence) of a line on the test
strip if the target protein is present at low concentration, or if the light conditions are
not ideal, for example. [8] In 2008, a study in the KwaZulu-Natal province of South Africa
investigated the performance of 4 commercially available PoCT for HIV, all lateral flow
tests (First Response HIV Card Test 1-2.0 (PMC Medical, India Pvt Ltd), Pareekshak
HIV Triline (UCB Pharma), Abbott-Determine HIV-1/2 (Abbott Diagnostics, USA) and
Sensa (Seyama Solutions, SA)). Nurses were asked to perform the tests in the field, and the
results were compared with the results of the same tests performed in the lab on the same
samples by trained technicians. The conclusion of the study was that there was a clear user
dependence. If the sensitivity and specificity of the tests proved to be as high as claimed
by the manufacturer when performed by trained technicians in the lab, it dropped by a
few percent when performed by nurses in the field, arguably because of the subjectivity
involved in interpreting the test result. [102]
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Figure 2.7: Lateral flow test principle. Adapted from [101]. The drop of sample is
mixed with gold nanoparticles functionalised with proteins that bind the target protein.
Complexes are formed if the target protein is present. The sample then flows through a
strip of paper using capillary action. A line in the middle of the paper strip is functionalised
with capture proteins engineered or raised against the target protein. If the target protein
is present, the complexes they formed with the gold nanoparticles binds to the line, forming
an immunosandwich which reveals the line with a red colour: the test is reactive. If the
target protein was not present, the gold nanoparticles do not bind the line, no colour
appears on the line and the test is negative. An additional line is engineered to bind to
anti-human antibodies in a similar way and is used as a control, to ensure the test result
is valid.
2.4.3 PoCT would benefit from connectivity
Recently, an optical device has been developed to detect the presence of fluorescently la-
belled nanoparticles in a sample. The device attaches to a smartphone and uses an inbuilt
laser diode to excite fluorescent nanoparticles, and a system of filters and lenses to facilit-
ate a smartphone camera read out of the signal. [22] In general, the smartphone camera and
processing power can easily be used, in principle, to perform the readout of simple lateral
flow tests. Using a smartphone to interpret the test result has already been applied to the
interpretation of drug-of-abuse lateral flow tests. [103] This technique would bring the joint
benefit of removing user bias in interpretation of the test result, as well as connectivity.
Indeed, lateral flow tests used without an electronic readout cannot record the test results
electronically. A recent systematic review of HIV self-tests highlighted the lack of post-test
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linkage, counselling and reporting of test result, [104] all of which would be made easier and
automatic by using the tests in association with a smartphone.
2.4.4 PoCT need to be simple to use
As mentioned earlier, the simplicity of use is crucial to correct usage. While a number
of studies have reported users finding tests easy to use, [105–107] in many studies users did
not perform the test correctly. A study conducted in South Africa highlighted the lack
of simplicity associated with the use of a commercially available PoCT for HIV (brand
not specified), as the sensitivity observed increased from 93.5% to 95.1% when providing
additional training to the staff performing the test, instead of relying simply on the in-
structions provided with the test. [17] In another recent study, a panel of lay participants
(i.e. untrained users) were asked to use 5 commercially available HIV self-tests, as well
as interpret the results of tests performed using these PoCT. The participants were filmed
and the protocol they used was analysed and compared with instructions provided by the
test manufacturer. More than three quarters of participants made at least one mistake
when performing the test, and test results were correctly interpreted by only 80% of the
participants. [24] Similarly, only 15% of participants were found to correctly use a HIVST in
a study conducted in Singapore where participants were asked to perform a test using the
Abbott Determine HIV-1/2 rapid test (Abbott Laboratories, Abbott Park, IL). [108] The
percentage of correct usage of the test can be improved by adapting instructions following
feedback from this type of study, as has been shown in Spain using the Determine HIV
Combo (Alere, USA) [109] and in Malawi using a commercially available oral HIVST. [110]
Aside from lateral flow tests, a recent development using microfluidic has been reported,
where an ELISA dongle is used to diagnose HIV and syphilis by performing all the steps of
a traditional ELISA on a small chip. The test can easily be connected to a smartphone and
has shown promising sensitivity and specificity to biomarkers of HIV infection. Because of
the complexity of ELISA, however, this test requires too many steps (currently 7) to be
performed by untrained users without prohibitive risk of mistakes and invalid results. [23]
Chapter 2. HIV Diagnostic Needs 50
Test Manufacturer
Time to result
(manufacturer’s
guidelines)
Determine HIV-1/2
Ag/Ab Combo
Alere, USA 20-40min
Sure Check HIV 1/2 As-
say
Chembio Diagnostic
Systems, Inc., USA
15-20min
SD Bioline HIV-1/2 3.0
Standard Diagnostics,
Inc., UK
10-20min
insti HIV-1/2
bioLytical Laboratories
Inc., Canada
5min
Table 2.3: Time to result of some common PoCT used in the UK.
2.4.5 The time to result needs to be reduced to less than 5 minutes
In a study conducted in South Africa, it was found that a majority of participants (nearly
70%) did not wait for long enough and read the test result before the time window recom-
mended by the manufacturers instructions. [17] Lateral flow tests usually require at least 10
minutes between sample injection and result [19], which exceeds both a typical doctors ap-
pointment (8-10min in the UK [20]) and the 5 minutes recommended by PATH for HIVST.
The time to result of some commonly used PoCT for HIV can be found in Table 2.3. The
fastest test on the market at the moment, the insti HIV 1/2 is not fast enough as it requires
5 minutes between sample injection and test result.
2.4.6 The window of detection needs to be reduced
Currently, only one commercially available PoCT is sensitive to recently acquired infections,
the Alere Determine HIV-1/2 Ag/Ab Combo (Alere, USA), which detects both antigen
(p24) and anti-HIV antibodies. Trials have been conducted and have shown very variable
results. When testing samples from sample in acute infection stage, the sensitivity varied
from 0% to 82.1% for the antigen, and from 0% to 66.7% for the antibody. The specificity
varied from 0% to 100%. When testing samples from patients past the acute infection stage,
the results were better: the observed sensitivity ranged from 88.2 to 99.8%, the specificity
from 89.5 to 100%. [111–121] These poor field trial results highlight the need for PoCT with
the capacity to detect both antibody and antigen.
Chapter 3
SAW Device for Biosensing
The previous chapter gave an insight on the structure of HIV and how it relates to the
choice of the best biomarkers of HIV infection. The benefits of developing better PoCT
for HIV were presented, as well as an overview of the state of the art in that domain.
The limitations of current commercially available tests were pointed out, in the light of
recommendations given by the WHO and PATH concerning the design of the ideal PoCT
for HIV. This chapter aims at explaining the choice of sensor used as the basis of the
smartphone-connected PoCT for HIV presented in this thesis. First, a general introduction
to the concept of piezoelectricity and related applications is given. A focus is then made
on the use of the piezoelectric effect for sensing perturbations, and the particular case of
acoustic wave based sensors is detailed, followed by a brief history of the different types
of surface acoustic wave (SAW) sensors. The particular case of the shear-horizontal SAW
(SH-SAW) sensor is then explored, with an introduction to the perturbation theory applied
to SH-SAW and how it justifies the choice of certain parameters (phase shift φ and insertion
loss IL) to monitor the perturbation of interest in the context of a biosensor. Finally, the
electric circuit used to monitor these parameters is explained.
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3.1 Acoustic wave based sensors
3.1.1 Piezoelectricity
Piezoelectricity is a phenomenon observed in some solid materials and is described as the
conversion of mechanical stress into a change in electrical polarization, and vice versa. The
word piezo is Greek for ”push” or “press”, therefore piezoelectricity can be interpretated
as “electricity resulting from pressure”. The phenomenon was discovered by Pierre and
Jacques Curie in 1880, and first reported in 1908 after Pierre Curie’s death. [122–124] The
direct piezoelectric effect refers to a change in the electrical polarization of the material
when it is subjected to a mechanical stress, whereas the inverse piezoelectric effect refers
to a deformation of the material when it is subjected to an external electric field. This is
illustrated in the schematics in Figure 3.1.
Direct
piezoelectric effect
Electrode
Consequence
Electric signal
Piezoelectric crystal
Action
Stress
Electrode
Inverse
piezoelectric effect
Consequence
mechanical vibration
Action
Stress
Action
Alternative current
Figure 3.1: Piezoelectric effect. Schematics to illustrate the piezoelectric effect. A
piezoelectric crystal is integrated into an electric circuit using two electrodes that are
directly attached to the crystal. When stress is applied to the crystal, an electric signal is
induced in the circuit, this is the direct piezoelectric effect (top). If an alternative current
is applied to the circuit, a mechanical vibration of the crystal is observed, this is the inverse
piezoelectric effect (bottom).
A range of solid materials exhibit the piezoelectric effect. Most of them do so as a result
of their anisotropic crystalline structure. [125] However, some materials can be engineered
to exhibit piezoelectric behaviour, by using a process called poling, whereby the crystal is
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subjected to a very high electric field, which incurs an anisotropy. The piezoelectric effect is
exhibited by 20 out of 32 crystal classes, [126] which are associated with noncentrosymmetric
crystals, meaning that their unit structure does not possess a centre of symmetry. Some
non-crystal piezoelectrics include ceramics and some large proteins have also been found to
be piezoelectric, such as DNA. [127]
There are a number of applications of the inverse piezoelectric effect, one of the most well
known being the use of piezoelectric crystals as actuators. As the movement, or change in
dimensions, of a piezoelectic crystal can be controlled down to sub-micrometre accuracy,
they are extensively used to position other objects with a high precision. One of the
most notable applications is the atomic force microscope (AFM), which uses a number of
piezoelectric crystals as actuators to bring the sensing cantilever tip down in contact with
the sample, but also to move the sample stage itself in two dimensions in order to scan an
area of the sample.
On the other hand, the direct piezoelectric effect finds a lot of applications in sensing: a
piezoelectric crystal can easily be used to transduce a mechanical vibration into an elec-
tric signal. Provided the perturbation of interest results in a mechanical vibration that
induces enough stress to generate a vibration of the piezoelectric crystal, the resulting elec-
tric signal is a direct indication of the initial perturbation. The most common application
of the piezolelectric effect from a sensing perspective is the detection of sound. Indeed,
the propagation of a sound wave through a medium corresponds to a variation of pressure
(compression and decompression) within this medium. A common example of this applic-
ation are the piezoelectric microphones found below the strings of an electric guitar. The
vibration of the strings generates a sound wave that travels towards the nearby piezoelectric
crystal. The sound wave propagates through the crystal and is transduced into an electric
signal that can then be amplified and sent to a speaker.
Because the phenomenon is reversible, it is possible to make use of both the direct and
inverse effects to induce the propagation of a mechanical vibration in a piezoelectric crystal
using an electric potential, while monitoring the electric signal generated by this mechanical
vibration. This allows the monitoring of the mechanical vibration propagating through the
crystal and forms the basis of most acoustic wave based biosensors, including the one
presented in this thesis. Such biosensors generate and monitor a baseline vibration that
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can be affected by very fine pertubations occuring on the surface of the crystal. [128,129]
These fine perturbations could not be detected using the direct piezoelectric effet only.
The mechanical vibration resulting from the application of an electric potential to the
piezoelectric crystal is characterised by its direction of propagation, as well as the particle
displacement direction, which indicates the direction of movement of the particles when
the wave propagates through the crystal. A piezoelectric crystal can be cut to different
angles with regards to its centre of symmetry and unit structure. The choice of the cut of
the crystal has important consequences for the use of the inverse piezoelectric effect, as it
defines the direction of propagation of the wave through the crystal, as well as the particle
displacement direction. [130] The following section details the main categories of acoustic
wave sensors that have been reported for sensing applications. Depending on the crystal
used and the cut chosen, different modes of acoustic wave propagation are observed. In order
to simplify the notation and compare between modes of operation of the different sensors
presented, all the propagation directions and particle displacement directions mentioned
refer to those as shown in Figure 3.3.
3.1.2 Quartz crystal microbalance (QCM)
The first acoustic wave sensor was reported in 1959 by Sauerbrey. [131] He described a gas
sensor based on a quartz crystal connected to a plate electrode on top and grounded at
the bottom. Applying an electric potential to this system generates an acoustic wave that
propagates as a thickness shear mode (TSM). In this mode, the wave propagates in the x3
direction, and the particles are displaced in a direction contained in the (x1x2) plane, as
can be seen in Figure 3.3.
Sauerbrey’s 1959 paper featured the equation that gives a directly linear relationship
between the shift in frequency and the mass added on the surface of the crystal:
∆f = C∆m, (3.1)
where ∆f is the shift in the acoustic wave frequency before and after perturbation, ∆m
is the mass added to the surface of the crystal and causing the perturbation, and C is a
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material constant that depends on the crystal density, shear modulus and surface area of
the crystal used, as well as the resonnant frequency.
Over the years, QCM has been very popular in the field of gas sensing, with many applic-
ations reported such as the detection of methane, [132] ammonia [133] or nitric oxyde. [134]
QCM was used as a sensor in liquid medium for the first time in 1980, when Nomura and
Minemura reported the application of QCM to detect the presence of cyanide in aqueous
solution. [135] This was a major step towards the use of acoustic wave sensors as biosensors,
most of which require the sample to be in liquid form. A few years later, Kanazawa and
Gordon derived the Sauerbrey equation to relate the frequency shift to viscosity and density
of the liquid. [136] QCM has since then been used for numerous applications, such as the
monitoring of phase transitions in polymers, [137] the study of protein adsorption [138] or the
detection of DNA for diagnosis. [139] However, one of the limitations of QCM is the thickness
of the crystal: the frequency shift in equation 3.1, which is key to the sensitivity of the
device, is inversely proportional to the thickness of the crystal. Therefore, for each type of
crystal, there is a physical limit to how sensitive a QCM can be, which corresponds to the
minimum possible thickness of the crystal used. Other types of acoustic wave sensors have
been developped since the early 1980s, using different modes of acoustic wave propagation.
3.1.3 Interdigitated transducer (IDT) induced surface acoustic waves
A number of other acoustic wave based sensors have been reported over the years, each
of them being associated with a particular type of acoustic wave. Those acoustic waves,
referred to as surface acoustic waves (SAW) differ by their mode of propagation, but have
in common the fact they are induced by IDTs in contact with the crystal. The concept of
IDTs was first introduced by White and Voltmer in 1965. [140] The IDTs play the role of
the electrodes that transduce the electric signal into a mechanical vibration (input IDT)
and vice-versa (output IDT). [141]
An IDT consists of an array of electrodes directly attached to the surface of the piezoelectric
crystal. [130] The array of electrodes consists of an alternation of positive and negative
electrodes. Applying an electric potential to an electrode generates a distortion of the
material around the electrode. Combined with all the electrodes in the array, when applying
an alternative current, the individual distortions construct into a mechanical wave that
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propagates in the crystal. This is schematised in Figure 3.2. As explained above, the mode
of propagation of the acoustic wave generated depends on the crystal type and crystal
cut. The design of the IDT defines the acoustic wavelength λ, as two electrodes of opposite
polarity are separated from each other by a distance of λ. Similarily, the operating frequency
of the device is dictated by the geometry of the IDT. [142] When two IDTs are present (input
and ouptut), the distance in between the two IDTs is called the delay line. Its surface
corresponds to the area of propagation of the SAW, and is also referred to as the sensing
area.
Figure 3.2: Interdigitated transducers. Schematic to illustrate the principle of oper-
ation of IDT. Applying an alternating current to the electrodes of opposite polarity (blue
and red) results in the electric field represented by the yellow arrows. The deformation
of the crystal around each individual electrode creates regions of tension and compression
alternating between the electrodes. The resulting mechanical wave then propagates away
from the IDT. Adapted from Kirschner et al. [143]
Acoustic waves generated by IDT are extensively used in the telecommunications industry.
As a radio wave is emited at a fixed frequency, if the IDT on the SAW device is designed
to operate at this resonance frequency, it will transduce the vibration of the radiowave into
an electric signal. Therefore, such devices are mainly used as frequency filters: out of the
many electromagnetic waves emited in its environment, the acoustic wave device will only
pick the one associated with its operating frequency and translate it into an electric signal.
Some of the different modes of acoustic wave propagation are detailed in Figure 3.3.
A Rayleigh SAW (R-SAW) propagates in the x1 direction, and the particles are displaced
in the x1 and x3 directions. Lord Rayleigh predicted the existence of R-SAW in 1885,
[25]
and the use of a Rayleigh wave based acoustic device as a gas sensor was reported for the
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Figure 3.3: Acoustic wave based sensors. Schematics to illustrate the different
acoustic wave modes of propagation. On each schematic, the green arrows represents the
direction of propagation, the red arrows represent the particle displacement directions.
first time in 1979 by Wohltjen and Dessy. [144] They demonstrated the ability of their sensor
to detect thermomechanical perturbations. They published two additional papers the same
year, one reporting the use of their Rayleigh wave based device as a way to detect phase
transitions in polymers, [145] the other one describing the use of such a device to perform
gas chromatography and detect various polar and non-polar molecules. [146] It was only a
few years later that the same authors published a proposition of an analytical explanation
of their experimental results, [147] based on the perturbation theory applied to SH-SAW
described later.
In 1987, Moriizumi et al. [26] reported the use of a leaky Shear Horizontal SAW (SH-SAW)
based device as a sensor in liquid, and also demonstrated a method to estimate the ideal
crystal cut in order to achieve the optimal sensitivity for biosensing applications. A SH-
SAW propagates in the x1 direction, particles are displaced in the x2 direction. The bio-
sensor presented in this thesis is based on a SH-SAW device. An approach to understanding
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the theory behind the sensing mechanism of SH-SAW devices was proposed by Auld [148]
and further refined by Kondoh et al. [149] A detailled description of the approach is provided
in the next section.
The use of Shear Horizontal Acoustic Plate Mode (SH-APM) as a sensor was first reported
by Ricco and Martin in 1987, when they described a device capable of measuring the
viscosity of liquid samples. [150] Later on that year, SH-APM was reported to be used as
a chemical sensor, for the detection of Cu2+ ions. [151] In this configuration, the acoustic
wave propagates in the x1 and −x3 directions, while the particles are displaced in the x2
direction.
In the Flexural Plate Wave (FPW) mode, the acoustic wave, also called a Lamb Wave,
propagates in the x1 and −x3 directions, and the particles are displaced in the x1 and x3
directions. In this configuration, the sensing surface is on the opposite side of the IDTs,
which adds complexity to the design of the device as it requires the crystal to be mounted
on a support, as can be seen in Figure 3.3. Indeed, the particles located in the section
formed between the IDTs on the opposite surface of the crystal have to be be able to be
displaced without being in contact with anything other than the sample. The use of a
Lamb Wave sensor was first reported by White and Wenzel in 1988. [152]
A leaky SH-SAW, which propagates both along the surface (x1 direction) and inside the
crystal (−x3 direction) can be transformed into a pure SH-SAW by adding a thin film
of a different material on the surface of the crystal, in between the IDTs. The resulting
wave, called a Love Wave, only propagates in the x1 direction, while the particles are
displaced in the x2 direction, as in the pure SH-SAW mode. To achieve this result, the
velocity of the acoustic wave through the guiding layer on the surface has to be significantly
smaller than the velocity of sound in the crystal below. The first sensor using a Love Wave
was reported in 1992 by Gizeli et al. [27] Since then, a number of biosensing applications
have been reported, for example the monitoring of adsorption of phospholipids [153] or the
detection of nucleid acids. [154]
3.1.4 Clinical applications of acoustic biosensors
Acoustic wave-based sensors have been used to detect the presence of a number of pathogens
in clinical samples. A study by Berkenpas et al. presented the detection of Escherichia
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coli O157:H7, present in food and water samples and responsible for severe diarrhea or
kidney failure. [155] They obtained their results using a prototype system which is a first
step towards a point-of-care test. Detection of the same pathogen was also detected by
Deobagkar et al. using a SH-SAW sensor. [156] Howe and Harding also reported the use of
a Love-wave device to quantitatively detect the presence of Legionella and E. Coli. [157]
Applications of acoustic wave-based sensors for viral infection diagnosis have also been
reported. A number of such applications involve using QCM to detect the presence of
avian influenza virus H5N1, [158,159] fish pathogenic virus (VHSV), [139] dengue virus, [160] or
more recently, hepatitis B. [161] Wang et al. demonstrated the use of a leaky SAW sensor
to detect the presence of human papilloma virus and quantify the levels of virus in human
samples, and reported a good agreement between their results and a more conventional
PCR-based method. [162] Hepatitis B surface antibodies (HBsAb) can also be detected in
whole blood samples, according to a study by Lee et al. [163]
The detection of presence of a number of biomarkers in human samples, down to clinic-
ally relevant concentrations, can be achieved using acoustic wave biosensors. Gizeli et al.
combined a SAW sensor and microfluidics to build a system able to detect multiple cardiac
markers in order to inform cardiovascular risk assessment. [164] Martin et al. demonstrated
the use of QCM for cholesterol determination in clinical samples, [165] while Yao et al. used a
SAW resonnator to analyse the amount of urease in whole blood samples, using the relation
between frequency shift and the solution conductivity. They showed the results obtained
with the biosensor compared favourably to gold standard methods and could therefore be
used for diagnostic purposes. [166].
Acoustic wave sensors can also be used to detect genetic mutations in DNA. Gronewold et
al. disentangled the mass and viscosity contributions of the signal measured using a Love-
wave sensor to detect individual point mutations in DNA fragements of genes associated
with cancer. [167] Another interesting application that was reported is the estimation of
blood pressure. Ye et al. reported the modelling and fabrication of a series of SAW devices
that can be used to evaluate the pressure of blood, in the hope this can be implemented to
a wireless and passive implantable blood pressure device. [168]
The work presented in this thesis explores the use of a SH-SAW device as a biosensor.
This was justified by the fact SH-SAW devices meet most of the criteria for the ideal
PoCT for HIV presented in Chapter 2. They are already mass-manufacturaed for the
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telecommunications industry, therefore their production cost is low enough to consider them
disposable. As will be shown in the following chapters, they can be enginereed to detect
biomarkers of HIV infection with very high sensisitivty and specificity, in a very simple one
step test. Additionally, they offer the potential for extremely fast time to result, as will
be described further on. To this date, a number of biosensing applications using SH-SAW
devices have been reported. Kondoh et al. immobilised different enzymes on the surface of
the delay line to detect variations in pH of the solution following enzymatic reaction. [169]
The detection of various antibodies [155,170] and bacteria [157] have also been reported, as
well as the detection of DNA hybridization. [171] In all of these cases, the general principle is
the monitoring of the SH-SAW and how it is affected by the perturbation of interest. The
following introduces the concepts and notations necessary to the study of the perturbation
of a SH-SAW.
3.2 Perturbation of a Shear Horizontal SAW
3.2.1 Parameters of interest and notations
A sensor measures the variation of one or more parameters. Those parameters vary follow-
ing the nature and intensity of the perturbations occuring at the sensor proximity or, in
the case of this thesis, on the sensor surface. In the following calculations, the indexes 0
and 1 are used to describe a given parameter before and after a perturbation has occured
on the surface:

W0 describes the parameter W before perturbation
W1 describes the parameter W after perturbation.
(3.2)
The wave velocity V (m.s−1) can be defined as:
V =
λω
2pi
= λf, (3.3)
where λ (m) is the wavelength, ω (radian.s−1) is the angular frequency and f (s−1) is the
frequency.
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The wave angular frequency ω, expressed in radians or in degrees, is linked to the wave
frequency f by the relation:

ω = 2pif (rad)
ω = 360f (deg).
(3.4)
In the particular case of the device used here, the frequency is fixed, therefore in the fol-
lowing no indices will be attributed to the notation f or ω (f0 = f1 = f and ω0 = ω1 = ω).
This is due to the choice of electric circuit used to drive the crystal and monitor the para-
meters, and is detailed further on.
The wave number k0 (m
−1) can be described using the wave angular frequency ω, the
wavelength λ and the wave velocity in the crystal V :
k0 =
2pi
λ
=
ω
V
. (3.5)
The acoustic wave is characterised by its complex propagation factor β, which can be
defined as [172]:
β = α+ jk0, (3.6)
where k0 is the wave number, α is the attenuation coefficient and j is the imaginary unit
satisfying the equation j2 = −1.
If we define the difference in complex propagation factor ∆β before and after perturbation
as:
∆β = β1 − β0, (3.7)
then the following expression of the difference in complex propagation factor ∆β normalised
by the wave number k0, can be derived, assuming that the change in velocity is comparibly
negligible with respect to the initial velocity (∆V  V0): [172]
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∆β
k0
=
∆α
k0
− j∆V
V0
. (3.8)
The imaginary part
∆V
V0
and real part
∆α
k0
will be referred to as velocity change and
attenuation change (respectively). Those two parameters contain useful information for
the analysis of the propagation of an acoustic wave submitted to perturbations. They are
the key parameters involved in the perturbation theory applied to SH-SAW devices, which
is presented below.
3.2.2 Perturbation theory, applied to SH-SAW
In 1973, Auld applied the perturbation theory to the problem of solving the propagation of
an acoustic wave launched on the surface of a piezoelectric crystal. He derived a relation
between the complex propagation constant defined in equation 3.6 and the acoustic wave
equation. [148] In 1993, Kondoh and Shiokawa applied Auld’s work to the specific case of a
SH-SAW device sensing perturbations in a liquid sample. They derived a relation between
some of the wave parameters (velocity change and attenuation change) and some of the
sample characteristics, presented below. [173]
The first set of equations corresponds to a viscosity perturbation, which means the SH-
SAW is perturbed by a change in viscosity only on the surface of the delay line. The
assumptions that lead to the following expression of the velocity change and attenuation
change are that the acoustic wave propagates in a pure SH-SAW mode, and that the sample
on the surface of the delay line is a Newtonian fluid. Under these assumptions:
∆V
V0
= −V0v
2
2
4ωP
(√
ωρ1η1
2
−
√
ωρ0η0
2
)
, (3.9)
∆α
k0
=
V0v
2
2
4ωP
√
ωρ1η1
2
, (3.10)
where V0 and k0 are the velocity and wave number (respectively) before perturbation, v2
is the particle velocity in the displacement direction x2, ω is the angular frequency, P is
the sample power flow, ρ0 and η0 are the sample density and viscosity (respectively) before
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perturbation. ρ1 and η1 are the sample density and viscosity (respectively) after perturba-
tion.
The second set of equations in the perturbation theory appplied to SH-SAW refers to a
mass perturbation. This means that the propagation of the SH-SAW is attenuated by the
formation of a thin film on the surface of the delay line. Once again, the acoustic wave is
assumed to propagate in a pure SH-SAW mode. In addition, the thin film formed on the
surface of the delay line is assumed to be uniform and isotropic, and the material that it
consists of is assumed to be a hard material. Under these assumptions, the velocity change
and attenuation change can be expressed as:
∆V
V0
= −V0h
4P
(
ρ1 − µ1β
2
ω2
)
v22, (3.11)
∆α
k0
= 0, (3.12)
where h is the thickness of the film deposited on the surface, µ1 is the Lame´ constant of
the film formed on the surface and β is the complex wave number.
A third set of equations gives an estimation of the electric perturbation however it is not
applicable here as the biosensor features a thin gold layer on top (see Chapter 4) that acts
as an electric shield for the crystal. Therefore the SH-SAW cannot be perturbed electric-
ally. Finally, an additional set of equations was derived by Kondoh et al. [174] to express the
velocity change and the attenuation change following a perturbation of the viscoelasticity
at the proximity of the crystal surface.
The velocity change and the attenuation change are the key parameters in the perturb-
ation theory applied to SH-SAW. Taking into account the assumptions that led to their
expression, they provide information about the perturbation of interest. In the following,
the exact approximation of the two parameters presented in equations 3.9 to 3.12 (as well
as the set of equations proposed by Kondoh et al.) will not be used as such as they require
some assumptions that are not matched by the perturbations of interest in the context of
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a biosensor. As an example, the binding of proteins to the surface of the delay line is very
unlikely to drive the formation of a hard, uniform isotropic thin film.
However, the fact that these equations show that the two parameters are directly linked
perturbations occuring on the surface of the delay line is key to justify the results presented
in Chapters 5 to 8. Indeed, the perturbation caused by the binding of proteins to the
surface of the delay line is likely to consist of a combination of the simple perturbations
considered in the perturbation theory described above (viscosity and mass). Because the
velocity change and the attenuation change are not directly measurable, it is essential to
relate them to measurable parameters in order to be able to monitor the perturbation,
and possibly extract information about the nature of the perturbation. The following
demonstrates how to express the velocity change and the attenuation change as a function
of measurable parameters.
3.3 Expressing the key parameters of the perturbation the-
ory applied to SH-SAW as a function of measureable
parameters
3.3.1 Relation between Velocity and Phase shift
The phase shift φ corresponds to the difference in phase between the initial electric signal
applied to the input IDT, and the electric signal measured at the output IDT after con-
version of the acoustic wave back into an electromagnetic wave. The phase shift is defined
as:
φ =
ωL
V
, (3.13)
where L is the length of the delay line. Therefore, the output phase shifts φ0 and φ1 before
and after perturbation (respectively) can be expressed as:

φ0 =
ωL
V0
φ1 =
ωL
V1
.
(3.14)
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If we define the difference in output phase shift before and after perturbation as:
∆φ = φ1 − φ0, (3.15)
and the difference in wave velocity before and after perturbation as:
∆V = V1 − V0, (3.16)
then the following relation can be obtained, assuming that the change in velocity is com-
paribly neglegible to the initial velocity (∆V  V0):
∆φ
φ0
= −∆V
V0
. (3.17)
From equation 3.17 and the definition of φ0 in equation 3.14, the relation between the phase
change and the velocity change can be derived:
∆V
V0
= − V0
ωL
∆φ = − V0
2pifL
∆φ. (3.18)
Note: The value of the initial wave velocity V0 can be modelled knowing the design of the
input IDT.
3.3.2 Relation between Attenuation and Amplitude
The amplitude A of a plane acoustic wave propagating through a crystal decays as a function
of the distance x, which is expressed by the equation:
A = A0e
−αx, (3.19)
where A0 is the initial amplitude and α is the attenuation coefficient.
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The output amplitude Aout of a SH-SAW device characterised by a driving amplitude Ain
and a delay line of length L can therefore be expressed as (assuming the SH-SAW propagates
purely in one direction):
Aout = Aine
−αL. (3.20)
If we define α0 and α1 as the attenuation coefficients before and after perturbation (re-
spectively), then the output amplitudes A0out and A
1
out before and after perturbation (re-
spectively) can be expressed as:

A0out = Aine
−α0L
A1out = Aine
−α1L.
(3.21)
If we define the attenuation change ∆α as:
∆α = α1 − α0, (3.22)
then it can be expressed, using equation 3.21 as:
∆α = − 1
L
ln
(
A1out
A0out
)
, (3.23)
which leads to the expression of the attenuation change:
∆α
k0
= − 1
k0L
ln
(
A1out
A0out
)
. (3.24)
Conclusion: Both key parameters in the perturbation theory applied to SH-SAW, the
velocity change and the attenuation change, can be expressed as a combination of known
quantities and the two measurable parameters that are the phase shift φ and the output
amplitude Aout. The results obtained using the SH-SAW device and presented in Chapters
5 to 8 were obtained by monitoring φ and a parameter called the insertion loss (IL). The
insertion loss is directly related to Aout, as will be shown in the following section.
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3.4 Monitoring the phase shift φ and insertion loss IL : elec-
tric circuit
Depending on the design of the electric circuit used to drive the SAW device, different
parameters can be monitored. There are two main types of circuits used: phase fixed
circuit, and frequency fixed circuit. In a phase fixed circuit, one of the measured outputs is
the frequency shift. This requires a feedback loop that allows the signal generator to adapt
the input signal in order to fix the phase shift to 0. In other words, this type of circuit
monitors the frequency shift needed to achieve a zero phase shift despite the perturbation
occuring on the surface of the delay line. The insertion loss is also an output.
The electric circuit used to obtain the results presented in this thesis is a frequency fixed
circuit. The output parameters are the phase shift φ and the insertion loss IL. A schem-
atic of the circuit is shown in Figure 3.4, and the following section details the differents
components on this schematic.
Input 
IDT
Output 
IDTDelay line
Acoustic
wave
Electromagnetic
wave
Electromagnetic
wave
Sin
𝜙, ILSin
Sout
Smix S’mix
VM ICLPF
Sout
Sin
Figure 3.4: SH-SAW electric circuit. Schmatic of the electric circuit used to monitor
φ and IL. The SH-SAW device receives the input signal Sin at the input IDT. The
electromagnetic wave is transduced into an acoustic wave which travels along the delay
line, before being transduced back into an electromagnetic wave at the output IDT. Sin
and the output signal Sout are multiplied together by the voltage multiplier VM. The
resulting signal Smix goes through a Low Pass Filter to eliminate the high frequency term
of Smix. The resulting signal S
′
mix is sent to the integrated circuit IC, which perfoms the
operations to output the phase shift φ. Both Sinand Sout are also sent directly to the IC,
which perfoms the operations to output the insertion loss IL.
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3.4.1 Phase shift
Monitoring the phase shift φ is the result of a process that involves an integrated cir-
cuit to perform operations on electrical signals. The signal sent to the input IDT is an
electromagnetic wave that can be described as:
Sin = Ain cos (ωt), (3.25)
where Ain is the amplitude of the input signal, measured at the input IDT.
As explained earlier, after being converted into an acoustic wave, travelling along the delay
line between the IDTs and converted back into an electromagnetic wave, the wave has been
submitted to a phase shift φ and an amplitude change. This is illustrated in Figure 3.5 at
the end of this section. The output signal has the form:
Sout = Aout cos (ωt+ φ), (3.26)
where Aout is the amplitude of the output signal, measured at the ouput IDT.
As can be seen in Figure 3.4, the input signal and the output signal are multiplied in a
voltage multiplier. The resulting signal, called Smix, can be expressed as:
Smix = γSinSout, (3.27)
where γ is a constant which depends on the configuration of the voltage multiplier.
Smix can be derived as:
Smix = γAinAout cos (ωt) cos (ωt+ φ)
=
γ
2
AinAout[cosφ+ cos (2ωt+ φ)].
(3.28)
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The term cos (2ωt+ φ) represents a high frequency signal. It is filtered out using a Low
Pass Filter (LPF). Therefore, the remaining signal S′mix after the voltage multiplier and
the LPF can be expressed as:
S′mix =
γ
2
AinAout cos (φ). (3.29)
The amplitudes Ain and Aout are measured directly at the input and ouput IDT (respect-
ively). The phase shift φ can therefore be extracted from the signal Smix measured at the
output IDT using the integrated circuit to perfom the following operation:
φ = arccos
(
2S′mix
γAinAout
)
. (3.30)
3.4.2 Insertion loss
3.4.2.1 Definition of the insertion loss
To introduce the concept of insertion loss, it is important to define the decibel (dB) unit.
A decibel is a relative measure of two different power levels. It is used for quantifying the
gain G (or loss, if the gain value is negative) of one device in relation to another one. It
is not an absolute number, but a ratio. The formula for calculating the gain between two
devices of respective electrical powers P1 and P2 is given by:
G = 10 log10
(
P1
P2
)
. (3.31)
In the particular case of comparing the output power Pout to the input power Pin of a
device, the gain will be defined as:
G = 10 log10
(
Pout
Pin
)
. (3.32)
If Pout > Pin, it is common to use the term gain, while if Pout < Pin, it is more common to
use the term loss. For example, if:
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Pout
Pin
= 10−3, (3.33)
it is common to say the device is characterised by a loss of -30dB.
In the particular case of the SH-SAW device used in this work, the loss of electrical power
is caused by the presence of the sensor in the circuit: the amplitude of the electromagnetic
wave measured at the ouput IDT is attenuated compared to the one sent to the input IDT.
This simply corresponds to an attenuation of the acoustic wave amplitude as a consequence
of being exposed to a perturbation. This is illustrated in Figure 3.5 at the end of this section.
In the case of an alternating current (AC), the electric circuit power P (measured in Watt,
W , averaged over a period of time proportional to the the wave time period), is defined in
relation to the electric current I (Ampere, A), electric voltage Ev (Volt, V ) and the circuit
resistance R (Ohm, Ω):
P =
E2v
R
= IR. (3.34)
In the circuit used in this thesis, the input signal is a sinusoidal wave that can be described
by the simple wave function:
z(t) = Ain cos (ωt). (3.35)
Although the electrical power can not be measured directly, the amplitude is a measurable
parameter as it corresponds to the electric voltage. By measuring the output voltage
(Ev)out, it is therefore possible to calculate the absolute output power Pout using equation
3.34 and then the loss due to the presence of the device in the circuit.
Note: In the particular case of the electric circuit used in this thesis, the circuit resistance
R is equal to 50Ω and the input power Pin is 1mW . Therefore, using equation 3.34, the
input voltage (Ev)in, or driving amplitude Ain can be calculated:
Ain =
√
RPin = 223mV. (3.36)
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3.4.2.2 Expression of the insertion loss
The insertion loss IL corresponds to the loss of electrical power in the circuit, which ac-
cording to equation 3.32 can be expressed as:
IL = 10 log10
(
Pout
Pin
)
. (3.37)
Combining with equation 3.34, this transforms into:
IL = 20 log10
(
Aout
Ain
)
. (3.38)
The insertion loss can therefore be monitored by measuring Ain and Aout. The change in
insertion loss ∆IL following a perturbation can then be defined as:
∆IL = IL1 − IL0. (3.39)
Since the input amplitude Ain is constant regardless of the perturbation, combining equa-
tions 3.38 and 5.2 leads to:
∆IL =
20
ln (10)
ln
(
A1out
A0out
)
. (3.40)
Finally, combining equations 3.24 and 3.40 leads to the following expression of the insertion
loss:
∆IL = − 20
ln (10)
∆αL. (3.41)
It was therefore shown that monitoring the amplitude at the output IDT Aout is directly
related to monitoring the insertion loss IL. In addition, monitoring the change in insertion
loss ∆IL before and after a perturbation is an easy way to get an indication of the change
in attenuation coefficient ∆α associated with that perturbation.
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3.4.3 Illustration of the effect of a perturbation on both the electromech-
anical and acoustic wave
As explained above, the principle behind using a shear-horizontal surface acoustic wave
device to detect and quantify a perturbation occuring on the surface of the delay line
relies on the transduction of an electromechanical wave into an acoustic vibration, and
vice versa. By being exposed to a perturbation when in the form of an acoustic wave, the
wave amplitude is attenuated and the wave undergoes a phase shift φ. This concepts is
illustrated in Figure 3.5.
Under the initial state (perturbation 0), which could correspond to the delay line being in
contact with buffer for example, the electromagnetic wave measured at the output IDT (top
left plot, blue line) is characterised by an initial phase shift φ0 from the input signal (black
line) as well as an amplitude A0out that differs from the initial amplitude Ain. This is because
the acoustic wave has been submitted to this first perturbation when travelling along the
delay line (blue line, right hand side plot). Under the next perturbation (perturbation 1)
- which could correspond to a change in sample viscosity, or to the binding of a protein
to the surface of the delay for example - the electromagnetic wave measured at the ouptut
IDT (bottom left plot, orange line) is characterised by a different phase shift φ1 as well as
a different amplitude A1out.
Monitoring the change in phase shift ∆φ and insertion loss ∆IL (based on the measure
of A0out and A
1
out) provides information on what happened at the surface of the delay
line, which corresponds to a change in the perturbation the SAW device was submitted
to. This change in perturbation can be measured from one sample to another. More
interestingly, as φ and Aout can be measured continuously, the change in perturbation can
be monitored continuously within the same sample. In this case, the change in pertubation
occurs over time instead of corresponding to a change of sample. This allows, for example,
the monitoring of proteins slowly binding to the surface of the sensor. Most of the results
presented in Chapters 5 to 8 were obtained using this principle.
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Chapter 4
Materials and Methods
4.1 SAW biosensor prototype
The prototypes of SAW biosensor used during this work consists of three components: (i)
a disposable SAW device; (ii) a control box sending and receiving the signal to and from
the SAW device; (iii) a portable device (smartphone or laptop) with processing power to
analyse the data generated by the control box. This device is also used to power the control
box.
Two versions of SAW biosensors were developed by industrial partners OJ-Bio Ltd. They
are presented in Figure 4.1. The laboratory version, described further on, was used through-
out this work to generate the results presented in Chapters 5 to 8. A more advanced devel-
opment prototype device, containing all the same elements as the laboratory prototype, is
shown in Figure 4.1b and 4.1d, where the SAW biochip is mounted on a disposable cassette
resembling a USB stick and results sent to a smartphone app either via a cable or via
Bluetooth. This prototype was not used for the work presented here.
4.1.1 Laboratory control box
The pocket-sized laboratory control box (14×10×4 cm3) sends and receives an analog signal
to and from the SAW devices, and converts it to a digital signal. Up to four SAW devices
can be connected in parallel to the control box via the four chip holders, allowing for
multiplex detection of different biomarkers and control measurements. The analog signal
75
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Figure 4.1: SAW biosensor prototype: laboratory and development versions.
a) Schematic to illustrate the components of the SAW biosensor laboratory prototype.
The control box sends/receives an analog signal to/from 4 SAW devices in parallel (one
per chip holder), and transmits a digital signal to the laptop. A software processes and
analyses the data. b) Schematic to illustrate the components of the SAW biosensor devel-
opment prototype. The control box sends/receives an analog signal to/from the disposable
SAW devices, and transmits a digital signal to the smartphone. An app processes and
analyses the data, before sending it to public healthcare systems. c) Photograph of the
laboratory control box and 4 chip holders. d) Photograph of the hand-held SAW biosensor
development prototype and disposable SAW device.
generated by the control box and sent to the input IDT is characterised by an amplitude
of 223mV (see calculations in Chapter 3, equation 38) and a frequency of 251.5MHz.
The elements of the electric circuit used by the control box to extract the phase shift and
insertion loss are detailed in Chapter 3. The file ouput by the control box is a .csv file
containing the phase shift and insertion loss measured every second, for each SAW device.
The SAW device described further on was slotted in the chip holder, and samples were
pipetted on and off the surface of the delay line using a manual pipette. An example of the
data output by the control box is presented in Figure 4.2.
4.1.2 OJ15 SAW device
The SH-SAW device referred to as OJ15 SAW device was designed using a quartz crystal
(36◦Y-cut 90◦X-propagation). Quartz was chosen over other commonly used substrates
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Figure 4.2: Example of data output by the laboratory control box. a) Plot to
show the phase shift recorded by the SAW biosensor as a function of time, before and
after sample injection. The effect of the perturbation following sample injection can be
monitored for four SAW devices in parallel. b) Plot to show the insertion loss recorded
by the SAW biosensor as a function of time, before and after sample injection. The effect
of the perturbation following sample injection can be monitored for four SAW devices in
parallel.
(such as lithium niobate or lithium tantalate) as the best compromise between temperature
coefficient and the velocity of the acoustic wave travelling through the substrate. The
temperature coefficient has to allow for measurements to be reproducible within the range
of temperatures of operation. In the case of a PoCT, this corresponds to approximately
0-40◦C.
Each OJ15 SAW device comprises two pairs of IDTs, with a delay line in between each pair
of IDTs. The gold IDTs were evaporated onto the crystal and consisted of 80 finger pairs
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with an aperture of 1mm, exciting a SH-SAW with a wavelength of 20µm at a frequency of
251.5MHz. A 2nm thin film of titanium was evaporated in between the IDTs, followed by
the evaporation of a 90nm thin film of gold to form the delay line. The IDTs were protected
from liquids by a glass lid and epoxy walls, which were constructed using a photolithography
technique as described by Kogai et al. [175,176] A schematic of the different components of
the final device (25×7×2 mm3) is presented in Figure 4.3.
The IDTs were wire bonded to the electrodes at the bottom of the plastic base, which is
then put in contact with the electric circuit comprising the control box once slotted into
the chip holder.
Top view
Bottom view
Printed circuit board 
(PCB)
Quartz crystal
Gold IDTs & delay line
Resin sealing
SU-8 wall
Glass lid
Titanium layer
a
b
Figure 4.3: OJ15 SAW device components. a) Schematic overview of the different
components deposited or formed on top of the quartz substrate. The substrate is fixed to
the printed circuit board (PCB) using imyde resin. For clarity, only one pair of IDTs and
one delay line are represented. Drawings not to scale. b) Schematic to illustrate the top
and bottom views of the OJ15 SAW device. The bottom view features the gold electrodes
that are used to connect the device to the electric circuit, once placed into the chip holder.
A schematic and photograph of the OJ15 SAW device is provided in Figure 4.4. As can be
seen on the schematics in Figure 4.4a, the two delay lines are identical except for the fact
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the lower one features a small pattern in its middle. This pattern is created by etching the
gold during the same step as the formation of the IDTs. The purpose of this feature is to
stop the surface component of the wave. The output IDT of the lower delay line therefore
measure the bulk component of the wave only. This signal can be subtracted from the
signal measured at the output IDT of the top delay line, in order to consider the surface
component of the wave only.
Input IDT Output IDT
Upper delay line 
Surface + bulk signal
Lower delay line 
Bulk signal only
OJ15 SAW device
a b
Figure 4.4: OJ15 SAW device. a) Top view schematic of the OJ15 SAW device,
featuring two identical IDTs and delay lines. The acoustic wave reflects off a pattern
located in the middle of the bottom delay line, leaving only the bulk component of the
wave to reach the bottom output IDT. Both the surface and bulk component of the wave
reach the top output IDT. b) Photograph of OJ15 SAW device measuring 25×7×2mm3.
In the following, a SH-SAW device will be referred to as a SAW device, for simplicity. In
addition, the SAW device described above will be referred to as SAW biochip once the
surface of the delay line has been functionalised with capture proteins, as described further
on.
4.1.3 Different generations of SAW devices
In parallel to the work presented here, industrial partners OJ-Bio Ltd. designed and op-
timised different generations of devices with better sensitivity, or added features. As a
consequence, different SAW devices were used during the course of this work. The results
shown in Chapters 5, 6 and 8 were obtained using OJ15 SAW devices, detailed above,
whereas the results presented in Chapter 7 were obtained using new generations of SAW
devices (OJ24/OJ28/OJ31). A schematic and picture of the latest generation (OJ31) are
presented in Figure 4.5.
These new SAW devices differ from OJ15 SAW devices on two main points. Firstly, they
feature a reflecting wall at one end of the delay line, off which the acoustic wave bounces
before travelling back to the input IDT. This IDT therefore acts both as input and output
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Lower delay line 
Figure 4.5: OJ31 SAW device a) Top view schematic of the OJ31 SAW device, featur-
ing two identical IDTs and delay lines. The acoustic wave reflects off a pattern located at
the end of the delay line, and is directed back to the IDT. A calibration pattern is printed
with gold onto the chip, outside of the delay lines and IDTs, to help the automatic spotter
find its initial position. b) Photograph of OJ31 SAW device.
IDT. The length of the delay line can be divided by two, as the acoustic wave travels
along it twice. This makes the SAW device smaller, and the volume of sample required for
OJ24/OJ28/OJ31 SAW devices is 6µl where the older OJ15 devices required 20µl.
Secondly, the new generations of SAW devices (OJ24/OJ28/OJ31) feature two identical
operational delay lines that can be used as a sensing area, instead of one in OJ15, where
the bottom delay line features a reflector to block the propagation of the acoustic wave on
the surface. This means that one of the delay lines can be used as a reference channel,
provided it is functionalised accordingly. This enables better correction of the signal with
regard to non-specific binding and other undesired effects, as it eliminates possible chip-to-
chip variation. The importance of this feature will be demonstrated in Chapter 7.
For logistical reasons, the results presented in Chapter 7 were obtained using different
generations of SAW biochips. This due to the fact the three generations of SAW biochips
were used chronologically, as they were developed by industrial partners OJ-Bio Ltd. The
minor differences in design between OJ24 and OJ28 SAW biochips (a slight increase in the
IDT aperture length to optimise the air insertion loss, and addition of a printed pattern
around the delay lines to help with the calibration of the automated spotting protocol), and
between OJ28 and OJ31 (line patterning around the delay lines to prevent the liquid from
spreading outside the sensing area) have not been shown to alter the performance (tests
performed by industrial partners OJ-Bio Ltd.). This confirmed that the result obtained on
the new generations of SAW devices (OJ24, OJ28 and OJ31) could be compared to each
other.
Due to the small size and proximity of the two delay lines, the functionalisation process
needed to be adapted. With OJ15 SAW devices, a 20µl droplet of capture proteins could
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be spread across the whole surface of both delay lines, as the same perturbation needed
to occur on both delay lines. With the new generations of SAW devices, however, the
one delay line was in most cases used as a control for the non-specific binding, meaning
the capture protein had to be different on each delay line. When manual functionalisation
using a pipette was experimented at the beginning, it required high dexterity and the
chances of contamination of the other delay line were too high. Industrial partners OJ-Bio
Ltd. developed an automated functionalisation process specifically for the capture protein
functionalisation step. The delay lines were functionalised with DSP following the same
protocol described above for OJ15 SAW devices, then a liquid spotter (Musashi Engineering
Inc, Shotmaster 300DS-s) was used to deliver a controlled 6µl of capture protein solution
on each delay line with high accuracy. The software used to operate the liquid spotter
(Mu-CAD) used the patterns on the outside of the lines for initial positioning.
4.2 Surface functionalisation: transforming a SAW device
into a SAW biochip
The surface of the delay line of the SAW devices presented above was functionalised with
capture proteins in order to detect the target protein in the sample. The functionalisation
process is described below. Once functionalised with the relevant capture protein, the SAW
devices will be referred to in the following and in Chapters 6 and 7 as SAW biochips.
4.2.1 Cleaning the surface of the delay line
5 different cleaning strategies, were used during this work. 4 strategies involved cleaning
the surface of the delay line in situ, by adding and removing various solutions from the
surface of the biochip whilst docked in the chip reader. The different steps involved are
detailed in Table 4.1.
The last cleaning strategy involved soaking the SAW devices in a series of cleaning baths
(30min in each of the following solutions, in order: acetone, 70% EtOH solution, 50% EtOH
solution, deionised water), before taking them inside a plasma chamber (Air plasma, 2mbar,
5min) and then docking them in the chip holder.
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Step # Action
1 Insert SAW biochip in chip reader.
2 Add a 20µl droplet of deionised water on the surface, leave
for 1min.
3 Replace the water by a 20µl droplet of the cleaning solution,
leave for 20min.
4 Replace the cleaning solution by a 20µl droplet of deionised
water, repeat 10 times.
Table 4.1: Protocol for cleaning the gold surface of SAW devices. The different
droplets of liquids are added and removed using a manual pipette. In step #3, the 4
different cleaning solutions testes were: Hellmanex 2% (Hellma Analytics, USA), and 3
solutions of Sodium dodecyl sulphate (SDS) (Sigma, UK) at various weight per volume
concentrations: 1%, 2% and 5%.
4.2.2 Chemical linker - DSP
DSP was purchased from Thermo Scientific Pierce, USA (Cat# 22586). it is not soluble
in water, the common solvent used to dissolve it is dimethyl sulfoxide (DMSO, Cat#
D/4120/PB08, Fischer Chemical, UK). The functionalisation of the surface of the delay
line with DSP was done in situ. A 20µl droplet of DSP in solution (4mg/ml) was left in
contact with the surface of the delay line for 30 minutes. The surface was then cleaned
with 5 addition/removal cycles of 20µl droplets of DMSO, then 10 cycles with 20µl droplets
of PBS (Cat# 14200-067, Life Technologies, USA, diluted 10x in deionised water). Unless
stated otherwise, results presented in Chapters 6 and 7 were obtained using SAW biochips
functionalised using DSP following this protocol.
4.2.3 Capture protein
Once the surface of the delay had been functionalised with DSP, a layer of capture proteins
was formed above the surface. To do so, a 20µl droplet of solution of capture protein in
PBS (100µg/ml) was left in contact with the surface of the delay line for 30 minutes. As
mentioned above, primary amine groups on the structure of the proteins in solution react
with the active head group of DSP to form a covalent bond between the protein and the
DSP molecule. The surface was then cleaned from non-specifically bound protein by 10
addition/removal cycles of 20µl droplets of PBS. A 20µl droplet of TBS-T (Cat# 524753,
Calbiochem, USA, dissolved in deionised water and filter through 0.22µm filter system Cat#
431097, Fischer Scientific UK) was then left in contact with the surface for 15 minutes, in
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order to block the unreacted DSP molecules: the tris molecule contains a primary amine
that reacts with the head group of DSP following the same reaction occurring between
DSP and primary amines on the structure of the capture protein. This is to avoid further
unspecific binding of any protein presenting a primary amine on its structure. An example
of the functionalisation process recorded using the SAW biosensor can be found in Figure
4.6.
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Figure 4.6: Surface functionalisation with capture proteins. Plot to show the
phase shift as a function of time, when functionalisation the DSP-coated surface of the
delay line of the SAW device. The different steps of the process are indicated on the plot.
A baseline was recorded, before injection of the capture solution protein in solution. After
incubation to let the capture protein bind to DSP, the delay line was incubated in TBS-T
to block the unreacted DSP molecules. The TBS-T was then washed 5 times with PBS.
Table 4.2 lists the various capture proteins used during this work along with the corres-
ponding target protein. The source of each protein is also indicated.
4.3 Anti-p24 llama VHH characterisation
In Table 4.2, 59H10 is an anti-p24 llama VHH used as a capture protein for HIV p24. A
representation of the structure can be found in Figure 4.7. 59H10 was produced in-house.
A host bacteria (E. Coli TG1) was used to express the llama VHH sequence contained in
a plasmid (pCAD51-59H10) gifted for this work by Prof. Weiss at UCL. A more detailed
description of the protocol can be found in Appendix A.
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Capture protein Source Target protein
Anti-HSA A0433 (Sigma-Aldrich, USA) HSA
HSA 230-005 (Novozymes Biopharma, USA) Anti-HSA
HIV p24 AG6054 (Aalto Bio Reagents, UK) Anti-24
Anti-p24
BC1071 (Aalto Bio Reagents, UK)
HIV p24
NIH-3537 (AIDS Reagents Program,
USA) [177]
NBS500-473 (Novus Biologicals, UK) [85]
Capricorn HIV 1/2 (Capricorn Products,
USA)
C65489M (Meridian Life Science,
USA) [85]
59H10 (in house)
Anti-GBP5 Ab89284 (Abcam, UK) GBP5
HIV gp41 30-AH26 (Fitzgerald, USA) Anti-gp41
Anti-gp41 AHP2209 (Abd Serotech, USA) HIV gp41
Table 4.2: List of capture proteins used during this work, and source.
Figure 4.7: Structural homology model of 59H10, rendered to show secondary
structure features of the protein (beta-sandwich) in rainbow colouring (blue to red for the
N-terminus to the C-terminus). This is a ’side’ view orientated to examine the CDR3
(complementary determining region) loop, at the top in orange, which is believed to be
integral to p24 ’capture’. Image courtesy of Dr. Jenny Brookes.
4.3.1 In solution characterisation using bio-layer interferometry
BLI is a technique used to observe and quantify the binding of a target protein to a surface.
In this sense, it is comparable to the gold-standard Surface Plasmon Resonance (SPR),
however, BLI is a significantly cheaper technique. The principle of operation is schematised
is Figure 4.8. The probe consists of a glass fibre dipped into the sample solution. A bio-
compatible optical layer is located at the edge of the probe, and its surface is functionalised
with capture proteins. White light is sent through the probe, and is reflected off two
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different surfaces: the glass/optical biocompatible layer interface, and the probe/solution
interface. A photodetector detects the reflected light waves and breaks the signal down into
individual wavelengths signals. The first interface acts as a reference. The reflection off the
second interface depends on the surface composition. Analysing the interferences pattern
between the light waves reflected off the two interfaces results allows the reconstruction the
interferometric profile as a function of time. A shift in the interferometric profile gives an
indication of the amount of proteins bound to the surface of the probe.
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Figure 4.8: BLI principle of operation. a) Schematics to illustrate the BLI glass
probe, with the optical layer on the edge and surface functionalisation with capture pro-
teins on the outside of the optical layer. b) Schematic to illustrate the reflection of the
light waves off two different interfaces: glass fibre/optical layer and probe surface/solu-
tion. c) Schematics to illustrate the interference patterns observed for different individual
wavelengths following reflection off both interfaces. d) Schematics to illustrate the shift in
wavelength observed between interferometric profiles. e) Schematic to illustrate the out-
put of the BLI, the shift in wavelength, which gives an indication of the amount of protein
bound to the probe surface, as a function of time. Adapted from [178]
BLI can be used to either qualitatively asses the best binder between two proteins, or
to quantify the affinity of one protein for another. Two experiments were conducted to
assess which anti-p24 protein to use as the capture protein in the HIV p24 detection as-
says conducted with the SAW biosensor. The instruments used was the model ForteBio
OctetRED96 System (Pall Life Sciences, USA).
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To study the relative affinity of llama VHH to p24, four different llama VHH (59H10,37E7,
59H4 and 48G11) were biotinylated using a commercial biotinylation kit (EZ-Link Sulfo-
NHS-SS-Biotin, Cat# 21331, ThermoScientific, USA). Streptavidin-coated probes (Strep-
tavidin Biosensors (Tray). Product 18-5019, Pall Life Sciences, USA) were functionalised
with different biotinylated llama VHH following the ForteBio designated protocol.
To study binding affinity, BLI probes (Amine Reactive Second Generation (AR2G) Bio-
sensors (Tray). Product no. 18-5092, Pall Life Sciences, USA) were functionalised with
each anti-p24 protein using NHS-EDC chemistry following the designated ForteBio pro-
tocol, then dipped in solutions of p24 in kinetics buffer (Kinetic Buffer 10X. Product no.
18-1092-dilute in PBS, Pall Life Sciences, USA) at various concentrations.
4.3.2 Functionalised surface characterisation with XPS
XPS is a technique used to analyse the elemental composition of a surface. A beam of X-
rays of known energy is focussed on the surface of the sample to analyse. The energy of the
irradiating photons excites the electronic state of the atoms on the surface, down to about
20 atomic layers. The excited electrons, ejected from the surface, are then filtered through
a hemispherical electron analyser and their kinetic energy is recorded by a detector. The
binding energy of the electron before their ejection from the surface is a direct indication
of which atoms are present on the surface and how they are bound together. The binding
energy is calculated knowing the emitting photon energy, the measured electron kinetic
energy, and a factor that depends on the spectrophotometer characteristics. An energy
spectra is obtained, which gives the count of electron per second (CPS) as a function of the
binding energy. A schematic of the principle can be found in Figure 4.9.
The binding energy of most atoms depending on the chemical bond they are involved in
is documented in the literature. The relative percentage of each atom of interested can
therefore be estimated by fitting the peaks of energy and comparing it to the literature
values. The software that was used to obtain the results below is CasaXPS.
The delay line of the SAW devices characterised with XPS was cleaned and functionalised
following the same protocols (described above) used to clean and functionalise the delay
line of the SAW devices that were transformed into SAW biochips capable to detect the
presence of HIV p24 in solution. After functionalisation, the SAW biochips were immersed
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Figure 4.9: XPS principle of operation. Schematics to illustrate the principle of
operation of XPS. A beam of X-rays is focussed on sample surface. The excited electrons
are ejected from the surface, filtered through the electron analyser and hit a detector
which records their kinetic energy. An energy spectra is obtained, which gives the count
of electron per second (CPS) as a function of the binding energy. Adapted from [179]
in deionised water and stored at 4◦C for 24 hours. Measurements were performed at the
NEXUS lab at Newcastle University, UK. The XPS used was the model Theta Probe
(Thermo Scientific, East Grinstead, UK) characterized by a monochromatic Al k-alpha
X-ray source with a pass energy of 40eV and dwell time of 100ms. The pressure in the
chamber was kept at 3.10−8mbar during the measurements. The focused beam hit the
sample surface as an elliptical spot of dimensions 400µm×800µm.
4.4 Gold nanoparticles functionalisation with antibodies
1ml of 20nm gold nanoparticles (Cat# 741965, Aldrich Chemistry, USA) were added to
a 2ml Eppendorf tube, and mixed with 100µl of a 40µg/ml solution of the antibody of
interest (in PBS). The solution was incubated for 20 minutes at 25◦C at 650 rpm. 100µl
of BSA 1 mg/ml diluted in deionised water were added to the tube. The solution was
incubated for 20 min at 25◦C at 650 rpm, before being centrifuged at 14000 rpm for 20
min at 4◦C. As much of the supernatant as possible was removed manually using a pipette.
The functionalised nanoparticles were then resuspended in 300µl of PBS.
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4.5 ELISA
PVC microtitres plates (Cat# 655001, GBO GmbH, Germany) were coated with a recom-
binant protein able to form a complex with the biomarker of interest. The surface was then
blocked with a solution of BSA (Cat# B4287, Sigma Life Science, USA) in PBS (2% w/v)
to avoid non-specific binding. The unknown sample was injected into the well at this point.
Calibration samples containing the biomarker of interest at different known concentrations
were run in parallel, in order to generate a calibration curve. After specific binding of the
biomarker of interest to the plate, a solution of detection antibody (HRP-tagged anti-human
antibody, A8667, Sigma Life Science, USA) was injected into the wells in order to tag the
bound biomarkers. Finally, a substrate (TMB solution, Cat# 00-4201-56, eBioscience, Inc.
USA) was made to react with the HRP, and the reaction was stopped using a solution of
sulphuric acid (0.2M H2SO4). The absorbance of the solution in each well was measured
for an emission wavelength of 450nm using a SpectraMax i3 (Molecular Devices Ltd., UK).
The absorbance of each well was normalised to a blank reading. The linear regression in the
linear region of the calibration curve was used to estimate the concentration of unknown
samples.
4.6 Clinical pilot studies data processing
As mentioned earlier, the control box outputs a file containing the phase shift and the
insertion loss as a function of time, for each SAW device. In the case of the new generations
of SAW devices featuring two operational delay lines, the file contains the data for each delay
line. When performing the pilot studies presented in Chapter 7 involving testing between
one to two hundred samples, the amount of data generated were too big to manually process.
An algorithm was therefore written in Wolfram Mathematica to handle these large amount
of data. The algorithm essentially imports the output file and processes it to make it easier
to visualise it in several ways. The process is described below, and the algorithm can be
found in Appendix B.
The first step of the algorithm is an initial loop where each iteration imports and processes
a different file. Processing involves:
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• Cleaning the data: selecting only the phase shift and insertion loss for each delay
line, normalising them to the beginning of the test, i.e. from sample injection, and
splitting the table, which contains the data of two or four SAW devices, into two
tables of similar dimensions, each one corresponding to one SAW device.
• Subtracting the reference delay line values from the test delay line values, for every
time point.
• Extracting the sample name and status (known positive, known negative or calibra-
tion sample) from the file name and associating it with the corresponding data.
• Merging all the individual tables obtained into a large one. At this point in the
algorithm, the program has in memory a table where each entry contains the sample
name and the test data (phase shift and insertion loss as a function of time).
A crucial step of the analysis was to evaluate the threshold used to distinguish between a
positive and a negative sample. It was decided to define this threshold using the average and
standard deviation of the measurements taken using calibration negative samples (pooled
confirmed HIV negative human plasma from LEEBIO Inc., USA). Depending on the number
of standard deviations added to the mean, this means that a certain percentage of the
measurements performed on negative samples have fallen under this threshold (assuming
the data is normally distributed, see Chapter 7). Provided the number of negative samples
is sufficiently large (usually about 20 is sufficient to assure normality), this can be expanded
to assume that the aforementioned percentage of the true negative samples measured with
the test will be correctly declared as negatives. As the calibration samples were run using
exactly the same protocol as the actual tests, a threshold value can be defined at every
point in time during the test protocol. At this point, it is possible to visualise the data in
a variety of ways, illustrated in Figure 4.10:
• Plotting the raw phase shift as a function of time, for any sample (Figure 4.10a).
• Representing the data of the whole pilot study as a barchart where results falling above
the threshold are displayed in green bars while those falling below the threshold are
displayed in grey bars (Figure 4.10b).
• Plotting the calculated clinical sensitivity and clinical specificity of the test, as a
function of time (Figure 4.10c).
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Figure 4.10: Examples of data visualisation. a) Raw phase shift plotted over time
for a given sample. Any sample in the study can be visualized individually by selecting its
number in the dialog box above the graph. b) Example barchart showing the phase shift
recorded by the SAW biosensor after a given time (t=138s). Each bar represents one test.
For clarity, a colour is associated to each bar depending on whether the recorded value
for the differential phase shift is below (grey) or above (green) the threshold for the time
considered (represented by the red line). In other words, a grey bar represents a sample
declared negative by the test, whereas a green bar represents a positive test. The results
can be visualized at any given time using the dialog box above the chart. c) Example plot
to show that the sensitivity and specificity can be calculated at any point in time.
Chapter 5
SAW Device Characterisation
The theory of perturbation applied to SH-SAW devices was presented in Chapter 3, along
with a general introduction to SAW devices and the state of the art of their application as
various biosensors. In Chapter 4, the particular prototypes of SAW devices used throughout
this work were described, with a particular emphasis on the OJ15 SAW device which was
used to obtain the majority of the results presented in the next chapters. In addition, the
prototype of control box used to drive the SAW device was presented, along with the details
of how it outputs the two main measurement parameters that are the acoustic wave phase
and amplitude, which are directly related to the acoustic wave velocity and attenuation,
respectively. This chapter presents the careful characterisation of the OJ15 SAW device, a
necessary step before using it to obtain all the results presented in the next three chapters.
Most of the characterisation results presented here apply to the next generation SAW
devices used at the later stages of this work (OJ24 and OJ31). The OJ15 SAW device
was characterised from three different approaches, consecutive and complementary to each
other. First, it was decided to study the sensitivity of the device from a theoretical point
of view, and use this analysis to show experimentally that three of the main characteristics
of the device contribute to confer it an optimal sensitivity in the context of being used
for biosensing applications. The three parameters studied were the driving frequency, the
length of the delay line, and the strategy used to cancel out the bulk component of the
signal in order to focus only on the surface component. Then, a second study focussed
on assessing the influence of the surface coverage of the delay by the liquid sample on the
output signal, and the possible consequences in relation to the future SAW biosensor being
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used as a PoCT. Finally, the reproducibility of the measurements taken with the SAW
device was assessed, with the idea that each SAW device had to be considered disposable
-and was treated as such during this work- as well as the fact the prototype control box used
allowed four different measurements to be taken at the same time, therefore introducing a
possible variable between measurements.
5.1 Optimising device design to improve sensitivity
The optimal value of some parameters of a SAW device can be estimated theoretically,
during the design process and before going into manufacture. The operating frequency,
geometry of the IDTs, length of the delay line and strategy used to eliminate of attenuate
the impact of bulk wave vibrations on the output signal are all examples of key parameters
that influence the device performance. Estimating the optimal conditions when designing
the device saves a lot of time and cost associated with a trial-and-error approach, where
a lot of different prototypes featuring different values of these key parameters would have
to be manufactured, tested and most of them discarded based on the results of these tests.
However, the ideal SAW device cannot be modelled perfectly and eventually, a small number
of prototypes have to be compared to each other in the lab. It is a common practice to
perform simple tests on different prototypes featuring different versions of key parameters,
in order to verify the initial hypothesis, optimise the parameters tested and at the same
time characterise the device.
5.1.1 Insertion loss and sensitivity
A common target associated with the design of a good SAW device is its sensitivity. The
definition of sensitivity can describe different concepts depending on the context in which
the term is used: the clinical sensitivity of a PoCT, as presented in Chapters 4 and 7, relates
to the proportion of samples in a panel correctly identified as either positive or negative to
the biomarker of interest, and has got a very different meaning to the sensitivity of a SAW
device.
The following explanations and results focus on the sensitivity of the SAW device, defined
as the magnitude of the response the SAW device produces to a given perturbation. This
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response takes the form of the attenuation of the acoustic wave amplitude observed between
the input IDT and the output IDT, when the wave travels along the delay line (sensing
area). This is called the insertion loss (IL) and is, in this context, directly associated with
the device sensitivity.
The difference in insertion loss (∆IL) measured before (IL0) and after (IL1) a perturbation
occurs on the surface of the delay line was expressed by equation 3.41 in Chapter 3 as:
∆IL = − 20
ln (10)
∆αL, (5.1)
where L is the length of the delay line and ∆α the difference in attenuation coefficients
before (α0) and after perturbation (α1). ∆IL and ∆α are defined respectively as:
∆IL = IL1 − IL0, (5.2)
∆α = α1 − α0. (5.3)
Therefore, if we consider the particular case where a sample is added onto the surface of the
dry delay line exposed to air, and generates a perturbation, the following general relation
can be derived:
ILsample = − 20
ln (10)
(αsample − αair)L+ ILair. (5.4)
The value of the attenuation coefficient α depends mainly on the characteristic of the
sample on the surface of the delay line. The attenuation coefficient in air αair is negligible
compared to the attenuation coefficient of any sample. The presence of obstacles such as
SU-8 walls or gold on top of the crystal explain the insertion loss observed in air (around
-20dB for OJ15 SAW devices). It can be approximated that at a given frequency, ILair is
a constant that depends on the design of the device (IDTs and SU-8 walls) but not on the
length of the delay line. The following expression of ILsample can therefore be expressed,
for any sample other than air:
Chapter 5. SAW Device Characterisation 94
ILsample = − 20
ln (10)
αsampleL+ ILair. (5.5)
5.1.2 Theoretical range of values for the insertion loss
The insertion loss only takes negative values. This is confirmed by equation 3.38 in Chapter
3, which gives the expression of the insertion loss as a function of the amplitude measured
at the input and output IDT (Ain and Aout respectively):
IL = 20 log10
(
Aout
Ain
)
. (5.6)
As the amplitude of the acoustic wave can only be attenuated when the wave travels through
the crystal (or in the ideal case of a perfectly designed device, remain unperturbed), the
following relation for the ratio of amplitudes is true for any sample:
Aout
Ain
≤ 1. (5.7)
The theoretical range of values the insertion loss can take is plotted as a function of the
ratio in Figure 5.1, confirming that it only takes negative values (or zero in the case of an
ideal device, measuring the insertion loss in air).
In the following, references to the size of the insertion loss are made in terms of absolute
value of the insertion loss: when comparing two values, the one referred to as the smallest
one is the one closest to zero.
5.1.3 Optimal operating frequency: minimising ILair
The first indicator of performance of a SAW device is its ability to minimize the insertion
loss in air. If a large insertion loss is required when testing a sample with the SAW device
(as it is directly related to the perturbation caused by the sample), a minimal insertion loss
is required in air. A crude way to look at it is the smaller the insertion loss in air, the more
signal there is to lose when a perturbation occurs on the delay line. This loss of signal is
the SAW device response to the perturbation, so the bigger it is, the better.
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Figure 5.1: Theoretical range of values for the insertion loss IL. Plot to show
the theoretical values the insertion loss (measured in dB) can take. The expression of the
insertion loss presented in equation 5.6 was plotted as a function of the ratio of amplitudes
measured at the output and input IDT, respectively. The insertion loss can theoretically
vary from −∞ to zero.
The insertion loss can be measured for a range of different frequencies using a network
analyser. This is useful to choose the best operating frequency, i.e. the frequency to use to
drive the crystal in order to obtain the minimum insertion loss when operating the SAW
device in air. Such measurements were performed on OJ15 SAW devices at Japan Radio
Company, (Kamifukuoka, Japan). The network analyser used for the measurements was
the model 8753D (Hewlett Packard, USA). The insertion loss is plotted as a function of the
driving frequency in Figure 5.2.
Note: As dual channel SAW devices (OJ24 and OJ31) had not been manufactured at the
time, it was not possible to perform these measurements on all the types of SAW devices
used throughout this work.
As can be seen in Figure 5.2, the frequency chosen to drive the SAW devices (251.5MHz)
generates an insertion loss that is very close to the smallest possible (minimum absolute
value) for the three SAW devices tested. This frequency was chosen based on the design of
the IDTs, but also on the hardware available and compatible with the requirements of the
chip reader prototype. The average of the frequencies giving the minimum loss (in absolute
value) for each of the three measurements was 251±0.16MHz, which is very close to the
frequency chosen to drive the device.
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Figure 5.2: Optimising the SAW device operating frequency to minimise ILair.
Plot to show the insertion loss (dB) measured as a function of the driving frequency for
three different OJ15 SAW devices. Measurements were performed using a network analyser
(model 8753D, Hewlett Packard, USA). The surface of the delay lines of the SAW devices
was only exposed to air (dry) during the measurement. The dashed line represents the
251.5MHz frequency chosen to drive the SAW devices.
5.1.4 Optimising sensitivity: the role of the different insertion loss
The insertion loss associated to the operating frequency of 251.5MHz (presented in Figure
5.2) was measured in air. The same measurement can be performed with any type of sample
on the delay line, and forms the basis of the mode of operation of the SAW biosensor.
In Chapter 3, it was presented that the perturbation theory applied to SH-SAW devices
shows that the attenuation of the acoustic wave is related to a change in viscosity on the
surface proximity. In the following, the relation between the insertion loss measured for
samples of different viscosities is studied. The model samples chosen were deionised water,
glycerol/water solutions at increasing glycerol content, and pure glycerol.
Note: the following study aims at investigating the effect of a change in the device design
(such as the delay line length for example) on the device sensitivity to a pure viscosity
perturbation. The study only investigates the performance of different device designs on
the insertion loss. Therefore, the results of the following study do not necessarily apply to
the results presented in Chapters 6 and 7 which were obtained by measuring the acoustic
wave phase shift. They provide, however, a good indication of the fundamental sensitivity
of the device to a pure viscosity perturbation, over a range of viscosity regions.
The signal measured at the output IDT has a surface component as well as a bulk compon-
ent. The latter is due to the fact the SH-SAW is not propagating purely in one direction and
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a minor bulk component is observed. The surface component can be removed by adding
pure glycerol on the surface of the delay line, leaving only the bulk (and minor spurious
component coming from the IDT). In the following, the insertion loss measured with pure
glycerol on the surface of the delay line is referred to as ILtotal.
The sensitivity of a SAW device, when looking at it from the insertion loss angle, is related
to three ratios between the insertion loss of different samples:
γ1 =
ILair
ILtotal
, (5.8)
γ2 =
ILsample1
ILsample2
, (5.9)
γ3 =
ILsample
ILtotal
, (5.10)
where ILsample is the insertion loss measured for any sample other than pure glycerol or
any sample generating the loss of all the surface component of the signal (ILtotal). The
viscosity of sample 2 is higher than the viscosity of sample 1, therefore ILsample2 is higher
than ILsample1. The different insertion loss measurements involved in the expressions of γ1,
γ2 and γ3 are shown as an example in Figure 5.3.
Those ratios vary from 0 (in the particular case of the SAW device being ideal and the
wave not being perturbed by the sample on the surface this would only be useful in air)
to 1 (the insertion loss is the same regardless of sample on surface which is not useful to
distinguish between samples). To increase the SAW device sensitivity, it is necessary for
each of these ratios to be minimised:
• a small γ1 means the insertion loss measured in air is small compared to the total
insertion loss. This signifies that the design of the device was good, that a minimal
amount of signal is lost when the device is exposed to air only, and that there is plenty
of signal to allocate for transducing the perturbation caused by the samples.
• a small γ2 means the perturbation - caused by what distinguishes the two samples
- generates a large insertion loss difference. The difference between the two samples
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Figure 5.3: Levels of insertion loss. Plot to show the insertion loss (dB) measured
with an OJ15 SAW device as a function of the driving frequency, for the 4 different samples
indicated in the legend. In the example chosen, Sample 1 and Sample 2 correspond to solu-
tions of glycerol at 10% and 30% (w/w), respectively. The vertical dashed line represents
the 251.5MHz frequency chosen to drive the SAW devices. The horizontal dashed lines
indicate the insertion loss measured for each sample. Measurements were performed using
a network analyser (model 8753D, Hewlett Packard, USA).
here is simply viscosity, but this would equally apply to sample 2 containing the target
protein, and sample 1 being the negative control sample or running buffer. A small γ2
improves the resolution and clarity of the measurements when looking at fine surface
perturbations, such as the binding of small proteins of proteins at low concentrations.
• Finally, a small γ3 corresponds to the fact that any perturbation of interest measured
by the SAW device generates an insertion loss far apart in absolute value - from the
total insertion loss ILtotal. ILtotal represents the upper limit (in absolute value) of
what the SAW device can measure in terms of insertion loss. Therefore, the further
away the insertion loss of a given sample is from ILtotal, the more room there is left
for measuring greater perturbations, and the larger the range of perturbations the
SAW device can measure.
Decreasing the values of γ1, γ2, and γ3 is a design consideration. Regarding γ1, the thickness
of the SU-8 walls (responsible for a constant loss of approximately 3dB on OJ15 SAW
devices) and the design of the IDTs play a role in reducing the value of ILair. In addition,
different strategies can be used to cancel out the bulk component of the signal measured.
Removing the bulk component can also have an effect on decreasing the values of γ2 and
γ3, as will be shown further on. Finally, tuning the length of the delay line can be used to
optimise the device sensitivity, as illustrated in the example below.
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The absolute value of ILsample is related to the length of the delay line L (see equation 5.5).
As the value of ILtotal is fixed, γ3 increases with L. However, equation 5.5 also means that
the difference between ILsample1 and ILsample2 increases with L, and therefore the value of
γ2 decreases when L increases. This is illustrated with an example in Figure 5.4.
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Figure 5.4: Influence of the length of the delay line on γ2 and γ3. Plot to show
the variation of γ2 and γ3 as a function of the length of the delay line L. The ratios γ2 and
γ3 were calculated using the expression of insertion loss presented in equation 5.5. In the
example chosen, sample 1 was deionised water, and sample 2 corresponds to a further loss
of 2dB (most perturbations measured during this project gave rise to 1 to 5dB compared
to the insertion loss of deionised water). The values of the attenuation coefficients were
estimated for each sample based on 5 independent measurements of the insertion loss for
the corresponding sample on OJ15 SAW devices (x = 9mm, f = 251.5MHz). The average
values used were ILair = -22dB , IL1 = -47dB, IL2 = -49dB, ILtotal = -65dB, α1 =
0.319dB.mm−1 and α2 = 0.344dB.mm−1. The vertical dashed line indicates the length of
the delay line on OJ15 SAW devices (9mm). In this example, all the signal is lost if the
length of the delay line is equal or greater than 14.4mm.
5.1.5 Improving SAW device sensitivity by varying the length of the
delay line
In the discussion above, the theoretical influence of the length of the delay line on the SAW
device sensitivity were studied. The analysis was based on the different expressions of the
insertion loss presented in Chapter 3, and the introduction of the three ratios insertion loss
ratios γ1, γ2 and γ3. In order to observe the influence of the length of the delay line on the
specific case of OJ15 devices, two different prototypes, identical in every aspect except for
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the length of their delay line, were tested. A schematic of the two devices is presented in
Figure 5.5.
Figure 5.5: Prototypes A and B used to study the influence of the length of
the delay line on the SAW device sensitivity. Schematics of the prototypes of SAW
device used to study the influence of the length of the delay line on the device sensitivity.
The two prototypes are identical apart from the length of the delay line (9mm for prototype
A, 5mm for prototype B). Drawings not to scale.
In order to study the influence of the length of the delay line on the device sensitivity,
the insertion loss was measured with both devices for 6 different samples: air, deionised
water, and water/glycerol solutions at 10%, 20% and 30% (w/w) glycerol, and pure glycerol.
Examples of the insertion loss measured and the analysis of the ratios γ1 (Figure 5.6) and γ2
and γ3 (Figure 5.7) are presented below. Glycerol was purchased from Yoneyama Yakhuin
Kogyo Co., Ltd., Japan (product number 02272). Measurements were performed at Japan
Radio Company, Kamifukuoka, Japan. The network analyser used for the measurements
was the model 8753D (Hewlett Packard).
As can be seen in Figure 6b, the ratio γ1 is very similar between prototypes A and B
(0.36±0.015, 0.37±0.001). This indicates that varying the length of the delay line from the
reference prototype (OJ15, 9mm delay line) does not influence this particular ratio. This
was to be expected, and confirms that when designing the SAW device, the design of the
IDTs and the surrounding SU-8 walls may have an impact on γ1, while the length of the
delay line is less likely to.
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Figure 5.6: Influence of the length of the delay line on the SAW device sens-
itivity: ratio γ1. a) Plot to show the insertion loss (dB) measured as a function of the
driving frequency on prototype A (blue) and B (green), when the SAW device was exposed
to either air or pure glycerol (total loss). The vertical dashed line represents the 251.5MHz
frequency chosen to drive the SAW devices. The horizontal dashed lines indicate the in-
sertion loss measured for each sample. b) Barchart to show the ratio γ1 measured for each
prototype. Each bar represents the average of 3 independent measurements, error bars
represent the standard deviation from the mean.
The analysis of ratios γ2 and γ3 presented in Figure 5.7 revealed some useful information. As
expected, the ratio γ3 (which indicates the magnitude of the gap between the insertion loss
measured for a sample, and the total insertion loss) was significantly reduced by reducing
the length of the delay line from 9 to 5mm, for all samples tested (0.77±0.018 to 0.67±0.011
for deionised water, 0.84±0.019 to 0.70±0.010 for 10% glycerol, 0.92±0.012 to 0.75±0.010
for 20% glycerol and 0.97±0.012 to 0.80±0.007 for 30% glycerol, Figure 5.7c). This confirms
the theoretical prediction presented in Figure 5a, showing that γ3 should decrease with the
length of the delay line. Similarly, Figure 5.4 showed that γ2 should follow the opposite
pattern and increase when reducing the length of the delay line. This was confirmed by the
experiments conducted as Figure 7b shows that γ2 was found to be smaller for prototype A
than for prototype B in 5 out of 6 cases (0.92±0.004 compared to 0.95±0.002 for deionised
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Figure 5.7: Influence of the length of the delay line on the SAW device sensit-
ivity: ratios γ2 and γ3. a) Plot to show the insertion loss (dB) measured as a function
of the driving frequency on prototype A (blue) and B (green), when the SAW device was
exposed to solutions of glycerol at various glycerol content. The glycerol content (v/v)
corresponding to each line is indicated on the plot. The vertical dashed line represents
the 251.5MHz frequency chosen to drive the SAW devices. The horizontal dashed lines
indicate the insertion loss measured for each sample. b) Barchart to show the ratio γ2
measured for each prototype. For each bar, the two samples used to evaluate the ratio are
indicated on the chart. Each bar represents the average of 3 independent measurements,
error bars represent the standard deviation from the mean. c) Barchart to show the ratio
γ3 measured for each prototype. For each bar, the sample used to evaluate the ratio is
indicated on the chart. Each bar represents the average of 3 independent measurements,
error bars represent the standard deviation from the mean.
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water over 10% glycerol, 0.84±0.016 compared to 0.88±0.004 for deionised water over
20% glycerol, 0.79±0.025 compared to 0.84±0.006 for deionised water over 30% glycerol,
0.91±0.015 compared to 0.93±0.001 for 10% glycerol over 20% glycerol and 0.87±0.026
compared to 0.88±0.005 for 10% glycerol over 30% glycerol), the only exception being the
ratio of insertion loss measured for the most viscous solutions (0.95±0.014 compared to
0.95±0.004 for 20% over 30% glycerol). However, the larger error bars observed for all
measurements involving 30% (v/v) glycerol solutions indicate that the SAW devices are
less suited to operate in this viscosity region, as they do not offer the same reproducibility
observed for samples of lower viscosities.
As explained above, a SAW device presenting a small γ2 ratio can be used to distinguish
two samples that are only differenced by a fine perturbation, while γ3 gives an indication
on the range of perturbations the SAW device can measure. In the particular case of
the application of biosensing, all perturbations of interest will be very fine and therefore
the γ3 ratio matters less than the value of γ2: the ideal SAW device should present the
smallest possible γ2 ratio in the region of viscosity that corresponds to the viscosity of
the samples tested. A 10% (v/v) glycerol solution has a viscosity of 1.21mPa.s at 25◦C,
which corresponds roughly to the viscosity of blood plasma at 37◦C, estimated to be in the
region of 1.10-1.30mPa.s. [180] As all the biological samples tested throughout this project
were either based on aqueous buffer solutions (for which the viscosity is comparable to that
of deionised water) or human blood plasma, the ideal criteria for the SAW device was to
present a small γ2 ratio for the water to 10% glycerol solution and 10% glycerol to 20%
glycerol transitions. As can be seen in Figure 5.7b, prototype A is better than prototype B
in that respect. A length of 9mm for the delay line is therefore preferable over 5mm, when
considering that the SAW device is going to be used as a biosensor. For other applications,
however, such as a pure viscosity sensor operating over a large range of viscosities, reducing
the length of the delay line would have proved beneficial.
5.1.6 Improving SAW device sensitivity by cancelling out the bulk com-
ponent of the signal
One of the features of the OJ15 SAW device prototype, as explained in Chapter 4, is the use
of a second delay line to cancel out the bulk component of the signal measured at the output
IDT. When the acoustic wave is generated at the input IDT, most of it propagates along
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the surface of the delay line, but a small bulk component is still observed. By introducing
a reflector on the lower delay line, the surface component of the wave is blocked on its way
to the output IDT, and therefore only the bulk component is measured. This can then
be subtracted from the upper delay line (the one used for sensing purposes) in order to
only consider the surface component of the signal. The effect of this feature on the device
sensitivity was studied by testing the two prototypes presented in Figure 5.8, which only
differ by the presence or not of the reflector on the lower delay line: in other words, one
prototype (prototype A) does not subtract the bulk component of the signal whereas the
other one (prototype C) does.
Figure 5.8: Prototypes A and C used to study the influence of cancelling out
the bulk component of the signal on the SAW device sensitivity. Schematics
of the prototypes of SAW device used to study the influence of cancelling out the bulk
component on the device sensitivity. The two prototypes are identical apart from the
presence (prototype A) or absence (prototype C) of a feature on the lower delay line to
cancel out the surface component. Drawings not to scale.
The same experiments presented above when studying the effect of the length of the delay
line on the device sensitivity were conducted. The insertion loss of different glycerol/water
solutions was measured, and the ratios γ1, γ2 and γ3 analysed. Results are presented in
Figure 5.9 and 5.10.
As can be seen in Figure 5.9, the ratio γ1 was slightly decreased by the cancellation of the
bulk component of the signal: 0.36±0.015 to 0.41±0.020. This insertion loss measured for
prototype C is reduced (in absolute value) by the presence of the bulk component. While it
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Figure 5.9: Influence of cancelling out the bulk component of the signal on
the SAW device sensitivity: ratio γ1. a). Plot to show the insertion loss (dB)
measured as a function of the driving frequency on prototype A (blue) and C (red), when
the SAW device was exposed to either air or pure glycerol (total loss). The vertical dashed
line represents the 251.5MHz frequency chosen to drive the SAW devices. The horizontal
dashed lines indicate the insertion loss measured for each sample. b) Barchart to show the
ratio γ1 measured for each prototype. Each bar represents the average of 3 independent
measurements, error bars represent the standard deviation from the mean.
is not fully understood how the bulk component of the signal varies with the perturbation
occurring on the surface of the delay line, it appears that cancelling it out it has a positive
impact on the ratio γ1, and therefore on the SAW device sensitivity.
As for the ratios γ2 and γ3, the same observations that were made above about Figure 5.7
apply to Figure 5.10. The presence of the reflector on the lower delay line, cancelling out
the bulk element of the signal and only focusing on the surface component appeared to help
reducing γ2 for all the combination of samples tested, while increasing γ3 (as expected when
decreasing γ2) for all the samples tested. Once again, with the application as biosensor in
mind, prototype A was therefore considered to be more relevant than prototype B, as it
proved to be more sensitive to fine perturbations (smaller γ2), particularly around the
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Figure 5.10: Influence of cancelling out the bulk component of the signal on
the SAW device sensitivity: ratios γ2 and γ3. a) Plot to show the insertion loss
(dB) measured as a function of the driving frequency on prototype A (blue) and C (red),
when the SAW device was exposed to solutions of glycerol at various glycerol content. The
glycerol content (v/v) corresponding to each line is indicated on the plot. The vertical
dashed line represents the 251.5MHz frequency chosen to drive the SAW devices. The
horizontal dashed lines indicate the insertion loss measured for each sample. b) Barchart
to show the ratio γ2 measured for each prototype. For each bar, the two samples used
to evaluate the ratio are indicated on the chart. Each bar represents the average of 3
independent measurements, error bars represent the standard deviation from the mean.
c) Barchart to show the ratio γ3 measured for each prototype. For each bar, the sample
used to evaluate the ratio is indicated on the chart. Each bar represents the average of 3
independent measurements, error bars represent the standard deviation from the mean.
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viscosity region of interest (0.91±0.004 compared to 0.93±0.006 for deionised water over
10% glycerol, and 0.91±0.015 compared to 0.93±0.005 for 10% glycerol over 20% glycerol).
Prototype A, corresponding to the OJ15 SAW device presented in Chapter 4, was therefore
shown to offer the best guarantees for offering a good sensitivity as a biosensor testing
either human blood plasma or aqueous buffer based mock samples. The combination of a
9mm long delay line (instead of a shorter 5mm delay line) and the presence of a reflector
on the lower delay line to cancel out the bulk component of the signal proved to give
prototype A the edge over prototypes B and C. This study could be used in the future to
make further refinement of the sensitivity of the SAW device, if the focus changes to testing
whole human blood instead of human blood plasma, as the viscosity of blood is higher than
that of plasma.
5.2 Influence of surface coverage of the delay line on output
signal
Having established the ideal parameters to give OJ15 SAW devices the optimal sensitivity
in the context of a biosensor, it was decided to study the influence of the surface coverage
of the delay line on the output signal. This was motivated by the observation that a signal
was still measured despite the sample not covering the entire area of the delay line. In
addition, the situation when the sample did not instantly spread across the entire surface
of the delay line occurred fairly frequently and was identified as a potential future problem
for the SAW device being a key component of a PoCT.
One of the main characteristics to focus on when designing a PoCT is the simplicity of use.
Ideally, the test would be designed to be performed by non-trained staff, with the simple
instructions coming with the test proving enough to make virtually anyone be able to use
the device and perform the test. It is crucial, however, to identify the possible mistakes
that could be made by the person performing the test and assess whether they would have
an impact on the test result or even on its validity. A 2014 study in Kenya and South
Africa has shown that prototypes of HIV self PoCT were used incorrectly by more than
75% of the lay users involved in the study, leading to invalid results. [24]
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Most PoCT for HIV are lateral flow tests, and the most common mistake that can be
made by the test user and lead to an incorrect result is a misinterpretation of a faint line.
This comes down to a combination of differences in eyesight and personal judgement, and
there is hardly a perfect solution to this problem. In the case of the biosensor presented
here, the readout is electronic and the analysis is performed by smartphone, avoiding any
human judgement and potential for misinterpretations. One step of the assay, however,
was identified as a potential source of error. When loading the sample onto the surface
of the SAW biochip, it is possible to leave a certain fraction of the surface uncovered by
any liquid and left exposed to air. This is due to the relative hydrophobicity of the surface
which sometimes leads to the small volume of liquid sample forming a droplet instead of
spreading evenly across the sensing area. An example is shown in Figure 5.11.
b Side viewTop view
Wet – contact with liquid sample
Total sensing area
Waterproof resin walls
Liquid sample
Dry – exposed to air
a Side viewTop view
Total sensing area
Waterproof resin walls
Liquid sample
Figure 5.11: Loading of liquid sample onto the SAW biochip. a) Picture taken
from the top of the SAW biochip (left) showing the 20µl droplet of deionised water covering
the whole surface of the sensing area, and side view schematics associated (right). Drawings
not to scale. b) Picture taken from the top of the SAW biochip (left) showing the 20µl
droplet of deionised water covering a fraction of the surface of the sensing area, instead
of spreading out across the whole surface, and side view schematics associated (right).
Drawings not to scale.
It was decided to investigate whether a mishandling of the liquid sample, resulting in
uneven coverage of the sensing area of the SAW biochip, had direct consequences on the
performance and validity of the test. To do so, a fraction of the sensing area of a SAW
biochip was put in contact with liquid, while the remaining dry fraction remained exposed
to air. This was achieved by carefully pipetting a 20µl droplet of deionised water onto
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the clean surface of the SAW biochip, and purposely making sure the liquid would form
a droplet instead of spreading out evenly across the surface. The change in phase shift
and amplitude loss was measured before and after deposition of the droplet. The surface
was then cleaned and dried before a new droplet was deposited. The process was repeated
76 times. The phase shift and insertion loss measured upon addition of each droplet are
presented on the barchart in Figure 5.12.
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Figure 5.12: SAW biosensor response to liquid droplets loading. Barchart to
show the signal measured by the SAW biosensor upon addition of 76 20µl droplets of
deionised water on the surface of the dry sensing area. Each orange bar corresponds to
one independent measurement and represents the phase shift (left axis) measured upon
addition of one droplet. The green bar directly to its right represents the corresponding
amplitude loss (right axis) measured for the same droplet.
As can be seen in Figure 5.12, all 76 droplets of liquid on the dry surface of the sensing area
were detected by the SAW biosensor, as all measurements show at least a small response
in both the phase shift and the amplitude loss. There is also a good correlation between
the phase shift and the amplitude loss measured for each droplet. This shows that the
SAW biosensor has the ability to show a response despite potential incorrect handling of
the sample from the person performing the test.
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It is important to note however, that despite all droplets being the same volume (20µl), the
signals measured for each of the 76 droplets vary quite a lot (phase shift as low as 20 degrees
and as high as 152 degrees, insertion loss varying from 1 to 19dB). As the hydrophobicity of
the surface of the sensing area varied slightly between each measurement, in addition to the
fact the manual pipetting technique is not perfectly reproducible, the shape of the droplet
changed between each measurement, therefore the fraction of the sensing area in contact
with liquid (referred to as θL below) was different for each measurement. It was therefore
possible to study the influence of the signal output as a function of θL. The estimation of
θL was based on pictures of the SAW device taken from the top, and an image recognition
software written in Mathematica, which compared the area of the sensing area and the area
of the droplet. As the pictures were taken from the top, the angle the droplet edges formed
with the surface (see Figure 5.11b) was not taken into account, and the value of θL was
slightly overestimated as a consequence. The results from this study are therefore not exact,
but as the process of image recognition was automated and applied to each picture in the
same way, they can be considered consistent relative to each other. They were separated
in three categories, depending on whether the droplet was in contact of the left hand side
of the sensing area (directly after the input IDT), the right hand side (directly next to the
output IDT) or simply sitting at the centre, not in contact with either sides. Examples are
shown in Figures 5.13. The phase shift and amplitude loss are plotted as a function of θL
in Figure 5.14.
θL = 68.4% θL = 70.1% θL = 57.1%
Left (directly after input IDT) Right (directly before output IDT)Centre
Figure 5.13: Examples of incorrect liquid sample loading onto the sensing area
of the SAW device. Three cases of liquid sample were studied, characterised by the
position of the droplet with respect to the IDTs: left hand side (blue), centre (orange) and
right hand side (green). All pictures were taken from the top of the SAW devices, with the
input IDT on the left hand side and the output IDT on the right hand side. In each case,
the estimated percentage of the surface covered in liquid (θL) is indicated underneath the
picture.
As can be seen in Figure 5.14, a very good correlation can be observed between θL and
both signal outputs (phase shift and insertion loss). Both in Figures 5.14a) and 5.14b), the
similarity observed between each set of data (left hand side, right hand side or centre, with
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respect to the IDTs) show that the portion of the sensing area left dry does not influence
the amount of output signal lost. However, they also show and this is confirmed by the
linear regression performed on the whole data (black line, Figure 5.14a and 5.14b) - that the
magnitude of the output signal does depend directly and proportionally on the percentage
of surface covered (θL).
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Figure 5.14: Influence of liquid sample coverage of the sensing area on the
loss of output signal. a) Plot to show the phase shift measured upon addition of 20µl
droplets of deionised water on the surface of the SAW device. Each point represents one
measurement. The black line represents the linear regression (1.4x + 1.33, R2 = 0.987)
performed on the whole data set, all three categories combined. b) Same as a), for the
insertion loss. The black line represents the linear regression (0.2x − 1.9, R2 = 0.993)
performed on the whole data set, all three categories combined.
This small study demonstrated the importance of correct handling of the sample by the
test operator. Despite the SAW biosensor being capable of giving a response upon addition
of a droplet of sample leaving a fraction of the sensing area dry, it was demonstrated that
the magnitude of this response was directly proportional to the fraction of the surface in
contact with liquid. In other words, a fraction of the magnitude of the signal is lost when the
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sample does not spread evenly across the whole sensing area. As the test response would
have been calibrated against results obtained with a fully wet sensing area, not making
sure the samples covers the whole sensing area would make the test result invalid. This key
conclusion will have to feature, in the future, in the instructions of use designed to help
non-trained staff to correctly use the test.
Additionally, it can be envisaged to implement a built-in test validity criterion within the
algorithm processing the data, as the amplitude loss measured will always have to be greater
than a minimal threshold value corresponding to the addition of deionised water on a dry
chip. Any other sample would be more viscous or contain proteins that can potentially
adsorb or bind to the surface, therefore leading to a greater perturbation. All results
presented in this thesis were obtained with the sensing area fully covered by the liquid
sample measured.
5.3 Statistical analysis of reproducibility and repeatability
OJ15 SAW device measurements
The SAW devices used throughout this work were considered as disposable devices, as in
only one measurement per device was made. The idea behind this was that ultimately the
SAW device would be the only component of the biosensor in contact with human blood
and therefore would have to be disposable. It was necessary to treat each SAW device as
such when optimising it. However, to do so, a careful statistical analysis was conducted, in
order to assess whether measurements made with different SAW devices could be compared
with confidence. As the lab control box had the capacity to drive 4 different SAW devices
using the 4 different holders at the same time, the agreement between the measurement
performed by each of the holders was studied.
As presented in Chapter 4, the prototype of the control box used to perform all the meas-
urements presented in Chapter 6 and 7 features 4 individual holders, each used to run a
test with a different SAW device. Most of the results presented later were obtained by
making use of this and either running an identical test on all 4 devices, or using some of
them as reference for the others. In both cases, relying on a good agreement between the
measurement performed by all 4 holders was crucial.
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As all 4 holders were always used at the same time as part of the same run, it was decided
to use the data obtained on runs where all 4 SAW devices were used to measure the same
sample. In order to study the agreement between the holders as accurately as possible, the
sample that was measured the most times was selected: the measurement of the insertion
loss corresponding to the addition of deionised water on the surface of the dry delay line of
the SAW device.
The method chosen was the Bland-Altman method. [181] It is commonly used to assess
the reproducibility of a measurement performed on the same sample using two different
instruments or methods. [182] Here, each holder was considered to be a different instrument
and the agreement between each pair of holders was studied, which corresponds to six
cases: if the 4 holders are called A, B, C and D, the six pairs are AB, AC, AD, BC, BD and
CD. The idea behind studying each possible pair was that if there is reasonable agreement
between the measurements performed on any pair of holders, any holder could be used as
a valid reference for the test running on another holder. Similarly, any test could be run in
duplicate on another holder and be compared with confidence.
The Bland-Altman method relies on studying the difference measured between the two
measurements of the sample by two different methods (here, each holder in the pair con-
sidered). The data was checked for normality with a Q-Q plot, and no evidence of non-
normality was found. The differences between two measurements are plotted against the
mean of the two measurements in Figure 5.15, for each pair of holders considered. Each
point represents the difference between two measurements run at the same time, on two
different holders.
The disparity observed in the mean of the measurements (from 37 to 43dB approximately)
can be explained by the fact the dataset includes runs taken over a long period of time
(three years), during which some settings that may affect the measurements are likely to
have taken place. These include the lab temperature, the sample temperature, the model
of prototype control box used (three different models were used) and the amplifier settings
used in the control box. None of these adjustments matter with regards to this study,
however, as each data point is associated to measurements taken at the same time and
therefore with everything being equal apart from the holder used.
On each plot, the solid red line on the plot indicates the mean of the differences, and the
dashed red lines the limits of agreement lim1 and lim2. The limits of agreement give a
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Figure 5.15: Reproducibility of measurements taken using different holders as
part of the same run. Blant-Altman plots of measurements of insertion loss (deionised
water) taken with two different holders as part of the same run. For each pair (indicated
above the plot), the difference in insertion loss measured between the first and second holder
(in alphabetical order) is plotted as a function of the mean of the two measurements. On
each plot, the red solid line indicates the mean of the differences, the red dashed line
indicates the limits of agreement of the mean (lim1 and lim2), and the black dashed
lines indicate the 95% confidence of interval around each limit of agreement. Each plot
represents 91 independent measurements.
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range within which 95% of future differences in measurements between the two methods
are expected to lie. The limits of agreement [183] are calculated as:

lim1 = Mean(differences) + 1.92SD(differences)
lim2 = Mean(differences)− 1.92SD(differences),
(5.11)
where SD(differences) is the standard deviation from the mean for the set of differences.
Finally, a 95% confidence interval (CI ) is calculated around each limit of agreement, as
these are estimated and also need their own limits of agreement. [183] It is calculated as
follows:
CI =
1.71SD(differences)√
n
, (5.12)
where n is the number of elements in the data set. On each plot in Figure 5.15, the dashed
black lines indicate the 95% confidence interval around each limit of agreement.
The limits of agreements used in the Bland-Altman theory only give an indication on how
far apart two measurements are expected to be for 95% of all measurements made using the
two methods tested. They do not indicate whether this is acceptable in the specific case of
measuring the insertion loss of deionised water with two SAW device holders, this has to be
determined with regards to the context in which future measurements will be made. [181–183]
The limits of agreement (and associated 95% confidence interval) are summarised in Table
5.1.
The largest theoretical disagreement between two measurements corresponds to pair BD
(-0.48dB). Given that the measurement studied here is lies between 38 and 42dB, it means
that even in the worst case, 95% of all measurements will differ by no more than 1.3% of the
measured insertion loss. The insertion loss measured in this study corresponds to quite a
large perturbation (air to deionised water). Such a small error in between two measurements
taken on different holders is therefore acceptable. The four holders were considered to be
equivalent and were used throughout this thesis interchangeably for reference or duplicate
tests run in parallel to the main test.
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Pair lim1 lim2 CI
lim2
−1.96CI
lim2
+1.96CI
lim1
−1.96CI
lim1
+1.96CI
AB 0.36 -0.27 0.014 -0.30 -0.24 0.33 0.38
AC 0.43 -0.32 0.017 -0.36 -0.29 0.40 0.46
AD 0.40 -0.40 0.018 -0.44 -0.37 0.37 0.44
BC 0.377 -0.35 0.017 -0.38 -0.32 0.34 0.40
BD 0.35 -0.44 0.018 -0.48 -0.41 0.31 0.39
CD 0.30 -0.41 0.016 -0.44 -0.38 0.27 0.33
Table 5.1: Limits of agreement between two measurements. Table to summarise,
for each pair of holders, the limits of agreement around the mean (lim1 and lim2), the 95%
confidence interval CI and the subsequent four limits obtained by adding and subtracting
CI from lim1 and lim2. For each pair of holders, the highest and lowest disagreement
between measurements are highlighted in red.
5.4 Discussion
The SAW device used to obtain the results presented in the next chapters was manufactured
by partner company Japan Radio Company (JRC, Japan). In this chapter, the device was
carefully characterised from three different yet complimentary approaches.
It was shown that the sensitivity of the device was optimal in the context of the device
being used to measure small perturbations in the viscosity region corresponding to that
of human plasma, or aqueous buffer which were used extensively to optimise the surface
chemistry, as will be described in the next chapter. The optimal sensitivity was shown to
be achieved by tuning three key parameters of the device: (i) driving the SAW device at
a frequency of 251.5MHz, corresponding to the closest achievable frequency from the ideal
frequency, which was shown to be 251±0.16MHz; (ii) having a delay line of 9mm instead
of 5mm, which gives the device the ability to distinguish between fine perturbation in the
viscosity of interest with greater precision; (iii) cancelling out the bulk component of the
signal, to measure only the surface component which is more directly influenced by the
perturbations occurring on the surface. Once again, it was shown that doing so gives the
SAW device a greater ability to sense small perturbations occurring in samples of viscosity
close to that of either human plasma or aqueous buffer.
During the course of this work, numerous measurements were performed to either optimise
the transformation of the SAW device into a SAW biochip, or to run a test on an optimised
SAW biochip. It was observed that sometimes, the sample pipetted onto the delay line had
to be forced to spread across the whole surface, as it sometimes formed a droplet on top of
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the relatively hydrophobic surface. It was also noted that in this situation, an output signal
was still delivered by the control box. The influence of the surface coverage of the delay
line by the liquid sample was studied, and it was shown that a strong correlation existed
between the fraction of the area of the delay line covered by liquid and the magnitude of the
output signal. This was identified as a key information in the context of turning the SAW
device into a component of a PoCT, as one of the main characteristics of a POC is to be
designed to avoid as many operator mistakes as possible. Knowing that the performance
of the test is directly related to a correct handling of the sample (a maximum signal is
obtained when the sample spread across the entire surface of the delay line) will be a key
factor in designing both the disposable SAW device, and also the test instructions.
Each device was considered to be disposable and, in the vast majority of cases, was used only
once to perform a single run of measurements. This was justified by the fact the SAW device
would ultimately be turned into a key component of the SAW biosensor, and that it would be
the only component in contact with human fluids and therefore would have to be disposable.
The fact that the results of each run of measurement performed with OJ SAW devices
were obtained from four independent holders connected to the same prototype control
box was studied, and it was shown that the variable introduced by performing a similar
measurement on independent pieces of equipment did not influence their reproducibility.
The Blant-Altman method was applied to measurements performed in parallel using four
independent holders. In the example, the insertion loss caused by the addition of deionised
water on the delay line was measured an example chosen for the high amount of relevant
data available. It was shown that each holder could be used interchangeably and that the
results obtained with any holder could be used as a reference for another test run at same
time using a parallel holder. Similarly, any test could be run in duplicate at the same time
using a parallel holder.
This careful characterisation of the SAW device paved the way for transforming it into
a SAW biochip capable of detecting the presence of a specific target protein in a sample.
Indeed, the process of optimising the SAW biochips required a high sensitivity across a large
number of independent measurements. All the results obtained with the SAW biochips, as
well as the process of optimisation, are presented in the next two chapters.

Chapter 6
Detecting Model Proteins and HIV
Markers of Infection
The objective of this chapter was to optimise the performance of the SAW biosensor as-
says for highly sensitive, specific, robust and rapid detection of HIV biomarkers. Initial
work focused on a model protein assay based on human serum albumin (HSA) and anti-
HSA antibodies. This assay was used to optimise the thiol linker chemistry, the loading
concentration of capture proteins on the SAW biochips and the response to different tar-
get antibody concentrations in solution. It was then decided to systematically optimise
the assay parameters for HIV biomarkers of interest, including (i) the response of differ-
ent antibodies and specificity testing using a non-specific antibody (negative control), (ii)
reproducibility of measurements on a single SAW biochip, (iii) the detection of clinically
relevant concentrations of anti-HIV antibodies; (iv) reducing the time to result for ultra-
rapid testing; (v) proof of concept detection of the HIV p24 antigen; (vi) benchmarking
to a benchtop quartz crystal microbalance (QCM) and (vii) signal amplification strategies
using gold nanoparticles. Highlight results include the detection of anti-p24 antibodies at
clinically relevant concentrations, proof of concept of result delivery within 10 seconds of
sample injection, and detection of HIV p24, the key target protein for fourth generation
PoCT for HIV.
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6.1 Proof of concept using a model protein complex: HSA/anti-
HSA
6.1.1 Cleaning the surface of the delay line
In the interest of trying to get the best possible response out of the SAW biochip when
performing an assay, every step of the functionalisation process that could potentially be
optimised was studied. It was first identified that the strategy used to clean the gold surface
prior functionalisation could have consequences on the quality of the capture protein layer,
and therefore on the response of the sensor to the target protein detection. In order to
assess the best way to clean the gold surface of the delay line of OJ15 SAW devices before
functionalising it, a systematic study was conducted. Several SAW devices were cleaned
with 5 different strategies (described in Chapter 4), after which antibodies were allowed
to adsorb on the surface by incubating the surface in a sample of antibodies in PBS at a
constant concentration (25µg/ml).
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Figure 6.1: Influence of strategy used to clean the gold surface of the delay
line. Barchart showing the change in phase shift (in blue) and insertion loss (in orange)
measured following the adsorption of anti-HSA antibodies on the gold surface of the delay
line. Each bar represents the average of at least 6 independent measurements, the error
bars represent the standard deviation from the mean. The strategy used to clean the gold
surface prior to antibody adsorption is specified on the horizontal axis. Values recorded
30min after sample injection.
As can be seen in Figure 6.1, the insertion loss measured when adsorbing antibodies on the
surface of the delay line does not seem to be greatly dependent on the cleaning strategy
used. For all strategies, the error bars are relatively large compared to the value of the
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average. With that in mind, the two cleaning strategies that gave the highest reading are
Hellmanex 2% (1.5±0.5dB) and SDS 1% (1.4±0.6). This trend is confirmed, and more
pronounced, when looking at the phase shift recordings. Using the SDS 1 % cleaning
strategy leads to the highest phase shift when adsorbing antibodies (62.6±2.1 degrees).
It is interesting to note that the air plasma cleaning strategy gave the worst results of
all strategies tested (0.8±0.4dB and 35.5±10.6 degrees), despite being in theory the most
efficient way to clean the gold surface out of all the strategies tested. This is likely to be
due to the fact that the antibody adsorption could only be performed about 10 minutes
after the surface had been cleaned, for logistical reasons. A more common practise is
to functionalise the gold surface straight after it comes out of the plasma chamber, as
the top layer of gold atoms is still very reactive following oxidation. In addition, using
an air plasma is not as efficient as a dedicated oxygen plasma for example. A plasma
created in a pure oxygen environment could potentially have helped to oxidise the top layer
of gold atoms more efficiently, making the surface ore reactive and therefore making the
subsequent functionalisation of the surface more efficient. Unfortunately, this equipment
was not available at the time of the study. Unless stated otherwise, the surface of the delay
line of all the SAW biochips that contributed to results presented in this thesis was cleaned
with a solution of SDS 1%.
6.1.2 Model assay: HSA detection
Initial proof of concept work focused on HSA as a model, to demonstrate the proof of
concept and optimise the assay parameters on the new SAW system. By way of background,
HSA is a protein found in human blood plasma. It is produced in the liver, and constitutes
about half of the blood serum protein, making it the most abundant protein in plasma.
HSA is a major protein of the circulatory system, one of its function being the transport
of hormones, fatty acids, and other low molecular weight compounds, as well as a number
of drugs. [184,185] As both HSA and anti-HSA antibodies were cheap and easily accessible,
it was decided to use the HSA/anti-HSA complex as a model protein for studying the
detection of proteins using the SAW biosensor. The test assay is schematised in Figure 6.2.
The gold surface of OJ15 SAW biochips was functionalised with anti-HSA antibodies, and
this platform was used to detect HSA at various concentrations.
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Figure 6.2: HSA assay schematic. The surface of the SAW biochip is coated with
anti-HSA antibodies via DSP linker chemistry to the gold surface of the delay line. HSA
proteins in the sample are detected when they form a complex with the capture proteins
on the surface of the SAW biochip.
6.1.3 Influence of chemical linkers on SAW detection signal
The various proteins or antibodies that may be used as the first capture layer of the im-
munoassay cannot bind strongly to the gold surface on their own. There is therefore a
need for an intermediate layer, strongly linking the proteins or antibodies of interest to the
gold surface. Once cleaned, the surface of the delay line was functionalised with a chemical
linker. A study of the best linking strategy is presented below. The results of this study
pointed at Dithiobis[succinimidyl propionate] (DSP, also known as Lomants Reagent) as
the best option as an intermediate to bind proteins to the gold surface.
DSP is an amine-reactive cross linker with NHS-ester reactive ends and a cleavable disulph-
ide bond in the middle of its 8-carbon spacer arm (12A˚). [186] There are two main reasons
why DSP is an ideal candidate for functionalising the gold surface in the prospect of cre-
ating a thin film of antibodies or other proteins. Firstly, the cleavable disulphide bond
yields two identical thiols once cleaved, which happens on contact with gold. [187] Thiols are
very good candidates for binding to gold as the formation of a strong non-covalent bond
between the gold and the sulphur is very favourable. This is schematised in Figure 6.3.
Secondly, DSP contains an amine-reactive N-hydroxysuccinimide (NHS) ester at each end
of the spacer arm (i.e. at the end of each thiol once DSP has been cleaved). NHS esters
react with primary amines at pH 7-9 to form stable amide bonds, along with release of the
N-hydroxysuccinimide leaving group. [186] Given that proteins usually have several primary
amines available on their structure, amine reactions are likely to occur, thus resulting in
the formation of a capture protein layer above the surface.
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Figure 6.3: Gold functionalisation with DSP. The sulphur at the tail forms a strong
non-covalent bond with the gold on the surface (blue arrow) while the NHS head group
(circled in blue) will be used to react with primary amines on the outside of the protein or
antibody structure.
DSP was chosen as the linker between the gold surface and the capture protein for all the
protein detection assays conducted throughout this thesis. This was motivated by a first
study on the effect of the nature of the linker on the protein detection signal. In this study,
OJ15 SAW biochips were functionalised with anti-HSA antibodies using different linking
strategies. HSA proteins were then detected from a sample solution of HSA proteins in
TBS-T at 10nM. The different linking strategies are presented in Figure 6.5a. Three differ-
ent linkers were tested: DSP, DTSSP (3,3 -dithiobis[sulfosuccinimidylpropionate], Thermo
Scientific, UK) - which is very similar to DSP except for the fact it is sulfonated and
therefore water soluble, see Figure 6.4 - and ORLA85, a protein designed by Orla Protein
Technologies Ltd to bind to gold surface on one end and to the Fc portion of IgG mo-
lecules (constant fragment of the heavy chain) on the other end, theoretically improving
the antibody orientation.
Figure 6.4: Chemical linkers tested to anchor the capture protein to the sur-
face. Chemical structure of DSP and DTSSP. The two molecules are similar except for
the fact DTSSP is sulfonated, which makes it soluble in water. DSP is soluble in DMSO.
Courtesy of www.thermofischer.com
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With both DSP and DTSSP thiol linker chemistries, the gold-sulphur bond drives the
formation of a relatively well defined self-assembled monolayer and the terminal reactive
ester group forms a covalent bond to the lysine residues on the protein used as the capture
protein (here anti-HSA antibody). Finally, allowing the anti-HSA antibodies to simply
adsorb onto the gold surface directly was also tested. The average phase shift measured
when functionalising the surface, and when subsequently detecting HSA, are presented in
Figure 6.5b and 6.5c respectively.
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Figure 6.5: HSA test assay: influence of linker on detection signal. a) Schematics
to show the different strategies used to link the anti-HSA antibody (in bold black) to the
gold surface. b) Barchart to show the phase shift recorded 30minutes after injection of
anti-HSA (100µg/ml in TBS-T). Each bar represents the average of at least 3 independent
measurements normalised to a buffer only equivalent measurement, error bars represent the
standard deviation of the mean. c) Barchart to show the phase shift recorded 30minutes
after injection of HSA (10nM in TBS-T). Each bar represents the average of at least
3 independent measurements normalised to a buffer only equivalent measurement, error
bars represent the standard deviation of the mean. The highest reading is observed for
SAW biochips functionalised with DSP.
As can be seen in Figure 6.5b, not using any linker and simply allowing the antibodies to
adsorb on the gold surface leads to the smallest phase shift (57±5.3 degrees), two similar
linker molecules DSP (74.7±5.1) and DTSSP (81.5±4.9) give similar measurements and
ORLA85 (111.3±3.2) gives the highest phase shift in the context of linking the capture anti-
HSA antibodies to the gold surface. However, in the context of optimising the biosensor,
the parameter that matters the most is the phase shift recorded when detecting the target
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protein. As can be seen in Figure 6.5c, the trend observed for linking antibodies to the
surface does not apply to the detection of the target protein. The highest phase shift is
consistently given by SAW biochips functionalised with DSP as a linker for the capture
protein (24.2±2.6). DSP was therefore considered to be the best candidate as a linker
between the gold surface and the capture protein, and was used throughout the thesis to
link any capture protein, in the interest of consistency and comparing different results.
6.1.4 Influence of capture protein density on detection signal
In order to observe the effect of the density of the capture protein on the detection signal,
different concentrations of anti-HSA antibodies were used to functionalise OJ15 SAW bio-
chips. Samples of HSA in TBS-T at a fixed concentration (10nM, equivalent to 670ng/ml)
were then tested. The phase shift recorded during HSA detection on biochips functionalised
with different densities of anti-HSA antibodies (from 0.1µg/ml to 1mg/ml) can be seen in
Figure 6.6.
The general trend is that the higher the anti-HSA concentration used during functionalisa-
tion, the higher the phase shift recorded after 30 minutes. The phase shift recorded increases
with the density of anti-HSA on the surface. An important difference in phase shift can be
observed between anti-HSA densities of 10µg/ml (6.5±2.2 degrees) and 100µg/ml (15±3.3
degrees). However, increasing the concentration of anti-HSA antibodies on the surface past
100µg/ml does not greatly improve the detection signal, as a concentration is ten times
greater (1mg/ml) yields a similar detection signal (18±1 degrees).
This presumably could be because at higher antibody concentrations the surface is too
densely packed with antibodies and antigen binding is sterically hindered. The results
suggest that using a concentration of 100µg/ml of capture protein when functionalising
the SAW biochip is a good compromise to achieve the highest detection signal when sub-
sequently detecting the target protein, while preserving costly reagents. In the context
of optimising a point-of-care biosensor, this is important as some capture protein can be
expensive or not easily accessible, and using the optimal amount can prove crucial both in
terms of performance but also manufacturing costs.
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Figure 6.6: HSA test assay: influence of concentration of capture layer anti-
bodies on the detection of target protein. Plot to show the change in phase shift
recorded when detecting HSA proteins in TBS-T buffer at 10nM, on OJ15 SAW biochips
functionalised with different concentrations of anti-HSA antibodies. Each point represents
the average of at least 4 independent measurements normalised to a buffer only equivalent
measurement. Error bars represent the standard deviation from the mean. The higher the
anti-HSA concentration used during functionalisation, the higher the phase shift recorded
when detecting HSA. The improvement in detection signal is found to be more important
anti-HSA concentrations of 10µg/ml and 100µg/ml than between anti-HSA concentrations
of 100µg/ml and 1mg/ml.
6.1.5 HSA titration using OJ15 SAW biochips
After having optimised the surface functionalisation by studying the impact of both the
nature of linker and the concentration of capture proteins used on the detection signal, it
was next decided to study the relationship between the concentration of target protein in
the sample and the phase shift measured by the SAW biosensor. The gold surface of OJ15
SAW biochips was functionalised with DSP, and a capture layer of anti-HSA antibodies was
created by incubating a 100µg/ml solution of anti-HSA antibodies in PBS on the surface
of the DSP functionalised gold for 30min. Samples containing HSA in TBS-T at various
concentrations were then loaded onto the chip and the change in phase shift was recorded
5 minutes after sample injection. The phase shift is plotted as a function of the HSA
concentration in Figure 6.7.
As can be seen in Figure 6.7, the phase shift measured 5min after sample injection depends
on the concentration of target protein in the sample. A sharp increase can be seen in the
range 0-6nM, where the phase shift recorded after 5min increases from 1.8±0.1degrees for
a 1nM sample to 8.5±0.2degrees for a 5nM sample, while for concentrations higher than
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Δφ = Δφmax C(Kd +C)
Δφmax = 15.8 ± 2.4 degrees
Kd = 4.5 ± 1.6 nM
R2 = 0.994
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Figure 6.7: HSA titration curve on OJ15 SAW biochips. Plot to show the phase
shift recorded 5min after injecting HSA samples at different concentrations in PBS on
OJ15 SAW biochips functionalised with anti-HSA antibodies. Each point represents the
average of at least 3 independent measurements normalised by subtracting the signal of
a buffer only equivalent measurement. Errors bars represent the standard deviation from
the mean. The blue line is a fit of the data, using the Langmuir equation displayed on the
plot. The dissociation constant KD and maximum phase shift ∆φmax extracted from the
Langmuir adsorption model are displayed on the plot.
5nM, the change in phase shift remains relatively constant (10nM HSA sample leads to a
phase shift of 10.1±0.2 degrees). The data obtained was fitted using a Langmuir adsorption
model [188] (equation displayed on the plot in Figure 6.7). The dissociation constant KD of
4.54±1.6nM extracted from the fit is in accordance with literature values. [189]
6.2 Detection of anti-HIV antibodies
6.2.1 Anti-p24: proof of concept of detection using the SAW biosensor
Anti-HIV antibodies are the most common target in PoCT for HIV infection and this
immunological response is typically detected several weeks after exposure to the virus. As
an initial proof of concept, and following the protocol optimised with the model HSA/anti-
HSA complex, the detection of anti-HIV antibodies raised against envelope proteins (gp120)
was achieved using OJ15 SAW biochips functionalised with recombinant HIV gp120 capture
ligands (data not shown). However, it was decided to focus on the detection of antibodies
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raised against the viral capsid p24, one of the most conserved and abundant proteins found
in HIV. This was achieved using SAW biochips functionalised with recombinant HIV p24
capture ligands (Figure 6.8a) via DSP thiol linker chemistry. As for anti-envelope antibody
detection, a 20µl drop of buffer was incubated for 2.5 minutes to establish a stable baseline,
before loading the sample. Three different antibodies were tested: two antibodies raised
against HIV p24 (BC1071 and 3537) and one antibody raised against a different protein
with no known affinity for p24 used as a non-specific control antibody (anti-GBP5). The
phase shift recorded 5minutes after sample injection is presented in Figure 6.8b below, for
the different samples tested.
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Figure 6.8: Detection of different anti-p24 antibodies on OJ15 SAW biochips.
a) Schematics at the top represent the surface of the SAW biochip functionalised with
recombinant HIV p24, and the different target antibodies in solution whereby colours
corresponds to the bars on the barchart. b) Barchart to show the phase shift recorded 5min
after injecting antibody samples at 100nM in PBS on OJ15 SAW biochips functionalised
with recombinant HIV p24. Each bar represents the average of at least 3 independent
measurements normalised to a buffer only equivalent measurement. Errors bars represent
the standard deviation from the mean.
As can be seen on Figure 6.8b, the phase shift recorded after 5min for both anti-p24
antibody samples (23±0.7 degrees for BC1071, 15.6±2 degrees for 3537) is significantly
higher than the one given by the non-binding control (0.2±0.1 degrees). The fact that
one anti-p24 antibody sample (BC1071) gives a higher reading than the other one (3537)
might suggest that the antibody has a higher affinity for the recombinant HIV p24 used to
functionalise the surface. Another factor that might play a role in explaining this difference
is the availability of the epitope on the recombinant HIV p24 that is recognised by the
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different anti-p24 antibodies tested. Each anti-p24 antibody has a different binding site
that binds individual epitopes on HIV p24. DSP molecules on the gold surface bind to
primary amines of the lysine residues present on the HIV p24 protein. Depending on
the spatial location of the primary amines involved in the chemical bond with DSP, the
epitope will be left more or less available to form a complex with the corresponding anti-p24
antibody. In the following experiments where anti-p24 is the target protein, BC1071 was
therefore the anti-p24 antibody used, unless otherwise stated.
6.2.2 Anti-p24: reproducibility of detection results
After having established the optimal conditions for the anti-p24 assay on OJ15 SAW bio-
chips, and before performing a titration of anti-p24 using this assay (see below), the number
of OJ15 SAW biochips was limited for logistical reasons for a short period of time. Instead
of trying out new combinations of proteins and having to dispose of biochips afterwards
regardless of the outcome of the experiments, it was decided to study the reproducibility
of the results obtained when performing the same experiments with one biochip, while try-
ing to regenerate the surface in between two assays. The assay presented in Figure 6.8 to
detect BC1071 was performed on a unique SAW biochip 28 times, with a wash sequence in
between each assay. The wash sequence consisted of an acid wash (HCl solution 100nM) in
between two buffer washes, in order to remove the anti-p24 antibodies bound to the surface
by disrupting the complexes formed with HIV p24. The phase shift recorded 5min after
each new addition of the 100nM anti-p24 antibody sample is presented in Figure 6.9b.
As can be seen in Figure 6.9b, the reproducibility of the results of the assay is good. The
phase shift reading was found to be consistent over the 28 repetitions of the assay (24.8±1.9
degrees), with a low variation over the first 7 assays (26.8±0.8 degrees). While it was known
that many different biochips were able to give a consistent result when being used to perform
an identical assay, it showed that a single biochip can give a fairly reproducible result several
times. This is equally good from a manufacturing point of view. The experiment also gave
a good indication that the capture layer of recombinant HIV p24 created on the gold surface
of the biochip was very resistant. This is important in the context of the optimisation of
the test, even though future work should focus on the sustainability of the biochip to time
and other factors such as humidity and temperature, in addition to chemical resistance.
Even if this conclusion was not directly not helpful in terms of optimising the assay in the
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Figure 6.9: Reproducibility of the detection of anti-p24 antibodies on one OJ15
SAW biochips. a) Schematic to represent the surface of the SAW biochip functionalised
with recombinant HIV p24, and the target antibody in solution binding to the surface.
b) Barchart to show the phase shift recorded 5min after injecting an antibody sample
at 100nM in PBS on one OJ15 SAW biochip functionalised with recombinant HIV p24.
Each bar corresponds to one independent measurement, and represents the phase shift
normalised to a buffer only equivalent.
context of PoCT (as in this cases the SAW biochips used would have to be disposable), it
was still interesting.
6.2.3 Anti-p24: titration: detection of anti-p24 antibodies at clinically
relevant levels
Having shown the proof of concept detection of anti-p24 antibodies using OJ15 SAW bio-
chips, it was decided investigate the relationship between the phase shift ∆φ measured as
an indication of the formation of anti-p24/complex on the surface of the biochip, and the
concentration of anti-p24 antibodies in solution at clinically relevant levels. OJ15 SAW
biochips were functionalised with recombinant HIV p24 using DSP as a linker, and samples
of anti-p24 antibodies at different concentrations were tested. A 20µl drop of buffer was
incubated for 2.5 minutes to establish a stable baseline, before loading the sample. The
assay is schematised in FIgure 6.10, and the phase shift is plotted over time in Figure 6.10b,
for the different samples tested.
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Figure 6.10: Anti-p24 antibody detection using a SAW biochip functionalised
with HIV p24 recombinant proteins. a) Schematic to illustrate the specific binding of
anti-p24 HIV antibodies to p24 coated biochips, and a negative control using an antibody
with no affinity for p24 (anti-GBP5 antibody) which shows no binding to the biochip. b)
Overlaid raw data plots to show the phase shift recorded between input and output IDTs
as a function of time. The sample containing the anti-p24 antibody is injected at t=0.
Each sample trace was normalised with the reference assay (containing buffer only, orange
line).
As can be seen in Figure 6.10b, the injection of 500nM (75µg/ml) anti-p24 antibodies trig-
gers a rapid increase in the measured phase shift leading to a total phase shift of 46degrees
after just five minutes. This phase shift indicates a change in mass and/or viscosity at the
surface proximity associated with the specific binding of anti-p24 antibodies to p24 capture
proteins on SAW biochips. The other anti-p24 samples at lower concentrations give rise
to a smaller phase shift following a similar pattern. However, the series of control tests
confirmed the specificity of the SAW signals to anti-p24 over anti-GBP5: an injection of
buffer only shows no significant change in phase shift (orange trace, Figure 6.10b and a
sample containing 500nM (75µg/ml) of anti-GBP5 shows a negligible response (negative
control, red trace Figure 6.10b).
The measurements presented in Figure 6.10b were repeated in triplicate, and the average
phase shift measured 5 minutes after sample injection was plotted as a function of the
anti-p24 antibody concentration. This is shown in Figure 6.11 below.
The data were found scaled to a Langmuir adsorption model, R2 = 0.994 (Figure 6.11a).
At low antibody concentrations (5-20nM, which corresponds to 0.75-3µg/ml), the phase
shift increases linearly from 4±0.1 to 22±0.6 degrees, R2 = 0.964 (Figure 6.11b). Above
20nM (3µg/ml) the signal begins to plateau, presumably when all the available binding
sites on the surface are occupied. Testing three independent biochips, anti-24 antibodies
Chapter 6. Detecting Model Proteins and HIV Markers of Infection 132
0 20 40 60 80 100
0
10
20
30
40
anti-p24 concentration (nM)
Δ
φ
(deg
re
es
)
0 5 10 15 20
0
5
10
15
20
25
30
anti-p24 concentration (nM)
Δ
φ
(deg
re
es
)
a b
𝑦 = 47.8 ±3.3 𝑥12.2 ±2.7 + 𝑥 𝑦 = 1.56𝑥 + 3.2𝑅0 = 0.994 𝑅0 = 0.964
Figure 6.11: Titration of anti-p24 antibody detection in buffer using SAW
biochips. a) Graph to show the total phase shift recorded after 5 minutes, plotted as
a function of anti-p24 antibody concentration. Each measurement was repeated 3 times;
error bars shows the standard deviation of the mean. Black line: Langmuir adsorption
model, equation displayed on plot. b) Zoom of linear regression in the range 2-50nM,
equation displayed on plot.
could reproducibly be detected down to 2nM (300ng/ml) within 5 minutes. The small
error bars reflect the high reproducibility of these assays between different biochips and
functionalisation steps. This results show comparable performance and even slightly better
than leading commercial lateral flow tests such as the Alere Determine which were found
to be able to detect 10-30nM (1.5-4.5µg/ml) (E. Gray, personal communication).
6.2.4 Testing times: ultra-fast diagnosis of HIV infection within seconds
Having established that SAW biosensors can detect antibodies at clinically relevant levels,
it was decided to test how quickly results could be delivered. This was motivated by the
observation that the phase shift measured within the first few seconds after sample injection
changes at a very fast rate (Figure 6.10b). In addition, as the SAW biosensor is designed
to ultimately be operated with a smartphone with computing processing power capable
to analyse the phase shift in real-time, it opens up possibilities of fine, fast, automated
signal analysis with the potential to produce results much faster than human readings and
interpretation could ever achieve.
The data presented in Figure 6.10b is reproduced in Figure 6.12a, aligned with the corres-
ponding first derivative in Figure 6.12b. The first derivative represents the rate at which
the phase shift changes. As can be seen, at high antibody concentrations, this rate can
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be as high as a few tens of degrees per minute within the first few seconds after sample
injection. It was therefore decided to investigate the phase shift measured within the first
few seconds after sample addition. Figure 6.12c shows the average phase shift (for three
biochips) recorded shortly after sample injection, for the range of antibody concentrations
tested. Two samples can be distinguished from one another if the error bars surrounding
their respective average measurement do not overlap. As all values have been normalised
to a reference negative sample, a sample can be considered positive if the error bars of the
corresponding point do not overlap with the zero horizontal black line. As can be seen,
clinically relevant HIV antibody concentrations can be detected and distinguished just 10
seconds after injection down to 50nM (7.5µg/ml).
While these results were obtained in buffer, this is the fastest reported HIV test and is
more than 100 times faster than commercially available tests such as the Alere Determine
lateral flow test, which exhibits a similar limit of detection to the same biomarker but
requires at least 20 minutes between loading the sample and reading the results out by eye
(manufacturers guidelines).
6.3 Detection of recent HIV infections using recombinant
p24 detection
Building on the detection of HIV antibodies on SAW biochips, it was next decided to
investigate whether SAW biochips could detect a virological marker of infection, namely
p24 antigen. This is a key virological biomarker of acute HIV infections and is used in
combination with antibody detection in gold-standard fourth generation HIV diagnostic
assays in centralised laboratories. However, this protein is only present in human blood
in minuscule levels, around a million-fold lower concentrations than its antibody coun-
terpart [82,83,89,190–192] and a billion times lower than human serum albumin, presenting a
major challenge for PoCT diagnostics. As mentioned in Chapter 2, the clinically relevant
concentrations of p24 are very low (0.1-1000 pg/ml). Fourth generation p24 PoCT are
beginning to emerge but their performance in the field has been suboptimal, and this has
been attributed to a number of factors including the difficulty of interpreting lateral flow
tests by non-healthcare workers. [17] The first proof of concept for detection of p24 using
the SAW biosensor is presented below.
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Figure 6.12: Ultra-fast detection of anti-p24 antibodies at clinically relevant
concentrations. a) Reprodcution of Figure 6.10b. Overlaid raw data plots to show the
phase shift recorded between input and output IDTs as a function of time. The sample
containing the anti-p24 antibody is injected at t=0. Each sample trace was normalised
with the reference assay (containing buffer only, orange line). b) First derivative of the
data plotted in a). Note: the first derivative appears wiggly as it is the direct derivative of
raw data recorded at discrete time intervals. c) Plot to show average phase shift recorded
every 5 seconds during the first twenty seconds after injection. Each point represents
the average of three measurements, errors bars represent the standard deviation from the
mean. Samples of different concentrations (from 50nM (7.5µg/ml) and above) can be
distinguished from one another 10 seconds after sample injection.
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6.3.1 Anti-p24 llama VHH characterisation
SAW biochips were functionalised with novel capture ligands engineered from anti-p24
llama antibodies. These novel capture ligands are llama VHH (the Variable region of the
heavy chain of heavy chain-only antibodies), and are one-tenth the size of conventional
antibodies, [193] as schematised in Figure 6.13. Their small footprint means that VHH can
access hidden clefts which are inaccessible to larger proteins and in principle they can be
packed into dense arrays of capture ligands for diagnostic applications. They have remark-
able temperature stability, [194] have shown strong affinity to p24 [195] and are therefore ideal
candidates for capture ligands on SAW biochips.
Figure 6.13: Llama VHH. Schematics to illustrate the llama VHH, or nanobodies, used
in this thesis. Unlike human antibodies which consist of two heavy chains and two light
chains, llama antibodies consist of two heavy chains only. The VHH is the variable part of
one of these heavy chains.
Three anti-p24 llama VHH (59H10, 37E7, 59H4) were initially available, each raised against
a different epitope on p24. In addition, a fourth VHH was generated in the lab (work done
by Dr. E. Gray) by mutating one amino acid in the complementary determining region
of the 59H10 sequence. Mutations occurring in this region are not thought to affect the
general structure of the protein. Bio-layer interferometry (BLI) was used to assess which
anti-p24 protein available (either antibody or llama VHH) was the best binder to p24.
Two experiments conducted using BLI showed that one particular VHH (59H10) had a
better affinity for p24 than other VHH to conventional mouse anti-p24 antibodies. They
are described below.
Chapter 6. Detecting Model Proteins and HIV Markers of Infection 136
In the first experiment, streptavidin-coated probes were functionalised with four different
biotinylated VHH (59H10,37E7, 59H4 and 48G11) and the relative affinity of the different
llama VHH was observed by dipping the different functionalised probe in a 50nM solution
of HIV p24. Results are presented in Figure 6.14. BLI data shows that 59H10 is the best
binder to p24, out of all four llama VHH available.
Figure 6.14: Relative affinity of different llama VHH to HIV p24. Plot to
show the BLI binding data of 50nM p24 over 30 minutes. Each p24- binding curve was
normalized to a reference control of the same llama VHH without p24 in the buffer. Data
are combined from experiments performed in triplicate.
In the second experiment, the binding affinity of three different anti-p24 proteins (two
mouse antibodies, NIH-3537 and Capricorn HIV 1/2 and the anti-p24 llama VHH, 59H10)
to HIV p24 was compared. The BLI binding data is shown in Figure 6.15 and results
are summarised in Table 6.1. The results show that 59H10 has a better affinity to the
recombinant p24 protein used in the p24 detection assays presented in this chapter.
Protein NIH-3537 Capricorn HIV 1/2 59H10 llama VHH
KD 1.2× 10−8 1.6× 10−9 6.9× 10−10
Table 6.1: Dissociation constant estimated with BLI for three anti-p24 proteins.
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e
Figure 6.15: BLI association curves of the three different anti-p24 proteins to
recombinant p24. Data were acquired through binding of anti-p24 proteins in solution,
on BLI sensors functionalised with recombinant HIV p24, over at least 1 hour before
dissociation. Each curve was normalized to the signal recorded for buffer without added
anti-p24 protein. The plateau value, estimated using the limit to infinity of the fitted
function of the different was used to estimate the dissociation constant KD using the
Langmuir adsorption model. Results are presented in Table 6.1.
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The surface of the delay line was characterised using X-ray photoelectron spectroscopy
(XPS) at each step of the functionalisation process with 59H10 anti-p24 llama VHH. The
three steps are detailed in Figure 6.16a. An example of the XPS survey obtained at each of
the three steps of the functionalising process is shown in Figure 6.16b. The relative atomic
percentage of the four elements studied (Au, C, N and S) is presented in Figure 6.16c.
The relative ratios of C:N:S could then be calculated. These ratios were also modelled in
parallel by finding the planar density of fcc (111) gold (the surface of the delay line) and
a self-assembled monolayer of DSP density and assuming geometrical constraints when the
anti-p24 llama VHH is modelled as a cuboid. As can be seen in Table 6.2, the ratios C:N:S
measured using XPS compare favourably to the calculated relative percentage of atoms on
the surface. Characterisation by XPS provides evidence of monolayer coverage of anti-p24
llama VHH, which, using the model described, was estimated to be around 0.11 VHH/nm2.
Element XPS (%) Calculation (%)
C 86.1±10.5 76.7
N 11.8±2.8 18.6
S 2.0±0.6 4.6
Table 6.2: C:N:S ratios measured with XPS and estimated theoretically. The
ratios measured with XPS compare favourably to the calculated relative percentage of
atoms on the surface. The ratios of C:N:S where calculated by finding the planar density of
fcc (111) gold (the SAW biochip surface) and a
√
3
√
3R30◦ SAM DSP overlayer density and
assuming geometrical constraints when the llama VHH is modelled as a 32.2×28.2×48.91A˚3
cuboid.
6.3.2 Proof of concept and signal amplification strategies
As for the previous assays, the llama VHH were immobilised on SAW biochips using DSP
chemistry. This time, instead of simply using PBS as the running buffer, the target protein
p24 was diluted in pseudoserum, a solution of BSA diluted in TBS-T at 2% (w/v). Because
it contains a large amount of proteins, this running buffer is a better approximation of the
samples that the SAW biosensor would ultimately need to be able to test, i.e. human
blood. It also meant that normalising the readings to a negative control (reading from a
pseudoserum only sample tested on identical SAW biochips) was even more important as
it would remove non-specific contributions, such as BSA adsorption on the surface, from
the test reading.
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Figure 6.16: XPS characterisation of SAW biochips functionalisation. a) Schem-
atics to illustrate the different stages of the functionalisation process analysed by XPS: bare
gold surface, after DSP functionalisation (and hydrolysis), after llama VHH functionalisa-
tion (and blocking of unreacted DSP with Tris). b) XPS spectrum survey. CPS (count of
electrons per second) as a function of the binding energy. Four elements were selected to
analyse the surface composition: Au, C, N and S. One example for each step is plotted.
Inset: Zoom on the sulphur peak region. c) Relative atomic percentage for the four ele-
ments analysed at the different stages of the functionalisation process. A minor amount of
impurities on the surface explain the presence of carbon atoms on the bare gold surface.
Each bar represents the mean of five independent measurements. Error bars represent the
standard deviation of the mean.
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Figure 6.17a below shows direct p24 detection on SAW biochips coated with anti-p24 llama
VHH. A sample of 4nM (96ng/ml) p24 gave rise to a phase shift of only 1.2 degrees, even
after waiting for 20 minutes. Since p24 is only one-sixth the mass of an antibody, a strategy
of signal amplification was required to achieve detection of p24 through the creation of a
larger immuno-sandwich, corresponding to a six-fold increase in mass per antigen. Five
combinations of detection antibodies were tested, using antibodies from commercial sources
and the AIDS Reagent Program. All antibodies used in Figure 6.17 are described in Table
6.3.
Sample HIV p24 Detection antibody Binding to HIV p24
1 (control) Yes - -
2 Yes BC1071 (Aalto Bio Reagents,
UK)
Yes
3 Yes NIH-3537 (AIDS Reagent
Program, USA) [177]
Yes
4 Yes NBS500-473 (Novus Biologic-
als, UK) [85]
Yes
5 Yes Capricorn HIV 1/2 (Capri-
corn Products, USA)
Yes
6 Yes C65489M (Meridian Life Sci-
ence, USA) [85]
Yes
7 (control) - NIH-3537 (AIDS Reagent
Program, USA) [177]
Yes
8 (control) Yes ab89284 (Abcam, UK) no (anti-BGP5)
Table 6.3: Samples used for HIV p24 detection assay optimisation. For all
samples, the proteins listed were diluted in TBS-T buffer containing 2% (w/v) BSA. When
HIV p24 is present (column 2), the concentration is 10nM. When a mouse IgG is present
(column 3), the concentration is 200nM.
It was found that the largest phase change was measured for a combination of llama VHH
capture ligand and the NIH-3537 detection antibody (labelled immune-complex 3 in Figure
6.17b. Figure 6.17b shows that this combination generated a 5.5 degrees phase shift in re-
sponse to 4nM (96ng/ml) p24 within 20 minutes. This corresponds to a five-fold increase in
signal generated by the larger mass of the immune-sandwich complex although additional
factors such as surface viscoelastic changes may also contribute to this enhancement. To
test the specificity of this signal, a series of control experiments were performed, including
a sample with no p24 and injecting non-p24-targeting detection antibodies (Figure 6.17c).
The phase shift measured was significantly smaller than when detecting a p24/anti-p24
immuno-sandwich, indicating that the immuno-sandwich complex gave specific and sensit-
ive detection of p24.
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6.3.3 Titration of HIV p24 using the SAW biosensor
It was then decided to titrate the concentration of p24 while keeping the anti-p24 antibody
fixed and in excess (200nM - 30µg/ml). The best assay from Figure 6.17b involved detecting
HIV p24 via the immunosandwich, which constituted of the anti-p24 llama VHH on the
surface and NIH-3537 anti-p24 antibody. It was repeated with different concentrations of
HIV p24. The phase shift was recorded after five minutes and is plotted in Figure 6.18 .
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Figure 6.18: Reproducible detection of HIV p24 antigen titration curves. a)
Titration of HIV-p24 using optimised immuno-sandwich with NIH-3537 anti-p24 antibody
(number 3 in Table 6.3). The phase shift was recorded 5 minutes after sample injection.
Black line shows Langmuir adsorption model, equation displayed on plot. Data shown are
the combined results from three measurements and error bars show standard deviation
of the mean. b) Zoom on the 0-40nM region and fitted with a linear regression model
(black line), equation displayed on plot. Data shown are the combined results from three
measurements and error bars show standard deviation of the mean.
A linear relationship can be observed in the range 2-40nM (48-960ng/ml) p24 (Figures
6.18a-b) followed by plateauing of the signal - closely fitting a Langmuir adsorption model
(Figure 6.18b solid black line fit, R2 = 0.96). This demonstrates the ability of the SAW
biosensor to detect HIV p24 proteins down to low nanomolar concentrations in the presence
of other background proteins at one million fold higher concentrations (2% w/v or 20mg/ml
BSA).
6.3.4 Benchmarking QCM study
A benchmarking study using a quartz crystal microbalance (QCM) was used to validate the
p24 assay using the immunosandwich anti-p24 llama VHH/NIH-3537 anti-p24 antibody.
QCM was chosen for its robustness, fairly low running cost and the fact it was easily
Chapter 6. Detecting Model Proteins and HIV Markers of Infection 143
accessible. It is also regarded as a gold standard method to observe and analyse the
formation of protein-protein complexes. In a similar way to the SAW biochips presented
here, the piezoelectric quartz crystal of a QCM chip is submitted to an electric potential,
generating mechanical vibration through the crystal. The frequency is monitored as protein-
protein complexes are formed on the surface, and the drop in frequency has been shown
to be proportional to the mass of protein binding to the surface of the chip, following the
Sauerbrey relation mentioned in Chapter 3. [131]
Typically, QCM crystal operate at a frequency of a few megaHertz to a few tens of mega-
Hertz, operational frequencies much lower than for SAW biochips. The QCM chips used
here (QSX 301, Biolin Scientific, UK) operate at 5MHz. They were cleaned and functional-
ised with DSP oﬄine, using the same protocol as the one used for the SAW biochips, then
inserted into the system (Q-sense E4, Biolin Scientific, UK) to be functionalised with llama
VHHs of similar molecular weight. VHH1 does not have affinity for p24 and is used as a
control, while VHH2 is the one used in the assay described in the study to detect p24. The
surface of both chips was then blocked with BSA, before samples containing an excess of
NIH-3537 anti-p24 antibodies (200nM - 30µg/ml) and an increasing concentration of p24
were tested. The change in frequency is plotted against time in Figure 6.19.
As can be seen in Figure 6.19a, both llama VHH generate a similar change in frequency
when binding to the surface of the chip (about 18Hz for VHH1 and about 15Hz for VHH2).
The two chips then also react in a similar way to the addition of BSA (about 25Hz for
VHH1 and about 23Hz for VHH2). However, Figure 6.19b shows that only the chip coated
with the anti-p24 llama VHH presents a significant frequency shift upon loading of the
sample with a high (1µg/ml) concentration of p24, indicating that this VHH has the ability
to capture p24/anti-p24 complexes. Moreover, this same chip does not show any significant
frequency shift upon addition of the previous less concentrated sample, despite the presence
of BSA and anti-p24 antibodies at high concentrations. This indicate the ability of the anti-
p24 VHH to specifically bind to p24. The results of the study suggest that with identical
surface chemistries, the SAW biosensor offers a 20-fold signal enhancement (about 50ng/ml
compared to 1µg/ml).
Chapter 6. Detecting Model Proteins and HIV Markers of Infection 144
0 20 40 60 80
-50
-40
-30
-20
-10
0
Time (min)
Δ
F
(Hz)
VHH1
VHH2
100 110 120 130 140
-15
-10
-5
0
5
Time (min)
Δ
F
(Hz)
VHH1
VHH2
b
a
Figure 6.19: HIV p24 detection assay using QCM. a) Frequency shift plotted over
time as the llama VHHs are injected in the system, and the functionalised surface blocked
with BSA (2% w/v in PBS) to avoid non-specific binding during the assay. b) Frequency
shift plotted over time as samples containing a mixture of p24 (increasing concentration,
as labelled on graph), anti-p24 (NIH-3537) (200nM) and BSA (2% w/v) in PBS buffer is
loaded in the system.
6.3.5 Improvement of the limit of detection with gold nanoparticles
As described earlier, the signal measured following the formation of a p24/anti-p24 complex
on the surface of the SAW biochip can be used to reliably detect p24 in a sample at con-
centrations down to about 50pg/ml. This is not sensitive enough to detect the presence of
p24 at clinically relevant concentrations (0.1-1000pg/ml). A promising strategy to enhance
the sensitivity involved the creation of an immunosandwich, whereby the added mass of
the complex leads to a bigger measured phase shift, and lowers the limit of detection of the
target protein.
In a bid to enhance the signal further, an improvement to this strategy was tested, involving
the use of gold nanoparticles. Gold nanoparticles are much denser and therefore have a
much higher molecular weight than proteins (3 to 5 orders of magnitude higher depending
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on the size of the nanoparticle). They can easily be functionalised with proteins on their
surface, either via simple protein adsorption on the surface or using more complex linking
chemistries. [196,197] They are notably used in lateral flow tests as a colour marker of protein
complex formation. [198,199] Herein, gold nanoparticles were functionalised with antibodies
by simple adsorption, as described in Chapter 4. They were then used in the HIV p24
detection assay to form enhanced protein complexes. An example is schematised in Figure
6.20a, where an immunosandwich is formed between the anti-p24 llama VHH on the sur-
face of the SAW biochip, the target protein HIV p24 and an anti-p24 functionalised gold
nanoparticle. An additional gold nanoparticle functionalised with anti-Mouse antibodies
binds to the Mouse anti-24 antibodies on the surface of the first gold nanoparticle. The
idea was to test whether the gold nanoparticles could enhance the sensitivity of the assay
compared to direct detection and help lower the limit of detection of the HIV p24 assay to
levels much closer to clinically relevant concentrations. The phase shift measured during
the assays is plotted over time in Figure 6.20b. 6 different assays were run, with a concen-
tration of 50pg/ml of HIV p24 for three of them (bright green traces), and 100pg/ml for the
remaining three (dark green traces). Because of the presence of dense gold nanoparticles
in steps two and three, the phase shift was normalised with a control signal measured with
a solution containing nanoparticles functionalised with a non-specific antibody.
As can be seen in Figure 6.20b, the normalised phase shift recorded during the various
assays run does not reveal the formation of protein complexes on the surface during steps
one and two. In fact, as the phase shift is slightly positive in step two, it seems to suggest
that biological mass is removed from the surface. This could be due to the much denser
gold nanoparticles dislodging loosely and non-specifically bound BSA proteins from the
surface. However, upon addition of the solution containing the anti-Mouse functionalised
gold nanoparticles, a significant change in phase shift can be observed. Depending on the
concentration of HIV p24 initially injected, the phase shift observed was around 5 degrees
(50pg/ml) or 11 degrees (100pg/ml) 10 minutes after the injection of the second solution of
nanoparticles. This is likely to be due to non-specific binding of the dense gold nanoparticles
to the exposed surface, following the dislodging of BSA in step two.
More work was needed to optimise the conditions of use of the gold nanoparticles, mainly
to avoid the alteration of the surface observed in step two. However, despite observing
consistency in the measurement during the first 10 repetitions of the assay, it became
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Figure 6.20: Improvement of the HIV p24 detection assay with gold nano-
particles. a) Schematics to represent the different steps of the HIV p24 assay. First,
the target protein binds to the anti-p24 llama VHH coated surface of the SAW biochips.
Then, gold nanoparticles (20nm diameter) functionalised with Mouse anti-p24 antibodies
bind to the p24 on the surface to form the enhanced immunosandwich around the target
protein. Finally, gold nanoparticles functionalised with anti-Mouse antibodies bind to the
mouse-anti-24 antibodies. b) Plot to show the phase shift recorded during the assays,
as a function of time. Each trace was normalised with the relevant control measurement
(pseudoserum only in step 1, and gold nanoparticles functionalised with a non-specific
antibody for steps 2 and 3).
impossible to obtain reproducible results using gold nanoparticles. It was therefore decided
to investigate the possible causes of the sudden change observed.
6.3.6 Troubleshooting non-reproducible nanoparticle assay results: anti-
body affinity
The first possible source of problem that was identified was the functionalisation of the
gold nanoparticles with the anti-p24 antibody. Physisorption is one of the most common
methods of functionalising gold nanoparticles, however, it is relatively poorly understood
and uncontrolled. If any step in the process had gone wrong, or if the antibody had unfolded
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in the process of adsorbing to the surface of the gold nanoparticle, then the complex [anti-
p24 / gold nanoparticle] could be inactive and unable to bind to the target protein p24.
It was therefore decided to characterise the nanoparticles with Dynamic Light Scattering
(DLS). The size of the bare 20nm gold nanoparticles was first measured, then the same
nanoparticles after being functionalised with either NIH-3537 or Capricorn HIV 1/2 anti-
p24 antibodies. The estimated size is shown on the barchart in Figure 6.21.
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Figure 6.21: Dynamic Light Scattering measurement of functionalised gold
nanoparticles. Barchart to show the estimate size of bar gold nanoparticles and gold
nanoparticles functionalised with anti-p24 antibodies. Each bar represents the average of
5 independent measurements, error bars represent the standard deviation from the mean.
As can be seen in Figure 14, the average size measured for the bare gold nanoparticle was
close to their theoretical size of 20nm in diameter (24.6±0.4nm). Since DLS measures the
hydrodynamic radius and takes into account the interaction of the particle with solvent
molecules, it is known to slightly overestimate the actual size of the particle measured.
Therefore, these results are in good agreement with the theoretical size of the gold nano-
particles. The same measurement performed on nanoparticles functionalised with anti-p24
antibodies gave higher readings (37.5±2.6nm for NIH-3537 and 41.2±0.8nm for Capricorn
HIV 1/2). The difference measured between the bare gold nanoparticles and the func-
tionalised ones was therefore about 13 and 17nm for NIH-3537 and Capricorn HIV 1/2,
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respectively. Once again, as the theoretical size of the long axis of an IgG is about 10nm,
these results are in good agreement with the assumptions that antibodies are present on
the surface of the nanoparticle after functionalisation. This did not, however, give any in-
dication as to whether the antibodies are functional and retain their affinity for the target
protein HIV p24 after being adsorbed on the gold surface of the nanoparticle.
If for some reason (fridge failure, protein unfolding) the antibody had lost its functionality
and affinity for the target, then it would not have been able to form a complex with the p24
bound to the surface. In order to test this hypothesis, it was decided to perform a series
of assays using the ELISA technique. As can be seen in the schematics in Figure 6.22a,
the plate was functionalised with anti-p24 llama VHH, then HIV p24 was bound to the
plate at variable concentrations. The anti-p24 antibody - either alone or adsorbed onto a
gold nanoparticle was then added to complete the immunosandwich, before an HRP-tagged
anti-Mouse antibody was bound to the resulting complex in order to reveal the results of the
ELISA. Two different anti-p24 antibodies were tested: NIH-3537 (used during the successful
nanoparticle assays) and Capricorn HIV 1/2, which was successfully used previously in the
process of optimising the p24 immunosandwich. Results are presented in Figure 6.22b.
As can be seen in Figure 6.22b, both antibodies, when used on their own, seems to bind
to the target protein p24 and these assays led to the detection of p24 at around 100pg/ml
and above. A very similar result can be observed for the assay involving gold nanoparticles
functionalised with Capricorn HIV 1/2 anti-p24. However, the assay performed with gold
nanoparticles functionalised with NIH-3537 was unsuccessful, as only a very small increase
in the absorbance can be observed at a concentration of 10,000pg/ml. These results show
that neither of the anti-p24 antibodies had lost their affinity for the target protein HIV
p24, and that the process of adsorbing the antibodies on gold nanoparticles did not affect
the ability for Capricorn HIV 1/2 to bind to HIV p24, as the results of this assay were
very much comparable to the one performed with the same antibody alone. However, the
functionalisation of the gold nanoparticles with NIH-3537 may have affected the ability for
the anti-p24 antibody to bind HIV p24.
These results suggest that, despite both antibodies undergoing the exact same process to
adsorb onto the surface of gold nanoparticles, one of them seems to have lost its ability
to bind to HIV p24 as a result. Unfortunately, it was not possible to perform the same
ELISA with the batch of gold nanoparticles that were used during the first few successful
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Figure 6.22: Testing antibody activity with ELISA. a) Schematics to illustrate
the different assays performed. The plate was coated with anti-p24 llama antibodies,
onto which HIV p24 was bound at different concentrations. Four different strategies were
tested to complete the immunoasandwich, involving two different anti-p24 antibodies alone
or bound to a gold nanoparticle. A HRP-tagged anti-Mouse antibody was used to reveal
the amount of complexes left on the plate after washing. b) Plot to show the measured
absorbance at 450nm at the end of the assay, as a function of the HIV p24 concentration.
Each point represents the average of 7 independent measurements, normalised to a negative
control. Error bars represent the standard deviation of the mean.
assays on the SAW biosensor. In addition, further attempts to use gold nanoparticles as a
single enhancement failed despite using Capricorn HIV 1/2 to functionalise the nanoparticle
instead of NIH-3537. While using ELISA confirmed the capability of the anti-p24 antibodies
to bind to their target protein, it was not conclusive in terms of explaining what went wrong
with the nanoparticles assays.
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6.3.7 SAW biochips insertion loss consistency
As the investigation of the reproducibility of the nanoparticles functionalisation process
using ELISA was not conclusive, and the confirmation that the antibodies used still had
an affinity for their dedicated target protein ruled out any reagent fault, it was decided to
look into the insertion loss of the SAW device before functionalisation. Each SAW device
is characterised by its insertion loss in air, with no liquid in contact with the surface and
nothing attached or adsorbed to the gold surface. This was triggered by the observation
that not all SAW devices had the same initial insertion loss.
The insertion loss of all the SAW devices used for various assays during the period January
2013-June 2014 is plotted in Figure 6.23 below. The SAW devices used to perform assays
involving gold nanoparticles are identified by crosses. A green cross indicates that the
nanoparticle assay was successful, i.e. a significant improvement was observed compared
to a similar assay ran without nanoparticles. A red cross indicates that no significant
improvement compared to a similar assay without nanoparticles was observed.
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Figure 6.23: Troubleshooting non-reproducibility of gold nanoparticle assays:
OJ15 SAW devices insertion loss. Plot to show the insertion loss of various OJ15
SAW devices. Each blue dot represents a unique SAW device, and its insertion loss is
plotted against the date it was used to perform an assay. The crosses highlights devices
used to perform an assay involving gold nanoparticles to enhance the signal. A green cross
indicates that the gold nanoparticles used during the assay enhanced the signal obtained
with a control experiment (identical assay without gold nanoparticles), a red cross indicates
the nanoparticles did not improve the control signal.
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As can be seen in Figure 6.23, the SAW devices can be distinguished by their initial insertion
loss in two distinct groups. The SAW devices used between January and July 2013, and
between February and May 2014 all had an insertion loss comprised within the interval
[21.7-22.7]dB, while the SAW devices used between October 2013 and January 2014 were
all characterised by an insertion loss comprised within the interval [21.2-21.7]dB.
Another observation is that all the successful assays (green crosses) involving gold nano-
particles were performed between October 2013 and January 2014, which corresponds to
one of the distinct groups in terms of insertion loss. The unsuccessful assays were performed
from November 2013 to April 2014, which corresponds to SAW devices from both groups.
While this observation is not conclusive enough in itself, it is interesting to note that all
successful nanoparticles assays are characterised by a specific parameter. While some assays
were unsuccessful using SAW devices from the same insertion loss group, all the assays in-
volving gold nanoparticles performed with SAW devices from the other insertion loss group
were unsuccessful. Unfortunately, it was not possible for logistical reasons to reproduce the
successful assays on SAW devices presenting an insertion loss lower than 21.7dB. However,
these observations are a good starting point for carrying on the troubleshooting of the gold
nanoparticle assays in the future.
6.4 Discussion
The SAW biosensor presented in this thesis comprises of different elements, of which the
SAW biochip was the main focus. The optimisation of structural parameters that influence
its performance such as the gold surface thickness were presented in Chapter 5. Another
aspect of the optimisation process is the surface functionalisation of the sensing area. As
the target proteins in the sample are detected when they form a complex with the capture
protein on the surface, designing the best capture surface is key to the biosensor perform-
ance.
The challenge consisted in finding a combination between finding the best protein to form
a complex with the target protein, and the best conditions to attach this protein to the
gold surface, in order to get the best signal output when detecting the target protein. It
was first decided to use a model protein-antibody complex to optimise the functionalisation
of the gold surface. The HSA/anti-HSA complex was chosen as both proteins were easily
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accessible. Several strategies were investigated to link the anti-HSA antibody to the gold
surface, and it was shown that using DSP as a chemical linker was the option that led to
the highest subsequent detection signal. DSP forms a stable bond with the gold surface
and a covalent bond with the lysine residues of the capture protein. It was also shown that
the ideal concentration to use when functionalising the DSP-coated surface with capture
proteins was 100µg/ml, which is the best combination between good detection signal and
protein economy (some capture proteins can be rare and/or expensive).
It was then shown that the immunoassay designed to detect anti-p24 antibodies, a common
marker of HIV infection, could be optimised enough to reproducibly detect the target
protein at clinically relevant concentrations within 5 minutes. A careful analysis of the first
few seconds after sample injection revealed that concentrations as low as 50nM of anti-p24
antibodies could be detected within just 10 seconds, opening up the possibility for ultra-
fast results. This was motivated by the fact the signal can be analysed in real time by
the computing power of modern smartphones, which form part of the SAW biosensor. In
addition, reducing the time to deliver a test result is crucial for its utility within a typical
primary healthcare setting, allowing treatment and care to be given on the spot, overcoming
the need for multiple visits and reducing the risk that patients may not return to receive
their results. The faster the test can be delivered the more time will be available for post-
test counselling and care. The Foundation for Innovative Diagnostics target product profile
for a HIV self-test for use in the home underlines the need for results in under 5 minutes. [31]
More work is needed to confirm these results in real test conditions, using complex samples
that make the signal analysis more challenging because of the large amount of non-specific
binding of proteins to the surface of the biochip.
A series of experiments were performed to optimise the immunoassay aiming at detecting
HIV p24, a key biomarker of early infection. The strategy of an immunosandwich, with
anti-p24 llama VHH on the surface acting as the capture protein, and NIH-3537 anti-p24
antibody at the top, was found to be the option that gave the best results. This working
immunoassay was confirmed by a benchmarking study using QCM. A titration performed
using the best combination showed that the antigen could reproducibly be detected in
pseudoserum at concentrations down to low nanomolar concentrations. More work needs to
be done in this direction, at these concentrations are still significantly higher than clinically
relevant concentrations needed to be detected by an early fourth generation PoCT for HIV.
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The challenge with the detection of HIV p24 is the relatively small size of the protein
compared to antibodies (24kDa compared to around 150kDa), and its presence at very low
concentrations in human blood. One way to overcome these barriers is to try and amplify
the signal obtained when detecting the antigen.
A further investigation into possible ways to amplify the signal using gold nanoparticles as
a signal enhancer was conducted. The target protein, once bound to the anti-p24 llama
VHH on the surface, was used as an anchor for gold nanoparticles functionalised with
Mouse anti-24 antibodies, which in turn were used as a target for nanoparticles coated
with anti-Mouse antibodies. A number of ways to optimise the process were identified
and opened up possibilities of lowering the detection limit of the assay to clinically relevant
levels. However, the initial measurements, despite being consistent, were not conclusive and
they could not be reproduced after the first initial attempts. The troubleshooting steps
performed in order to explain this change in results were presented. While DLS measure-
ment confirmed the presence of the antibodies on the surface of the gold nanoparticle after
functionalisation, a series of ELISA highlighted the loss of activity, after being adsorbed on
gold nanoparticles, of the anti-p24 antibody used during the initial successful SAW assays
(NIIH-3537). However, another anti-p24 antibody retained his activity after undergoing
the same functionalisation process. Both antibodies were confirmed to have an affinity for
HIV p24, ruling out a possible unfolding of the protein due to a fridge failure for example.
Finally, an investigation into the SAW biochips insertion loss revealed the possibility of a
link between a successful assays involving gold nanoparticle enhancement, and the SAW
biochip initial insertion loss in air. More work is needed to explore the potential of enhan-
cing the p24 detection signal, which could take the SAW biosensor a step closer to becoming
the fastest and first smartphone-connected fourth generation PoCT for HIV. Suggestions
are presented in the Conclusion and Future Work at the end of this thesis.

Chapter 7
Clinical Pilot Studies: Testing
Real Patient Samples
The previous chapter established the feasibility of detecting key biomarkers of HIV infection
at clinically relevant concentrations in mock samples (i.e. buffer samples spiked with both
the biomarker of interest and large amounts of serum albumin) using the SAW biosensor.
The natural next step forward was to investigate the ability of these biosensors to detect
HIV biomarkers in real patient samples. A proof of concept study was first conducted, us-
ing human serum spiked with biomarkers of HIV infection at known concentrations. This
was followed by two pilot clinical studies using real HIV-positive patient samples, which
were conducted in order to assess the sensitivity and specificity of the SAW biosensor as a
diagnostic test for HIV. Care was taken to fit the test within an 8-10 minute time frame,
which is the approximate duration of a typical doctors appointment in the UK. [20] The
process of going from proof of concept studies to pilot studies testing real patient samples
was accompanied with an evolution of the materials and methods used to run the tests.
Various improvements were made in order to achieve the ultimate goal of being able to run
a large scale clinical study testing patient samples with the cheapest, most accurate and
most easy-to-use prototype of SAW biosensor. Along the way, the SAW biochips used were
optimised to feature an in-built reference channel, as opposed to two individual biochips,
thus requiring smaller sample volumes, making the testing easier, and the potential cost
even smaller. The functionalisation of the SAW biochips was also automated in collab-
oration with industrial partners OJ-Bio Ltd., using an automated liquid spotter in order
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to increase the chip to chip reproducibility as well as to prepare for the potential large
scale manufacturing process. Finally, it was necessary to develop a software using Wolfram
Mathematica to automate data analysis, therefore removing any potential user bias asso-
ciated with manual data analysis. The software also opened up opportunities to go further
in the analysis of the results of the pilot studies conducted, and helped preparing for the
potential next step large scale studies.
This chapter presents the proof of concept of detecting biomarkers of HIV in real patient
samples, as well as the design, results and analysis of the two pilot studies conducted using
SAW biosensors. All the results presented in this chapter were obtained in collaboration
with Dr Eleanor Gray (UCL) and Dr Vicki Lawson (OJ-Bio Ltd.).
Ethics statement : The University College London Hospital Research Clinical Microbiology
Department reviewed and exempted the HIV-positive samples used in the following pilot
studies from ethics review because it was an assay development, and waived the need for
consent due to the fact the patient material used was fully anonymized. HIV-negative
samples were obtained from UCL staff and students who gave full informed consent. The
study was reviewed by UCL Ethics Board and given study number 6109/001.
7.1 Proof of concept of detecting biomarkers of HIV infec-
tion in human plasma samples
7.1.1 Proof of concept using single-channel OJ15 SAW biochips
In Chapter 6, it was established that SAW biochips have the ability to rapidly detect both
virological and immunological biomarkers of HIV infection with high reproducibility down
to low nanomolar concentrations using model samples in buffer with 2% (w/v) BSA. As
a next step towards the proof of concept of their clinical utility, the performance of the
SAW biochips was tested in human plasma. Due to the presence of many different proteins
and other components like lipids, fats or metabolites at concentrations of around 70mg/ml,
plasma has a higher viscosity than buffer, increasing the amount of non-specific binding
on the surface of the biochip. With these high - and variable - viscosities, it is essential to
differentiate the contribution of the biomarker binding to the surface from the larger non-
specific contributions. Therefore, for each sample type a reference SAW biochip was run
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in parallel, as can be seen in Figure 7.1a. Using OJ15 SAW biochips, this reference takes
the form of a physically different sensor chip. The signal recorded by the reference SAW
biochip was then subtracted from the test SAW biochip chip signal, in order to remove the
effect of non-specific binding to the surface.
In these experiments three different types of SAW biochips, each characterised by a different
capture coating, were used. Two were coated with p24 and gp41 capture ligands to detect
anti-p24 and anti-gp41 antibodies respectively, and are referred to as test biochips. A
reference biochip was functionalised with non-animal protein (NAP) to account for non-
specific signals, as NAP has no affinity for any human protein. [200] The SAW biochips
were incubated in buffer for 30 seconds to record a stable baseline. Two human plasma
samples were then tested: one HIV positive sample, and the other was negative for anti-HIV
antibodies. The HIV-positive sample was obtained from The University College London
Hospital Research Clinical Microbiology Department (see ethics statement below), while
the HIV-negative sample was obtained from a healthy UCL student who gave full informed
consent.
The phase shifts of both the reference and the tests biochips are plotted against time in
Figures 7.1b and 7.1c. Upon addition of the plasma samples, the phase shift of both the
test and reference biochips immediately shifts by approximately 20 degrees. This is due
to differences in viscosity between buffer and plasma. Moreover, within seconds, the phase
shift of the test and reference biochips have clearly separated for the HIV positive sample,
whilst remaining at similar levels for the HIV negative sample. The differential signal
calculated by subtracting the reference signal from the test signal is shown in Figure 7.1d,
and indicates that the binding of the biomarker to the test capture ligand occurs with
high specificity. For both HIV biomarkers - anti-p24 and anti-gp41 - the differential phase
change was found to be 65 and 35 degrees respectively for the HIV-positive plasma sample.
By contrast a much smaller response was seen for the HIV-negative plasma sample which
gave rise to 7 and 12 degrees respectively. These findings show that SAW biosensors could
potentially be able to detect the presence of both anti-HIV antibodies in human plasma
samples. This feasibility study warranted a larger pilot study with more patient samples.
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Figure 7.1: Detection of anti-HIV antibodies in a plasma sample from a patient
with HIV using OJ15 SAW biochips. a) Schematic of the reference chip functionalised
with non-animal protein (NAP), and test chip functionalised with recombinant HIV protein
corresponding to the biomarker (HIV p24 or HIV gp41). Non-specific binding of various
plasma proteins and antibodies occurs on both chips, but the biomarker (anti-p24 or anti-
gp41) only binds specifically to the test chip. b) Anti-gp41 detection. Phase shift plotted
as a function of time for two different samples (HIV-positive in red and HIV-negative in
green). Dashed lines represent the reference chips, and the solid lines the test chips. c)
Anti-p24 detection. Phase shift plotted as a function of time for two different samples
(colours and lines allocation as for (b). d) Barchart to show the differential response of
test and reference chips for anti-p24 and anti-gp41 detection in patient samples, recorded
5 minutes after sample injection. The differential test readout represents the change in
phase shift due the specific binding of the biomarker to the SAW biochip, and removes the
effect of other non-specific perturbations such as the difference in viscosity between buffer
and plasma.
7.1.2 New generation of SAW biochips (OJ24/OJ28/OJ31)
During the course of this work, new generations of SAW biochips (OJ24/OJ28/OJ31) were
designed in collaboration with industrial partners OJ-Bio Ltd. and Japan Radio Company.
In essence, the new SAW biochips feature an in-built reference channel to help suppress
the background noise in the signal due to non-specific adsorption of unwanted proteins and
other viscosity effects. They require less sample volume (6µl instead of 20µl). For these
reasons, and in the context of aiming to develop the best SAW biosensor for use as a PoCT,
it was decided to move from single channel (OJ15) to dual channel (OJ24/OJ28/OJ31) SAW
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biochips before conducting the pilot study. A new proof of concept study was therefore
required and is presented below. As described in Chapter 4, only minor differences distin-
guish the three generations of SAW biochips. In the context of the proof of concept or pilot
studies presented below, it was assumed that using either of the new generations of SAW
biochips would not have an impact on the studies conducted.
7.1.3 Proof of concept using dual-channel OJ24 SAW biochips
The proof of concept study using OJ24 SAW biochips was very similar to the one conducted
using single-channel OJ15 chips, with the main difference being the functionalisation of the
biochip with the relevant proteins. With single-channel chips, a manually pipetted droplet
of solution containing the relevant capture protein could be left to incubate on the whole
surface of the sensing area, after this had been functionalised with DSP. With the dual-
channel chips, care had to be taken to functionalise each channel with a different protein,
and to avoid cross contamination between the channels. This was first achieved by carefully
pipetting 1µl of capture protein solution onto one channel, and covering up the chip with
a lid during the fifteen-minute incubation period. While this protocol seemed to work (see
proof of concept results), it required a lot of dexterity and in the context of developing a
reliable biosensor, reproducibility of this step of the process would have been an issue. It
was therefore decided to move to an automated functionalisation, using a liquid spotter.
This process is described in Chapter 4 (Materials and Methods) and was optimised by
industrial partners OJ-Bio Ltd.
In this experiment two types of SAW biochips were designed. The test channel on the sens-
ing area was coated with the relevant recombinant protein (p24 or gp41) used as capture
ligand to detect the corresponding antibody (anti-p24 or anti-gp41). The reference channel
was functionalised with non-animal protein (NAP) to account for non-specific signals, as
NAP has no affinity for anti-HIV antibodies (Figure 7.2a). The SAW biochips were in-
cubated in buffer for 1 minute to record a stable baseline. Three types of mock samples
(all based on human serum H4522 AB male, Sigma, UK) were then tested: two positive
samples spiked with either polyclonal human anti-p24 antibodies or polyclonal anti-gp41
antibodies at a clinically relevant concentration of 100µg/ml, and the other was negative
for anti-HIV antibodies, i.e. serum only. The negative samples were tested on SAW bio-
chips functionalised with p24 as well as on SAW biochips functionalised with gp41. The
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average differential phase change recorded after five minutes is represented on the barchart
in Figure 7.2b.
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Figure 7.2: Detection of anti-HIV antibodies in a plasma sample from a patient
with HIV using OJ24 SAW biochips. a) Schematic of the reference channel function-
alised with non-animal protein (NAP), and test channel functionalised with recombinant
HIV protein corresponding to the biomarker (HIV p24 or HIV gp41). Non-specific binding
of various plasma proteins and antibodies occurs on both chips, but the biomarker (anti-
p24 or anti-gp41) only binds specifically to the test chip. b) Barchart to show the average
differential response of test and reference channels for anti-p24 and anti-gp41 detection in
mock samples, recorded 5 minutes after sample injection. Each bar represents the average
of 6 independent measurements. Error bars show the standard deviation from the mean.
It was found to be 35±8 degrees on average for the anti-24 positive serum sample, while a
much smaller response was seen for the negative samples which on average gave rise to 4±3
degrees. Similarly, the differential phase shift was found to be 45±8 degrees on average
for the anti-gp41 positive serum samples, and 15±3 degrees for the negative samples. This
confirmed that dual-channel SAW biochips were able to detect the presence of anti-HIV
antibodies in human serum samples, and could distinguish between a positive and a negative
sample.
7.2 Clinical pilot studies: Method
7.2.1 Diagnostic test performance indicators
The pilot study can be seen as a binary classification test, where for each sample tested,
there are only two possible answers: either positive or negative to HIV. As the SAW
biosensor is the system that performs the test and outputs the answer, it is necessary to
assess its performance statistically. When it comes to defining the performance of such a
test, there are a number of parameters that can be considered (examples). In the context
Chapter 7. Clinical Pilot Studies: Testing Real Patient Samples 161
of a diagnostic test, two parameters are most commonly used: the test sensitivity and
specificity.
The clinical sensitivity is defined as the ratio between the number of true positives (TP)
and the sum of TP and false negatives (FN):
Sensitivity =
TP
TP + FN
. (7.1)
A TP refers to a sample which is known as being positive (the reference being a gold-
standard test) and is correctly declared positive by the diagnostic test. A FN is defined
by a sample known as positive but declared negative by the diagnostic test. Therefore, the
sum TP+FN is the total number of sample known as being positive, and the sensitivity
can be defined as the proportion of positive samples that are correctly identified by the
diagnostic test.
The clinical specificity is defined as a mirror image of the sensitivity, for negative samples.
It is defined as the ratio between the number of true negatives (TN) and the sum of TN
and false positives (FP):
Specificity =
TN
TN + FP
. (7.2)
A TN refers to a sample correctly identified by the diagnostic test as negative, as opposed
to a FP which is declared positive by the diagnostic test despite being negative. Therefore,
the sum TN+FP is the total number of negative samples, and the specificity measures the
proportion of negative samples correctly declared as such by the diagnostic test.
Both the clinical sensitivity and the clinical specificity are important in the context of a
diagnostic test: a test with a high sensitivity is only useful if the specificity is also high,
otherwise the test will declare most samples as positives and be wrong about the negative
samples. Similarly, a test with high specificity and low sensitivity will correctly identify the
negative samples but could not be trusted to identify the positive samples. While an ideal
test would be 100% sensitive and 100% specific, a trade-off has to be found, that can vary
slightly depending on the test application. For instance, when performing a screening test,
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it is necessary for the test to have a high sensitivity, while the specificity can be slightly
lower. Indeed, false negative results cannot be tolerated, as the patient would not only not
get access to treatment but also be likely to pass on the infection. [66] False positive results
are less problematic as a second confirmatory test is usually performed after a positive
result by the first diagnostic test. In some extreme cases, a confirmatory test is not easily
available and even false positives cannot be tolerated. This was the case in the recent
Ebola outbreak, as Ebola is highly contagious and people declared as positive were put
in contact together, therefore making it likely for a healthy patient to become infected.
In these extreme cases, both the sensitivity and the specificity ideally need be as close as
possible to 100%.
7.2.2 Clinical Sample Types
Three types of samples were run during the pilot studies:
• Fully anonymized HIV positive samples, obtained from The University College Lon-
don Hospital Research Clinical Microbiology Department (see ethics statement be-
low).
• HIV-negative samples, obtained from healthy UCL staff and students who gave full
informed consent.
• Calibration samples. The calibration samples were a commercial pooled human
plasma (screened for biomarkers of HIV infection) and were used to validate the
assay with known levels of spiked anti-HIV antibodies. Some calibration samples
were not spiked with HIV biomarkers and run as negatives, or zeros, to define the
threshold between positive and negative samples.
7.2.3 Protocol: doctor appointment model
In order to reproduce, as much as possible, the conditions of a real diagnostic test, the
protocol used to test each sample was designed to fit within an 8-10 minute time frame,
which is the approximate duration of a typical doctors appointment in the UK. [20] About
a minute was allowed to turn the control box on, insert the SAW biochip in its holder and
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load a 6µl drop of TBS-T buffer on the surface of the SAW biochip. The buffer was then
replaced with an equal volume of sample, and a 5-minute detection period was recorded,
before washing off the sample with buffer (this last step was only performed out of interest
and would not have been necessary in the context of a real diagnostic test). Therefore, a
few minutes out of the 8-10 minute appointment duration could have been used to welcome
the patient, collect the sample, and then deliver and explain the result.
7.3 Processing/Analysis software
A software was written using Mathematica (Wolfram language) to process and analyse the
result of the pilot study as a batch rather than require each individual result to be analysed
separately, which would be time consuming. In addition to saving time and repetitive
effort, this approach made it easier to perform further statistical analysis of the pilot study,
such as a time-dependent study of the diagnostic test performance indicators and removed
any potential user bias from data interpretation. As a result of this form of analysis, some
valuable information could be extracted, about how fast the SAW biosensor can operate
while keeping the required level of performance in terms of sensitivity and specificity. The
method of analysis is amenable to a mobile phone app which could interpret test results.
The principle of the software is presented in Chapter 4.
One of the main advantages of the software developed to analyse the results of the pilot
study as a batch is time. The algorithm takes about 3 seconds to compile (2.8s, average
of 10 measurements, with a standard deviation of 0.8s), which compares favourably with
the 2-3 hours (approximately) required to manually process each file individually, and to
plot the results. In addition, the test performance in terms of sensitivity and specificity
would also normally have to be calculated separately after processing all the test data. The
software incorporates these calculations and therefore makes the analysis of the pilot study
easier and more complete.
The time-dependent visualization of the test performance (see Chapter 4) provides very use-
ful information about how fast the test can reliably be performed. The key requirements of
PoCT according to the WHO aside from low cost, sensitivity and specificity, ease of use and
transportability, is the capacity to provide the test result to the patient quickly. [56] Rapid
HIV testing has been proven to increase the return rate of patients to receive confirmatory
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results of HIV testing and other sexually transmitted infections. [201] The target product
profile for an HIV self-test underlines the need for results in under 5 minutes. [31] Diagnostic
test performances are traditionally evaluated after a defined time period post sample in-
jection, as they rely on a human reading that cannot be performed continuously (like the
interpretation of the colour of a line on a lateral flow test for example). The advantage of
this SAW biosensor, combined with the analysis software, is that a data point is recorded
every second, and the test performance can therefore be assessed in a continuous way from
the sample injection. This enables very fine estimation of how long the test needs to be run
for, in order to perform with the required sensitivity and specificity, rather than a more
traditional approximation.
Finally, the analysis software, once written and optimised, can be saved and re-used for the
next pilot study without further work needed. As part of the final optimisation of the SAW
biosensor, a number of pilot and/or clinical studies might have to be performed. While
the end user of the PoCT would ultimately only need a single test readout, the software
analysis can prove to be a useful tool in the various stages of product optimisation.
7.4 Preliminary blind clinical pilot study
A preliminary blind study was conducted with ten patient samples: 5 HIV positive samples,
and 5 HIV negative samples. They were blinded to the operator with labels A to J. This
was done by a third party who also retained the blinding details until post-analysis. Dual
channel OJ24 SAW biochips were functionalised with recombinant HIV p24 proteins (test
channel) and NAP (reference channel), and were used to conduct the tests.
7.4.1 Calibration
In order to define a threshold between negative and positive samples, calibration negative
samples were tested on the SAW biosensor first. 6 samples of pooled plasma (LEEBIO Inc,
USA) were tested, and the mean (+3SD) of the differential phase shift recorded 5 minutes
after sample injection was used as the test threshold.
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7.4.2 Summary of results, test performance indicators
Each of the 10 patient samples was tested 3 times independently on the SAW biosensor. The
differential phase shift was recorded 5 minutes after sample injection. It was decided that
a sample would be considered positive if the sum of the mean and the standard deviation
of the 3 measurements was greater than the threshold value obtained with the calibration
samples. Results are presented in Figure 7.3.
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Figure 7.3: Preliminary blind pilot study: readings 5 minutes after sample
injection. Differential phase shift measured 5 minutes when testing the 10 unknown
samples. The red line represents the threshold value (4.9 degrees), defined as the mean
(+3SD) of the negative calibration samples measurements. Error bars represent standard
deviation from the mean. For each samples, the bar is coloured green if the mean (+SD)
is greater than the threshold value (i.e. if the top of the positive error bar is above the red
line), and grey if not. Samples A, B, D, F, G and I returned a positive response from the
test. Samples C, E, H and J were declared negative.
As can be seen on Figure 7.3, six samples (A, B, D, F, G and I) were declared positive by
the test, while the remaining 4 (C, E, H and J) were declared negative. A summary of the
results after comparison with the blinding details is presented in Tables 7.1 and 7.2.
After comparison with the real status of the samples tested, it was found that all positive
samples were declared positive by the test, giving a sensitivity of 100%. 4 out of the 5
negative samples were correctly identified as negative, giving a clinical specificity of 80%.
Only 1 sample gave a false positive result (sample G).
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Sample A B C D E F G H I J
True status + + - + - + - - + -
Test prediction + + - + - + + - + -
Result TP TP TN TP TN TP FP TN TP TN
Table 7.1: Preliminary blind pilot study results. Table listing, for each sample, the
known status, the test prediction and the consequent result (True Positive, True Negative,
False Positive or False Negative). Only sample G resulted in an incorrect result.
+ samples - samples
Sensitivity Specificity
Total TP FN Total TN FP
5 5 0 5 4 1 100% 80%
Table 7.2: Preliminary blind pilot study: summary of results.
7.4.3 Discussion
The results of this preliminary pilot blind study were very encouraging. Using the threshold
defined by the measurements of negative calibration samples, the SAW biosensor was able
to correctly identify 9 out of the 10 samples tested. The specificity was found to be 80%, and
the sensitivity 100%. A more accurate threshold value could have been achieved by testing
a higher number of negative calibration samples. of patient samples and investigating the
performance indicators of the SAW biosensor. In addition, some of the SAW biochips used
in the study were dropped on the lab floor by accident just before being used to conduct
the test. The surface of the sensing area was cleaned with dehydrated water and dried
with nitrogen straight away. While the SAW sensors are designed to be resistant to being
dropped on the floor, no investigation has been conducted at this point about the sensing
area, i.e. after the sensor have been turned into SAW biochips. This incident can be seen
as encouraging though, as results were still very good despite the biochips being dropped
on the floor before being used. Nonetheless, these results made a strong case for larger
pilot studies, testing a higher number of samples. It was therefore decided to move on to
the second clinical pilot study.
7.5 Second pilot clinical study
This time, the samples were not blinded, but the study involved testing all the samples avail-
able (31 HIV-positive samples, 6 HIV-negative samplessee clinical samples types above).
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All samples were tested on OJ28 SAW biochips functionalised to detect either anti-gp41
or anti-p24 antibodies. Most SAW biochips were functionalised with an automated liquid
spotter (see Chapter 4). The protocol that was optimised to functionalise the SAW bio-
chips, and that was used to obtain the results presented in Chapter 6, was adapted to be
used with the automatic liquid spotter. Due to a failure of the automatic liquid spotter dur-
ing the functionalisation process, a small number of SAW biochips had to be functionalised
manually.
7.5.1 Calibration
A series of control samples were tested on the SAW biosensor before moving on to patient
samples. They consisted of pooled plasma (LEEBIO Inc, USA) spiked with commercially
available anti-HIV antibodies. The control samples were tested on OJ28 SAW biochips
functionalised to detect either anti-p24 or anti-gp41, at least 4 times for each concentration.
The differential phase shift is plotted against the concentration of the biomarker in Figure
7.4, for both biomarkers tested.
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Figure 7.4: Second pilot study: validation of the assay using mock samples
of known concentration. Differential phase shift measured after 5 minutes when test-
ing mock samples with known concentration of anti-HIV antibody. Anti-gp41 results are
presented in blue, anti-p24 in red. Each dot represents the value of one test, the line repres-
ents the average of all measurements for one concentration, with the error bars representing
the standard deviation of the average. The dotted line represents the linear regression of
the averages values.
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The Pearson product-moment correlation coefficient (PPMCC) was evaluated for both data-
sets. A PPMCC value close to +1 or -1 indicates a strong correlation between the two data
sets, while a value close to 0 (or more generally in the -0.5 / +0.5 interval) indicates a very
weak correlation. A good correlation was observed between the biomarker concentration
and the differential phase shift (PPMCC of 0.898 for anti-gp41, and 0.76 for anti-p24). The
assay was therefore validated and it was decided to move on to testing of patient samples.
7.5.2 Summary of results, test performance indicators
A summary of all the data obtained during this study is presented in Figure 7.5 and Table
7.3. Each sample was tested in duplicate for both biomarkers (anti-gp41 and anti-p24).
In other words, each sample was tested on 4 different disposable SAW biochips. It was
therefore decided to consider all measurements to be independent when estimating the
sensitivity and selectivity of the test. The sensitivity and selectivity presented in Table 2
were calculated for each biomarker independently, and as a combined test. This reflects the
fact that, under real test conditions, the detection of only one of the two biomarkers would
prove sufficient to rank the sample as being positive. The differential phase shift was read
5 minutes after sample injection, and compared to the threshold value defined as the mean
(+3SD) of the negative calibration samples measurements.
+ samples - samples
Sensitivity Specificity
Total TP FN Total TN FP
Anti-gp41 62 58 4 12 12 0 93.5% 100%
Anti-p24 64 30 34 12 12 0 46.9% 100%
Combined 62 59 3 12 12 0 95.2% 100%
Table 7.3: Second pilot study: summary of results. Each sample tested was assigned
to one of the 4 categories (TP, FN, TN, FP), depending on the nature of the sample (known
positive or negative) and the value of the phase shift recorded after 5 minutes in comparison
with the threshold value, defined as the mean (+3SD) of the negative calibration samples
measurements. The test sensitivity and specificity were calculated for both biomarkers
separately. A combined sensitivity and specificity is also presented, which reflects the fact
that the detection of one of the biomarkers only would be enough to conclude on the
positivity of a sample.
58 out of the 62 tests performed on samples from patients with HIV gave a positive reading
for anti-gp41 detection, giving a sensitivity of 93.5%. Anti-gp41 is usually the first antibody
to appear after HIV infection and therefore a key immune marker of HIV infection. [81] For
anti-p24 detection, 30 tests (out of 64 two samples were tested three times instead of two)
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Figure 7.5: Second pilot study: readings 5 minutes after sample injection.
a) Barchart showing the differential phase shift recorded by the SAW biosensor after 5
minutes. Each bar represents one test. Two tests were conducted for each sample. The
red line indicates the threshold value defined to discriminates between positive and negative
values. The nature of the sample (known positive, known negative or calibration sample) is
indicated at the bottom of the barchart. A grey bar represents a sample declared negative
by the test, whereas a green bar represents a positive test. (b) As in (a), but for Anti-p24
detection.
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gave a true positive reading, giving a sensitivity of 46.9%. The combined sensitivity of the
test (at least one biomarker detected) was found to be 95.2%. Neither marker was detected
in any of the healthy volunteer samples, giving a specificity of 100% of detection for both
antibodies, though this is based on only 6 samples (with multiple readings).
7.5.3 Comparison with ELISA
All the samples tested in the pilot study were used in another study, aiming at estimating
the concentration of the two biomarkers (anti-gp41 and anti-p24). The SAW biosensor
fulfils the requirement of a PoCT for HIV in the context of diagnostics, by simply distin-
guishing between a positive and a negative sample. However, being able to estimate the
actual concentration of a given biomarker could potentially be useful in the context of mon-
itoring. The calibration results presented in Figure 7.4 demonstrate the clear correlation
between the phase shift recorded by the SAW biosensor and the biomarker concentration
in mock samples. The purpose of this parallel study was to investigate the extension of this
conclusion to real patient samples.
The estimated concentration of a biomarker was compared to the magnitude of the signal
recorded by the SAW biosensor, and the possibility of a correlation between the two was
investigated. The concentration of the HIV biomarkers in each sample was estimated using
ELISA (enzyme-linked immunosorbent assay). The principle of the assay is described in
Chapter 4. As the concentration of human IgG in a patient sample is very high (around
10mg/ml) compared to the concentration of the biomarker of interest, there is a high risk of
non-specific adsorption of any human IgG to the plate. In order to avoid such complications,
which would lead to a misleading assay conclusion, a number of extra washing steps (with
buffer) were incorporated into the protocol, between each binding step. In addition, each
assay was performed using a dilution range of the original samples, from the undiluted
sample down to a dilution of 1 to 4000.
Each of the 31 HIV-positive patient samples was tested in triplicate, at 4 different dilutions.
For each dilution, the average absorbance reading was injected in the equation of the
linear regression of the calibration curve to estimate the concentration of the biomarker
at this specific dilution. The result was multiplied by the dilution factor to obtain the
final estimation of the concentration of the biomarker in the sample. Out of the final
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estimated concentrations, only those who fell in the linear part of the calibration curve were
considered. The results are presented on the barchart in Figure ??, along with the SAW
results. As can be seen, the estimated concentration of antibodies in the negative samples
(empty bars, on the far right) is high. For anti-gp41, the 4 samples tested were estimated
to present a concentration of antibody higher than 100µg/ml. When tested for anti-p24
levels, 2 of these negative sample also presented high concentrations of antbody (higher
than 10µg/ml). These values are quite a lot higher than expected for negative samples that
should not present any anti-HIV antibodies. This was likely to have been triggered by non-
specific adsorption of any human antibodies onto the plate before addition of the tagged
anti-human antibody used at the end of the assay to reveal the amount of biomarker bound
to the plate. This is probably due to the inability of the blocker used to efficiently prevent
non-specific adsorption of human antibodies, and was subsequently confirmed as part of
another project. More work would therefore be needed on the estimation of concentrations
of biomarkers using ELISA to pursue the study of a possible correlation between the two
techniques.
7.5.4 Discussion
Overall, the second pilot study conducted using SAW biosensors showed very promising
results. It showed that the SAW biosensor was able to detect key biomarkers of HIV
infection in patient samples with very high sensitivity and specificity. However, during the
course of this first pilot study, a problem arose in the process of functionalising the SAW
biochips with the recombinant protein using the automated liquid spotter. A number of
SAW biochips had to be functionalised manually. The fact that two different techniques
were used to functionalise the SAW biochips, and that the manual pipetting cannot be
assumed to be as reproducible as the automated technique, meant that the results of this
second pilot study had to be considered with caution. In addition, there was a doubt as
to whether all the SAW biochips that were functionalised manually had been prepared
following a similar protocol. The reference and the test channel may have been inverted on
some SAW biochips, which were used only to test negative samples for precaution. Those
doubts led to the conclusion that a third pilot study had to be conducted, with SAW
biochips functionalised solely using the automated spotter.
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Figure 7.6: Second pilot study: comparison between SAW biosensor results
and estimated biomarker concentration. a) Superimposed barcharts to show the
comparison between SAW biosensor and ELISA results. Left axis scale: Phase shift recor-
ded by the SAW biosensor (green and light grey bars, colouring as in figure 7.5a. Right axis
scale: Concentration of Anti-gp41 (dark grey bars). The concentrations were estimated
using ELISA. The phase shift was recorded after 5 minutes. b) As in a), but for Anti-p24.
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7.6 Third clinical pilot study
This third pilot study was conducted following a very similar protocol to the one used for
the second pilot study, with the exception that all SAW biochips were functionalised using
the automated protocol. The SAW biochips used for this study are called OJ31 and are
described in more details in Chapter 4.
7.6.1 Calibration
As for the previous pilot studies, a series of control samples (pooled plasma spiked with anti-
HIV antibodies) were tested on the SAW biosensor before moving on to patient samples.
The differential phase shift is plotted against the concentration of the biomarker in Figure
7.7, for both biomarkers tested (anti-p24 and anti-gp41). The PPMCC was evaluated for
each data set and was found to be 0.978 for anti-gp41 (R2 = 0.958) and 0.9666 for anti-p24
(R2 = 0.934), indicating a good correlation between the phase shift recorded by the SAW
biosensor and the concentration of the biomarker. These are both improved when compared
to the calibration results from the second pilot study (0.898 for anti-gp41 and 0.76 for anti-
p24) and probably relate to improved performance and reproducibility using automated
biochip functionalisation. However, it is interesting to note that the intercept of the linear
regression is close to 0 (0.2) for anti-gp41, but not for anti-p24 (3.5). One would expect the
intercept to be close to 0, as the interaction of the sample with both the test channel and
the reference channel is supposed to be similar in the absence of the biomarker of interest.
This interaction is indeed mainly non-specific adsorption of proteins onto the functionalised
gold surface, with no specific interaction with the capture protein. A non-null intercept
might therefore indicate that the capture protein chosen for the reference channel is not
ideal when used in combination with the recombinant gp41 used on the test channel.
7.6.2 Measurement reproducibility
Each sample was tested on two independent prototypes of the SAW biosensor. While the
two prototypes are designed to be identical, the question of reproducibility and reliability
of the measurements taken was investigated. The phase shift measured by the different
SAW biosensors (labelled 1 and 2) is plotted in Figure 7.8. The dots corresponding to
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Figure 7.7: Third pilot study: validation of the assay using mock samples
of known concentration. a) Differential phase shift measured after 5 minutes when
testing mock samples with known concentration of anti-HIV antibody. Anti-gp41 results
are presented in blue, anti-p24 in red. Each dot represents the value of one test, the
line represents the average of all measurements for one concentration, with the error bars
representing the standard deviation of the average. The dotted line represents the linear
regression of the averages values.
the same sample are linked with a line. If one of the prototypes was consistently giving
a higher reading than the other one, the joining lines would all follow the same direction
(either upwards or downwards depending on which prototype gives the higher reading).
The absence of any obvious similarities in the joining lines indicates there is no calibration
issues between the two prototypes.
In addition, the dependence of the measurement on the user was investigated. That is,
looking at whether the person operating the SAW biosensor influences the result of the
test. For each type of SAW biosensor (designed to detect anti-gp41 or anti-p24), each
of the two operators (data acquired with Dr. Eleanor Gray) tested the same negative
calibration sample six times. This sample was not spiked with any of the biomarkers. It
was tested on both SAW biosensors (anti-p24 and anti-gp41 detection SAW biosensors).
The average phase shifts recorded after 5 minutes for the calibration sample are reported
in Table 7.4, and indicates no user dependence.
Chapter 7. Clinical Pilot Studies: Testing Real Patient Samples 175
-10
-5
0
5
10
15
20
25
30
35
40
45
Δ
φ 
(a
nt
i-p
24
) (
de
gr
ee
s)
SAW biosensor prototype
1                   2
-10
-5
0
5
10
15
20
25
30
35
40
45
Δ
φ 
(a
nt
i-g
p4
1)
 (d
eg
re
es
)
SAW biosensor prototype
1 2
ba
Figure 7.8: Independence of the measurement on prototype used. Plot to show
the absence of dependence on the prototype of SAW biosensor used for the measurement.
The measurements (differential phase shift recorded after 5 minutes) taken using prototype
number one are plotted next to the measurements taken by prototype number 2. Two
measurements corresponding to the same sample are joined with a line. a) Anti-gp41
detection. b) Anti-p24 detection.
Average phase shift (degrees)
User 1 User 2
Anti-gp41 1.1 ± 1.2 2.2 ± 2.1
Anti-p24 2.9 ± 1.7 1.9 ± 1.1
Table 7.4: Third pilot study: Summary of calibration sample measurements.
A calibration negative sample (pooled plasma not spiked with anti-HIV antibodies) was
tested 6 times by each user, on both SAW biosensors. Results indicates no apparent user
dependence.
7.6.3 Investigating correlation between biomarkers (anti-gp41 and anti-
p24)
For each sample, the correlation between the two biomarkers of interest was investigated.
The levels of anti-p24 and anti-gp41 in HIV-infected patients blood are not known to be
dependent, and therefore the two were not necessarily expected to be correlated in this
study. The phase shift values recorded by the SAW biosensor for each biomarker are
plotted against each other in Figure 7.9.
By eye, this seems to suggest that there is no obvious correlation for the HIV-infected
patient samples (plotted in blue). However, the negative samples (in green) seem to show
some correlation, which is to be expected as they should both generate a consistent, nearly
zero phase shift. The PPMCC was evaluated for the whole data set, but also for the positive
samples only, as well as for the negative samples only. It was found to be 0.4565 (R2 =
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Figure 7.9: Third pilot study: correlation between biomarkers. For each sample,
the differential phase shift recorded by the SAW biosensor for anti-p24 detection is plotted
against the value recorded for anti-gp41 detection. Negative samples are plotted in green,
positive samples in blue. The yellow dot represents the commercial pooled plasma tested.
The PPMCC was evaluated for the negative samples and the positive samples separately, as
well as for the whole data set. There was no evidence of correlation between the biomarkers
in terms of signal recorded by the SAW biosensor, unless the sample was negative.
0.2084) for the whole data set, 0.2364 (R2 = 0.0559) for the positive samples and -0.8183
(R2 = 0.6696) for the negative samples. As expected, there is therefore no evidence of
correlation between the phase shift recorded by the SAW biosensor for the two different
biomarkers in the same sample, unless it is a negative sample.
7.6.4 Summary of results, test performance indicators
A summary of all the data obtained during this third clinical pilot study is presented in
Figure 7.10 and Table 7.5. As for the second pilot study, each sample was tested twice,
on two different disposable SAW biochips and all measurements were considered to be
independent when estimating the sensitivity and selectivity of the test. The differential
phase shift was read 5 minutes after sample injection, and compared to the threshold value
established as the mean (+3SD) of the negative calibration samples measurements.
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Figure 7.10: Third pilot study: readings 5 minutes after sample injection.
a) Barchart showing the differential phase shift recorded by the SAW biosensor after 5
minutes. Each bar represents one test. Two tests were conducted for each sample. The
red line indicates the threshold value defined to discriminate between positive and negative
values. The nature of the sample (known positive, known negative or calibration sample) is
indicated at the bottom of the barchart. A grey bar represents a sample declared negative
by the test, whereas a green bar represents a positive test. (b) As in (a), but for Anti-p24
detection.
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+ samples - samples
Sensitivity Specificity
Total TP FN Total TN FP
Anti-gp41 62 62 0 12 12 0 100% 100%
Anti-p24 62 53 9 12 12 0 85.5% 100%
Combined 62 62 0 12 12 0 100% 100%
Table 7.5: Third pilot study: summary of results. Each sample tested was assigned
to one of the 4 categories (TP, FN, TN, FP), depending on the nature of the sample (known
positive or negative) and the value of the phase shift recorded after 5 minutes in comparison
with the threshold value defined as the mean (+3SD) of the negative calibration samples
measurements. The test sensitivity and specificity were calculated for both biomarkers
separately. A combined sensitivity and specificity is also presented, which reflects the fact
that the detection of one of the biomarkers only would be enough to conclude on the
positivity of a sample.
All of the samples taken from patients with HIV gave a true positive reading for anti-gp41
detection, giving a sensitivity of 100%. For anti-p24 detection, 53 out of the 62 samples
gave a true positive reading, giving a sensitivity of 85.5%. The combined sensitivity of the
test (at least one biomarker detected) was found to be 100%. Neither marker was detected
in any of the healthy volunteer samples, giving a preliminary specificity of 100% of detection
for both antibodies, though only 6 samples were tested (with multiple readings).
7.6.5 Comparison with competing diagnostics technologies
The samples from the patients with HIV were obtained at the stage of discard by the
laboratory, and had been kept at 4◦C for three weeks. It is unclear what effect this might
have on the samples although degradation, rather than the opposite, is probable. In order
to validate the results obtained, the samples were therefore also run on two commercially
available PoCT currently in use in the UK. The OraQuick Advance is available over the
counter in the United States, and the Alere HIV-1/2 Ag/Ab Combo is currently the only
available PoCT with p24 antigen detection, although the performance of the precursor
Alere Determine HIV 1/2 Ag/Ab test in the field has been variable. [115,116,202] The results
of these rapid tests with the samples used in this study are shown in Table 7.6.
All HIV-positive samples gave clear positive antibody readings on both the Alere HIV-1/2
Ag/Ab Combo and the OraQuick Advance tests. None of the samples gave a positive
antigen reading using the Alere HIV-1/2 Ag/Ab Combo test. The two rapid tests both
detect anti-gp41, which was also positive in all samples by the SAW assay. These results
verified the validity of the results obtained using the SAW biochips.
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Sample SAW
biosensor
OraQuick
Advance
HIV-1/2
Alere HIV-1/2
Ab/Ag Combo
Antibody/Antigen
(Ab/Ag)
Ab Ab Ab Ag
All HIV-positive
samples (31)
+ + + -
All healthy volunteer
samples (5)
- - - -
Pooled donor plasma
(1)
- - - -
Table 7.6: Third pilot study: summary of PoCT comparison results. Each
sample tested was assigned to one of the 4 categories (TP, FN, TN, FP), depending on the
nature of the sample (known positive or negative) and the value of the phase shift recorded
after 5 minutes in comparison with the threshold value defined as the mean (+3SD) of
the negative calibration samples measurements. The test sensitivity and specificity were
calculated for both biomarkers separately. A combined sensitivity and specificity is also
presented, which reflects the fact that the detection of one of the biomarkers only would
be enough to conclude on the positivity of a sample.
7.6.6 Discussion
This third pilot study demonstrated once again the ability of the SAW biosensor to detect
key biomarkers of HIV in patient samples. The 100% combined sensitivity and specificity
achieved in this small trial cannot be improved, though testing with an increased number
of samples was needed to confirm these results, particularly control samples from health
volunteers (at this stage only 6). In addition, this small study used samples (from HIV
patients) that were at the stage of discard from the diagnostic laboratory, had been stored
for three weeks between receipt and discharge, and were therefore not fresh upon use on
the SAW biosensor. It is not known at which stage of infection the patients were at the
time of sampling, though as they had uncontrolled viral load (at >5,000c/mL) it is not
probable that they were taking effective antiretroviral therapy and it is formally possible
that they were recently diagnosed. All samples were negative for the HIV-1 antigen p24,
which can be detected using the Alere Determine HIV-1 Ag/Ab Combo test, suggesting
that samples were not taken during the stage of acute infection, though the performance
of the antigen component of this test is poor, so this is not conclusive. [203,204] Given these
caveats, therefore, the levels of sensitivity achieved are exceptional and warrant a further,
larger trial with fresh samples.
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7.7 Fourth clinical pilot study
A final pilot study was conducted following the same protocol as the one used for the third
pilot study. An additional 100 confirmed negative samples were tested, in order to refine the
test performance indicators. For logistical reasons, the confirmed positive samples could not
be tested again and the results from the third pilot study were used. A total of 28 negative
calibration samples were run. In addition, the threshold value was adjusted separately for
each biomarker, to achieve the best test performance indicators, as described below.
7.7.1 Threshold value adjustment
In the previous three clinical pilot studies, the cut-off value used to discriminate between
a positive and a negative sample was defined as the mean +3SD of the measurements per-
formed on negative calibration samples (pooled plasma from confirmed healthy individuals).
This meant that statistically, 95% of the future potential true negative samples tested would
be expected to give a reading below this threshold value and count as true positives. The
decision to define the threshold as this value was arbitrary, and did not necessarily reflect
on the specific results recorded by the test with confirmed negative samples.
Ideally, the threshold should be defined so that it lies in between the highest reading
recorded for a confirmed negative sample, and the lowest reading recorded for a confirmed
positive sample. If there is an overlap, it should be adapted to exclude most false positives
and false negatives. This method can only be applied, however, if a large amount of test
results is available. In previous studies, only 6 confirmed negative samples were tested (in
duplicate), therefore the statistical approach was more justified than this empirical method.
For this fourth pilot study, as the number of confirmed negative samples was significantly
increased (over a hundred), it was decided to consider the differences observed between
samples (confirmed positive versus confirmed negative) to define the optimal threshold for
the test.
7.7.2 Summary of results, test performance indicators
A summary of all the data obtained during this fourth clinical pilot study is presented in
Figures 7.11, 7.12 and Table 7.7. The differential phase shift was read 5 minutes after
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sample injection, and compared to a threshold value specific to each biomarker. For anti-
gp41, the mean (+4SD) of the negative calibration samples measurements was used, for
anti-p24, the mean (+5SD) of the negative calibration samples measurements was used.
+ samples - samples
Sensitivity Specificity
Total TP FN Total TN FP
Anti-gp41 62 62 0 106 106 0 100% 100%
Anti-p24 62 41 21 106 106 0 66.1% 100%
Combined 62 62 0 106 106 0 100% 100%
Table 7.7: Fourth pilot study: summary of results. Each sample tested was assigned
to one of the 4 categories (TP, FN, TN, FP), depending on the nature of the sample
(known positive or negative) and the value of the phase shift recorded after 5 minutes in
comparison with the threshold value. The test sensitivity and specificity were calculated
for both biomarkers separately. A combined sensitivity and specificity is also presented,
which reflects the fact that the detection of one of the biomarkers only would be enough
to conclude on the positivity of a sample.
Using these respective thresholds, all the confirmed negative samples tested gave a negative
reading, giving a 100% specificity for both antibodies. All samples taken from patients with
HIV gave a true positive reading for anti-gp41 detection, giving a sensitivity of 100%. For
anti-p24 detection, 41 out of the 62 samples gave a true positive reading, giving a sensitivity
of 66.1%. The combined sensitivity of the test (at least one biomarker detected) was found
to be 100%.
7.7.3 Reducing test waiting time
As the calibration samples were run following the exact same protocol as the test samples,
it was possible to define a discriminative threshold value as a function of time. It was then
possible to compare each test value to a threshold value at any point in time, and therefore
count the number of TP, FN, TN, and FP, starting from sample injection and all the way
to the end of the 5 minutes measurement, and to evaluate the sensitivity and the specificity
of the test as a function of time. The results are presented in Figure 7.13.
This study was very instructive as it revealed that there was no need to wait for 5 minutes
after sample injection to achieve high levels of performance. As can be seen in Figure 7.13a,
the test only requires 1 min to declare a sample as true positive with a 100% sensitivity, and
only 4 minutes and 30 seconds to declare a sample as true negative with a 100% specificity.
This shows that, with further development, the SAW biosensor has great potential to deliver
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Figure 7.11: Fourth pilot study: readings 5 minutes after sample injection.
Anti-gp41 a) Barchart showing the differential phase shift recorded by the SAW biosensor
after 5 minutes, for confirmed positive samples. Each bar represents one test. Two tests
were conducted for each sample. The red line indicates the threshold value defined to
discriminate between positive and negative values. A grey bar represents a sample declared
negative by the test, whereas a green bar represents a positive test. b) As in a), but for
confirmed negative samples detection.
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Figure 7.12: Fourth pilot study: readings 5 minutes after sample injection.
Anti-p24 a) Barchart showing the differential phase shift recorded by the SAW biosensor
after 5 minutes, for confirmed positive samples. Each bar represents one test. Two tests
were conducted for each sample. The red line indicates the threshold value defined to
discriminate between positive and negative values. A grey bar represents a sample declared
negative by the test, whereas a green bar represents a positive test. b) As in a), but for
confirmed negative samples detection.
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Figure 7.13: Fourth pilot study: sensitivity and specificity of the test over
time. a) Plot to show the test sensitivity over time, for both biomarkers. The green
window indicates the time necessary to cinfirm a sample as true positive (at least one
biomarker detected with a 100% sensitivity). b) Plot to show the test specificity over
time, for both biomarkers. The green window indicates the time necessary to cinfirm a
sample as true positive (both biomarkers detected with a 100% specificity).
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results with high levels of sensitivity and specificity within a shorter time frame than all
current commercially available PoCT.
7.7.4 Discussion
This final clinical pilot study confirmed the ability of the SAW biosensor to detect both
biomarkers of HIV infection with 100% sensitivity and specificity under 5 minutes. A
higher confidence in the test specificity was achieved by testing a high number of confirmed
negative samples form healthy individuals (106). It was also shown that the it was possible
to achieve shorter time to result, the highlight being the ability of the test to declare a true
positive result with a 100% sensitivity within a minute from sample injection
7.8 Conclusions
After optimising the characteristics of the SAW biochips and demonstrating their ability
to detect the presence of key HIV biomarkers in mock samples, it was decided to move a
step closer to real point-of-care conditions, and investigate the performance of the SAW
biosensor with real patient samples. Due to logistical considerations, two proof of concept
studies using two different types of SAW biochips had to be conducted, and they both
showed the SAW biochips were capable of detecting the two biomarkers of HIV (anti-gp41
and anti-p24) in a complex matrix (serum or plasma. It was therefore decided to conduct
a series of pilot studies using 31 HIV positive patient samples. Progress was made step
by step through the four small pilot studies presented in this chapter, in parallel with the
optimisation of the SAW biochips. Reducing the size of the SAW biochip warrants smaller
manufacturing costs and enables the test to be run with a minimal amount of patient
sample (6µl). The implementation of an in-situ reference channel to account for the high
risk of non-specific binding events due to the complexity of the samples tested has made the
SAW biosensor even more simple to use and has taken it to the next level of performance.
The evolution of the key results of the pilot studies is presented in Table 7.8 below.
The results from the latest pilot study highlight the very good performance of the SAW
biosensor as a PoCT. Both the sensitivity and the specificity of the test were found to be
100%, and further analysis showed that only one minute between sample injection and test
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Pilot
study
Number of samples
tested
independently
Test performance
indicators
Highlights and
improvements
1 10 (blind study) 100% sensitivity
80% specificity
First study involving
patient samples
2 62 confirmed positives
12 confirmed negative
95.2% sensitivity
100% specificity
Promising results nuanced
by SAW biochips
functionalisation issues
3 62 confirmed positives
12 confirmed negatives
100% sensitivity
100% specificity
Levels of sensitivity and
specificity excellent, larger
trials needed
4 62 confirmed positives
112 confirmed negatives
100% sensitivity
100% specificity
High number of confirmed
negative samples / time to
result reduced to 1min for
100% sensitivity and 99%
specificity
Table 7.8: Evolution of the results of the clinical pilot studies.
reading are sufficient to achieve a 100% sensitivity and 99% specificity, which gives the SAW
biosensor a competitive advantage over current commercially available PoCT. A summary
of the different characteristics and performance indicators of four PoCT is presented in
Table 7.9. It shows that it out performs the other experimental smartphone-connected
PoCT in terms of sensitivity and specificity. In addition, for a comparable sensitivity and
specificity, the SAW biosensor prototype requires a smaller sample volume than the Alere
HIV 1/2 Ab/Ag Combo. More importantly, it out performs all other tests in terms of time
to result. Finally, it is characterised by its connectivity and possibility of data linkage,
which none of the current commercially available PoCT offer at the moment.
These promising results should serve as a platform for larger pilot studies conducted using
fresh samples. Testing a large number of healthy volunteers samples would help assessing
the test sensitivity and specificity with a higher accuracy. Another step forward would
involve testing whole blood instead of blood plasma. This would reduce the number of
steps required to perform the test, making it even cheaper, faster and more simple overall.
The test could then potentially be performed anywhere and require a very minimal amount
of training. Work has already begun on this, using the pore structure of a paper strip to
filter out most of the blood cells from the initial drop of blood sample, and at the same time
taking advantage of the capillary effect to deliver the plasma sample to the SAW biochip.
In order to make the test more versatile, implementing additional channels to the SAW
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SAW
biosensor
(4th pilot
study
OraQuick
Advance
HIV-1/2
Alere
HIV-1/2
Ab/Ag
Combo
ELISA
smartphone
dongle [23]
Sensitivity
(limit of
detection)
10µg/ml
(anti-gp41)
25µg/ml
(anti-p24)
10µg/ml
(anti-gp41).
No anti-p24
detection
5µg/ml
(anti-gp41)
100µg/ml
(anti-p24)
NP
Clinical
sensitivity
100% 100% 100% 92 to 100%
Clinical
specificity
100% 100% 100% 79 to 100%
Volume of
sample
required
6µl 2.5µl 50µl fingerprick
Time to result <5min 20-40min 20-30min 15min
Connectivity
and data
linkage
Yes No No Yes
Table 7.9: Comparison of some key characteristics of four different PoCT. The
SAW biosensor has better or comparable sensitivity to two PoCT available in the UK. It
requires less sample volume than Alere HIV 1/2 Ab/Ag Combo, and delivers a result faster
than the other three currently available PoCT. It is the only one to offer connectivity with
the experimental ELISA smartphone dongle, which presents lower levels of sensitivity and
specificity. NP = not published.
biochip and functionalising each of them accordingly could allow for multiplexed testing
of different biomarkers, and therefore potentially testing for multiple infections with the
same SAW biochip. The SAW biochips can be used as a platform for detecting virtually
any biomarker, provided the sensing area can be functionalised with the relevant capture
protein against the biomarker of interest. Finally, further studies will ideally be conducted
using the development hand-held prototype connected to a smartphone, instead of using
the laboratory prototype and a laptop.

Chapter 8
Model to Characterise SAW
Device Response, Sample and
Target Protein Properties
Building on the promising results obtained with the SAW biosensor and presented in
Chapters 6 and 7, the aim of this chapter was to characterise the fundamental physical para-
meters contributing to the signal output measured with the SAW biochips used throughout
this thesis. The approach involved applying the model developed by Saha and Gizeli, [38]
which relies on the combination of a precise calibration of the sensor and the assimilation
of proteins into non-interacting solid particles to disentangle the contribution of different
physical parameters contributing to the measured signal. As the method offers a way to
characterise some of the parameters defining both the sample and the sensor itself, using
this analysis could potentially contribute to optimising the SAW biosensor even further to
make it faster, more sensitive and able to answer more questions about a given sample.
More generally, the idea behind this work was to potentially be able to predict the charac-
teristics of the output signal based on the type of sample, or to extract useful information
other than the presence or the concentration- about the biomarker of interest.
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8.1 Introduction
The main results presented in chapters 6 and 7 demonstrate the ability of the SAW biosensor
presented in this thesis to differentiate between two samples, based on the comparison of the
signal (phase shift or insertion loss) recorded for each sample separately. Using this concept,
it was showed that samples characterised by different concentrations of the biomarker of
interest could be distinguished from one another. Furthermore, the unknown concentration
of a given sample could be estimated using a titration curve created beforehand using
mock samples of known concentration. It was also shown that real patient samples could
be assessed as being either positive or negative to a given biomarker of HIV. Once again,
this was achieved by comparing the recorded signal for the unknown sample to a reference
value established beforehand in this case a threshold value determined based on the average
signal recorded for a number of known negative samples. The promising results of the three
pilot studies conducted are paving the way for larger clinical studies, and contributed to
establishing the SAW biosensor as a better alternative to current commercially available
PoCT for HIV.
These results all rely on a simple approach: carefully establishing one or several reference
values recorded under the same conditions as when the actual test is carried out, and
comparing the value recorded for the unknown sample to the reference value(s). This is
the general description of the mode of operation of most biosensors. As for any system,
understanding the mechanisms leading to a signal change could potentially help optimise
the biosensor, and extract absolute information about the sample tested, instead of limiting
the analysis to a relative comparison to one or several reference samples.
As mentioned in Chapter 3, the perturbation theory applied to SH-SAW can be used
to derive equations describing the wave velocity and attenuation, which relate directly
to the change in the phase shift and insertion loss (respectively) measured by a SAW
device supporting a SH-SAW. Different sets of equations can be derived depending on the
initial assumptions on the nature of the perturbation occurring on the surface of the SAW
sensor. An analytical solution can be expressed in two specific cases. The first case is
when the viscosity at the surface proximity is altered by changing the solution in contact
with the sensor, assuming nothing is adsorbed or binds to the surface and the solutions
are Newtonian fluids (see Equations 3.9 and 3.10 in Chapter 3). The second case is when
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mass is adsorbed on the surface of the sensor, in the form of a uniform isotropic thin film.
The typical example being a thin film of metal grown or evaporated on the surface (see
equations 3.11 and 3.12 in Chapter 3).
While these two sets of equations can be very useful in the specific cases where they are valid,
there is no current analytical solution to describing the adsorption or binding of proteins
to the surface of the sensor. Particles (proteins or nanoparticles for example) binding to
the surface lead to a combination of non-ideal perturbations involving mass, viscosity, and
possibly a combination of both. Such perturbations are typical in the context of using the
SAW sensor as a biosensor. Being able to understand the changes in mass, viscosity and
viscoelasticity on the surface proximity, when objects such as proteins bind to the surface of
the sensor, could therefore prove to be an essential tool to the development of SAW sensors
as biosensors. It was therefore decided to try and characterise as many as possible of the
parameters involved in the process of the biosensor giving a response to a given sample:
the sensor itself, some of the liquid sample properties and finally some properties of the
proteins binding to the surface of the biosensor.
8.2 Review of Saha/Gizeli method
In 2003, a group at Cambridge University proposed a method to evaluate the mass cov-
erage on the surface of their SH-SAW sensor, based on a simple device calibration with
glycerol/water solutions, and the assimilation of proteins binding to the surface as non-
interacting solid particles. [38] In summary, their method only requires the measure of the
insertion loss induced by the perturbation occurring on the surface of the SAW sensor
to probe the mass added on the surface of the delay line of the SAW sensor. Along the
way, the method estimates different parameters characterising the sample solution (such as
density and viscosity), as well as the sensor itself. They reported a good agreement between
the surface mass coverage obtained using their method and a gold standard method such
as Surface Plasmon Resonance (SPR). As can be seen in Figure 8.1, the device used to
generate the SH-SAW and measure its insertion loss is very similar to the SAW devices
used throughout this thesis, with two IDTs separated by a delay line on top of a quartz
substrate. Despite the fact Saha et al. used a polymer film as a waveguide, their device
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was considered similar enough, and therefore the Saha/Gizeli method was assumed to be
suitable to characterise the SAW device.
Figure 8.1: SH-SAW device used by Saha/Gizeli.. Schematic to illustrate the SH-
SAW device used by Saha/Gizeli. The device consists of two gold IDTs and a gold delay
line (used as the sensing area) on top of a quartz piezoelectric crystal. A 1.2m thick
polymer film covering the top surface of the crystal, the IDTs and the delay line is used as
a waveguide. Adapted from [38]
.
8.2.1 Principle of the Saha-Gizeli method
The principle of the method is presented in Figure 8.2. The main objective of the method is
to relate, for a given sample, the measured insertion loss ∆IL to the mass per surface
area Mnorm added on the surface of the SAW device. The relation between the two is
outlined in red in the diagram, and is shown as a dashed arrow to underline the fact the
link between the two is indirect. Indeed, the method involves a series different steps and
calculations that are inter-dependent.
The authors introduced the concept of glycerol equivalent weight fraction (wgly), which
translates the fact that adsorbing proteins on the surface of the SAW device is similar, for
viscoelastic purposes, to adding glycerol to the solution until it contains wgly glycerol.
Another concept introduced is the sensing volume Vsens, which represents the volume of
solution affected by the acoustic wave. It is schematised in Figure 8.3, and is defined as:
Vsens = δAsens, (8.1)
where δ is the acoustic penetration depth, and Asens the sensing area. Asens is effectively
the surface area of the delay line of the device.
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SAW device calibration 
using glycerol/water solutions
‘Equivalent glycerol weight fraction, wgly’  
expressed as a function of the 
Fitting viscosity values from literature 
for glycerol/water solutions
Solution viscosity η
expressed as a function of ΔA
Einstein relation for solid particles
Volume fraction of particles Ω
expressed as a function of η
Mass per surface area
Mnorm
expressed as a function of Ω and 𝝳
Acoustic penetration depth 𝝳
expressed as a function of η and ρ
Solution density ρ
expressed as a function of Ω
Measured insertion loss
ΔIL
Figure 8.2: Diagram to present the Saha/Gizeli approach. The mass per surface
area Mnorm of proteins binding to the surface of the SAW device is estimated indirectly via
the measurement of the insertion loss ∆IL. A calibration of the device using glycerol/water
solutions (grey block) is used in combination with an estimation of the solution viscosity
from literature values (purple block) to relate the solution viscosity η to ∆IL. Applying
the Einstein relation for solid particles gives a relation between the volume fraction of
particles Ω and η (yellow block). The solution density ρ can be expressed as a function of
Ω (blue block), and the acoustic penetration depth δ can be expressed as a function of ρ
and η (green block). Finally, Mnorm can be expressed as a function of Ω and δ.
𝝳 VsensAsens
Liquid sample
Wave propagation
Figure 8.3: Sensing area, penetration depth and sensing volume. Schematics to
show the propagation of the acoustic wave through the sensing volume Vsens (red dotted
volume), defined as the product of the sensing area Asens (yellow area), and the wave
penetration depth δ. Any part of the liquid sample that is not included in the sensing
volume is not affected by the wave, and therefore only the proteins contained within Vsens
can be probed by the sensor. Drawing not to scale. Note: the acoustic wave is evanescent
and its amplitude decreases exponentially as it propagates along the sensing area.
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Finally, the method relies on considering the proteins binding to the surface as non-
interacting solid particles. This is schematised in Figure 8.4, with the example of antibodies
adsorbing onto the surface of the sensor.
Reality Model
Antibody Solid particle
Vsens
Asens
Liquid sample
Figure 8.4: Assimilating proteins to non-interacting solid particles. Schematics
to show one of the main assumptions involved in the Saha-Gizeli method. Proteins in the
sample are assimilated to non-interacting solid particles. In the example shown, antibodies
in the sample simply adsorb on the surface of the sensor. Only the particles contained
within the sensing volume (red box) can be probed by the sensor. Drawing not to scale
.
The total mass of particles Mpar contained within Vsens therefore relates to Mnorm as
follows:
Mnorm =
Mpar
Asens
. (8.2)
The volume fraction of particles, Ω is defined as:
Ω =
NparVparticle
Vsens
, (8.3)
where Vparticle is the volume of one particle and Npar is the number of particles contained
within the sensing volume, defined as:
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Npar =
MparNA
MW particle
, (8.4)
where MW particle is the molecular weight of a particle, and NA is the Avogadro constant
(6.02 ∗ 1023mol−1). By combining equations 8.1, 8.2, 8.3 and 8.4, the following expression
for Mnorm can be derived:
Mnorm =
δΩMW particle
VparticleNA
. (8.5)
The acoustic penetration depth δis defined as function of the solution viscosity and density
ρ , as well as the device frequency f : [136]
δ =
√
η
pifρ
. (8.6)
As the device frequency f is known, and both MWparticle and Vparticle are known quantities,
the remaining unknown in Equation 5 are the solution viscosity η and density ρ, as well as
the volume fraction of particles Ω.
The Einstein relation for solid particles gives a relation between the solution viscosity η
(with and without particles) and the volume fraction of particles Ω within the sensing
volume Vsens:
[205]
η2
η1
= 1 + νΩ, (8.7)
where η1 is the viscosity of the solution without particles, η2the viscosity of the solution
containing the particles and ν is the particle shape factor (2.5 for a sphere [205]). This
relation is only valid if Ω ≤ 0.2.
In the following, the model solution will consist of water, or buffer, containing proteins (the
model particles). η1 will therefore be considered as the viscosity of water, or buffer, and
η2will be the viscosity of the solution defined earlier, η. The only remaining unknowns in
Equation 8.5 are therefore the solution viscosity η and density ρ.
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The solution density ρ is defined as the ratio between the mass and volume of solution
that is affected by the wave. The mass of solution affected by the wave can be expressed
as the sum of the mass of water within the sensing volume (Mwater), and the mass of
particles contained within the sensing volume (Mpar). Therefore, the solution density can
be expressed as:
ρ =
Mpar +Mwater
Vsens
=
Mpar
Vsens
+ ρwater, (8.8)
which using Equation 8.5, can be expressed as:
ρ =
ΩMW particle
VparticleNA
+ ρwater. (8.9)
The only unknown remaining in Equation 8.5 is therefore the solution viscosity η. It is
estimated using the following method.
Firstly, a calibration of the SAW device is performed, using different glycerol/water solu-
tions of known weight percentage of glycerol. A direct proportional relationship is observed,
with a slope γ. This yields the following relation between the glycerol weight fraction wgly,
and the normalised insertion loss ∆ILnorm(measured insertion loss ∆IL divided by the
device sensing area Asens):
∆ILnorm =
γ
Asens
wgly. (8.10)
Then the solution viscosity η is expressed as a function of wgly by fitting the literature
values of the viscosity of glycerol/water solutions based on their glycerol weight fraction.
Combining Equation 8.10 and the fitted function yields a direct relationship between the
measurement of ∆IL and the solution viscosity η. It is therefore possible to estimate
the mass per surface area adsorbed on the surface of the SAW device, Mnorm, using the
measurement of ∆IL.
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8.2.2 Advantages and limitations of the model
The main advantage of the approach presented by Saha et al. is its simplicity. Once
the device calibration with glycerol/water solutions is done, the function expressing the
viscosity η as a function of the measured insertion ∆IL can easily be expressed. From this
point, one only requires to input the values of ∆IL into a series of equations to estimate
the mass of protein binding to the surface, the solution viscosity and density, and the
acoustic wave penetration depth amongst other parameters. The method can also be used
to characterise the sensor and therefore predict its response in terms of insertion loss, to
perturbations due to particles of different size, weight and shape.
The method can also be used stepwise, to estimate the mass of protein binding to the
surface at different stages. For example, it is possible to apply the method twice, starting
with a simple adsorption of antibodies on gold, then considering the antibody-coated gold
surface as a new starting point to estimate the mass of antigen binding to the layer of
antibodies.
Finally, the authors report a good agreement between their estimations and the measure-
ment of mass binding to the surface of a gold chip using the gold-standard Surface Plasmon
Resonance (SPR), as can be seen in Figure 8.5.
The possible limitations of such an approach reside in the initial assumptions made. By con-
sidering the proteins binding -or adsorbing- to the surface as non-interacting solid particles,
it is possible to apply the Einstein relation for solid particles. This ultimately solves the
problem of not being able to directly measure certain quantities that would be necessary
to estimate the mass added on the surface, by expressing this as a function of the solution
viscosity. However, depending on their nature, as well as the concentration on the surface,
some particles might interact between one another to form a network, and effectively con-
tribute to altering the viscoelasticity within the sensing volume. Therefore, this assumption
might not be true for all systems, making the model inapplicable in some cases, for examples
non-Newtonian fluids. Other more advanced versions of the model exist, which take those
interactions into account.
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Figure 8.5: Validation of the Saha-Gizeli method: comparison of the results
with equivalent gold standard method (SPR). The mass per surface area of IgG
adsorbed on the bare gold surface of a 155MHz SAW sensor was estimated using the Saha-
Gizeli method. Results are plotted as a function of the IgG concentration in solution
(square markers). Measurements of the mass per surface area of IgG on bare gold SPR
sensors were performed using the same solutions of IgG, and the results are plotted on the
same graph (cross markers). There is a good correlation between the estimated results
obtained using the method, and the measurement performed using the gold standard SPR
method. Plot reproduced from Saha et al. [38]
8.3 OJ15 SAW device calibration and characterisation
Two different SAW devices were used in the method presented by Saha et al. They both
have a very similar design to the SAW biochips used throughout this thesis. Both are
based on a quartz piezoelectric crystal supporting a SH-SAW propagating along a delay
line located between two sets of IDTs. Both sets of IDTs, as well as the delay line, are
made of a thin film of gold deposited on the surface of the piezoelectric crystal. The devices
used operate at a frequency of 108MHz and 155MHz, respectively. The following results
were obtained using OJ15 SAW biochips operating at 251.5MHz, also based on a quartz
piezoelectric crystal supporting a SH-SAW generated using gold IDTs and propagating
along a gold sensing area.
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8.3.1 OJ15 SAW device glycerol/water calibration studies
OJ15 SAW devices were calibrated using glycerol/water solutions of known weight fraction
of glycerol, ranging from 0 to 0.72. The different solutions were put in contact with the
sensing area of the biochip for 5 minutes, after which the sensing area was washed with
deionised water. The real time insertion loss and phase shift of the SAW device calibration
are presented in Figure 8.6.
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Figure 8.6: OJ15 SAW device calibration. a) Plot to show the evolution of the
insertion loss ∆IL over time, as various glycerol/water solutions are added and left to
incubate over the surface of the SAW device. The surface was washed with deionised
water after each incubation. The seven different solutions were tested in a random order,
as indicated on the plot (sample #1 to #7, in decreasing weight fraction of glycerol). b)
Plot to show the insertion loss ∆IL as a function of the glycerol weight fraction. The
insertion loss was recorded 5 minutes after sample injection. Each point is the average
of 4 independent measurements, error bars represent the standard deviation of the mean.
The blue line represents the linear regression y = 24.4x,R2 = 0.998. c) Same as a, for the
phase shift ∆φ. d) Same as b, for the phase shift ∆φ. The linear regression yields the
equation y = 147x,R2 = 0.999.
As can be seen in Figures 8.6b and 8.6d, a linear relationship was found between the
signal output by the SAW biosensor and the solution glycerol weight fraction, for both the
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insertion loss ∆IL and the wave phase shift ∆φ. The R-squared of the linear regression
was found to be 0.998 and 0.999 for ∆IL and ∆φ respectively.
8.3.2 Comparison with other SAW sensors
In order to assess the performance of the OJ15 SAW devices in terms of sensitivity to
different glycerol/water solutions, the results of the calibration were compared to the ones
presented in the Saha et al. paper, obtained with different SAW sensors. When a per-
turbation occurs within the sensing volume of the SAW sensor, the higher the response
measured (either ∆IL or ∆φ), the more sensitive the SAW sensor is. Therefore, a good
indication of the sensitivity of a given sensor is the slope of the linear regression performed
on the data acquired from the sensor calibration with different glycerol/water solutions.
The slopes obtained for both ∆IL and ∆φ are presented in Table 8.1, for the two SAW
sensors presented by Saha et al., as well as for the OJ15 SAW devices.
Saha et al.
108MHz
Saha et al.
155MHz
OJ15 SAW
biochip
Insertion loss per
percent of glycerol
weight fraction (dB)
3.2× 10−2 20.8× 10−2 24.4(±0.14)×10−2
Phase shift per percent
of glycerol weight
fraction (degree)
11.8× 10−2 91.1× 10−2 147(±9.1)× 10−2
Table 8.1: Sensitivity of different SAW sensors to a given viscosity change. Slope
of the linear regression performed on the data obtained with the SAW device calibration
using different glycerol/water solutions. The slope of the linear regression represents the
insertion loss (or phase shift) recorded by the sensor in response to a change of 1% glycerol
weight fraction. For the two Saha et.al. sensors, the slope was estimated using the data
available in the paper. [38] For the OJ15 SAW biochips, the slope corresponds to the linear
regression of the data presented in Figure 8.6b and 8.6d. The OJ15 SAW biochip has a
greater sensitivity to a given perturbation than the other two sensors presented.
As can be seen in Table 8.1, the OJ15 SAW device shows a greater response to a 1% change
in glycerol weight fraction than the other two SAW sensors presented, when measuring
either ∆IL or ∆φ. The response was found to be 24.4 ±0.14 dB for the insertion loss and
147 ±9.1 for the phase shift, while out of the two the SAW sensors used by Saha et. al.,
the one with the greater response to a comparable perturbation gave responses of 20.8dB
and 91.1 degrees, respectively. OJ15 SAW devices used throughout this thesis are therefore
more sensitive than comparable sensors used by Saha et al.
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8.4 Characterisation of the liquid sample viscosity and dens-
ity
8.4.1 OJ15 SAW device calibration curve for sample viscosity
In order to express the sample viscosity as a function of the equivalent glycerol weight
fraction wgly, literature values were used.
[206] The glycerol weight fraction values and their
corresponding solution viscosity values were fitted to a function of the form y = ηwater(ax
b+
1), were y represents the solution viscosity as a function of x, the glycerol weight fraction.
The literature values of viscosity of glycerol/water solutions as a function of the glycerol
weight fraction are plotted (in blue) in Figure 8.7, along with the fitted function obtained
(in red).
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Figure 8.7: Solution viscosity expressed as a function of the glycerol weight
fraction. Literature values for the viscosity of glycerol/water solutions, [206] plotted as a
function of the glycerol weight fraction. The red line represents the fitted function obtained
when fitting the data to the equation y = ηwater(ax
b+1), where the coefficients (a,b) where
found to be (4.6, 1.3) and the literature value of ηwater is 1.002mPa.s.
Using the fitted function in combination with the proportional relation found between
∆IL and wgly following the sensor calibration, the sample viscosity η can be plotted as a
function of the measured insertion loss ∆IL. This is presented in Figure 8.8. For clarity,
only values up to 20dB are considered as this is the range of insertion loss covering most of
the perturbations measured during this thesis. This plot can be seen as a characteristic of
operation of the SAW biosensor. It can be used to either estimate the change in viscosity
corresponding to a given measured loss in insertion, or to get an idea of the insertion loss
when causing a perturbation with a known change in viscosity to the solution.
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Figure 8.8: Solution viscosity expressed as a function of the measured insertion
loss ∆IL. Plot to show the relationship between the insertion loss measured by the OJ15
SAW device and the corresponding solution viscosity. The measured insertion loss for
a solution viscosity of 1. 002mPa.s (viscosity of water at 25◦C) is 0dB, as the sensor
calibration was performed with water as the starting reference point.
8.4.2 Calibration method validation
Key steps of the Saha-Gizeli model which were applied to estimate the mass per surface
area are the OJ15 SAW device calibration with glycerol/water solutions, and the estimation
of the sample viscosity based on this calibration. In order to validate the calibration, the
relationship between the measured insertion loss ∆IL and the estimated sample viscosity η
was investigated.
First, the density of glycerol water solutions was expressed as a function of the glycerol
water content. Similarly to what was done for the viscosity, theoretical values of density [206]
were plotted as a function of the glycerol weight content, and fitted to obtain a relation
between the two quantities. This is presented in Figure 8.9.
Weiss et al. showed and verified that, when using SH-SAW devices, the relationship between
the density-normalised insertion loss and the square root of the solution viscosity was
linear. [207] The two quantities are plotted against each other in Figure 8.10. The relationship
was indeed found to be linear, with a linear regression correlation coefficient of 0.999,
suggesting that the Saha-Gizeli model can be applied to the OJ15 SAW devices, and further
analysis involving protein solutions instead of glycerol/water solutions can be undertaken.
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Figure 8.9: Solution density expressed as a function of the glycerol weight
fraction. Literature values for the density of glycerol/water solutions, [206] plotted as a
function of the glycerol weight fraction. The red line represents the fitted function obtained
when fitting the data to the equation y = ρwater(ax
b+1), where the coefficients (a,b) where
found to be (0.14, 0.83) and the literature value of ρwateris 999.97kg.m
−3.
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Figure 8.10: Insertion loss viscosity relationship. Plot to show the dens-
ity normalised insertion loss as a function of the square root of the solution viscosity.
Each point represents the average of 4 measurements, error bars represent the stand-
ard deviation. The blue line represents the linear regression of the data, with equation
y = 530.3x− 16.7, R2 = 0.999.
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8.4.3 Using the Saha-Gizeli method to estimate the solution density
Using equations 8.7 and 8.9 presented earlier, the solution density can be expressed as:
ρ =
1
ν
(
η2
η1
− 1
)
MW particle
VparticleNA
+ ρwater, (8.11)
where in this case η1 is the viscosity of the running buffer and η2 the sample viscosity. In
the following, the running buffer (PBS, solution without particles) was assimilated to water
at 25◦C when considering its density and viscosity.
As the viscosity of the sample has been expressed as a function of the measured insertion
loss ∆IL, six parameters remain in the equation. Four of them can be found in the literature
(Avogadro constant NA, viscosity of water ηwater, density of water ρwater, particle shape
factor ν), and the remaining two are intrinsic properties of protein probed (molecular weight
of the particle MW particle , volume of the particle Vparticle). For clarity, they are listed in
Table 8.2.
Parameter Value
Avogadro constant NA 6.02.10
23mol−1
Viscosity of water ηwater at 25
◦C 1.002mPa.s
Density of water ρwater at 25
◦C 999.97kg.m−3
Particle shape factor ν 2.5
Particle molecular weight
MW particle
Depending on protein
Particle volume Vparticle Depending on protein
Table 8.2: List of parameters involved in the expression of the solution density.
The values for the viscosity and density of water at 25◦C were taken from the literature. [206]
The particle shape factor was set to 2.5 to begin with, which corresponds to particles being
modelled as spheres. [205] This coefficient can take different values depending on the particle
shape assumptions, as will be discussed below.
In the model presented, the expression of the solution density depends on the nature of the
protein. It was therefore decided to plot the solution density as a function of the measured
insertion loss ∆IL for different proteins. Different model proteins used throughout this
thesis, with different intrinsic characteristics (volume and molecular weight) were chosen as
examples: HIV p24, an anti-p24 Llama VHH and an anti-p24 IgG. Table 8.3 summarises
the different proteins properties.
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Protein Anti-p24 llama
VHH (59H10)
HIV p24 IgG
Protein
structure
Protein
immersed
in water
sphere
Radius
(nm)
2.3 4.5 8.5
Volume
(nm3)
51.6 389 2527
Molecular
weight
(kDa)
12.47 24 150
Table 8.3: Intrinsic properties of some proteins used as examples. Table to sum-
marise the Radius, volume and molecular weight of three proteins used in the experiments
presented in this section. Protein sequences were either obtained in-house for the 59H10
anti-p24 VHH (courtesy of Dr. E. Gray), or from the protein data bank, pdb code 1E6J
(p24) and 1HZH (IgG). The proteins were immersed in a water sphere that just contains
all the atoms in the protein and the radius calculated. Models are built and rendered
using Visual Molecular Dynamics. [208] Modelling structure and protein radius and volume
courtesy of Dr. J. Brookes.
In addition, three different protein complexes were considered, each involving the binding of
HIV p24 to either one or two anti-p24 antibodies/llama VHH. In these cases, the complex
was assimilated to one spherical particle. The molecular weights of the different proteins
involved in the complex were added together to express the molecular weight of the complex.
Similarly, the radius of the complex was considered to be the sum of the radius of the
different proteins involved in the complex. The resulting molecular weights and sizes of the
different complexes are listed in Table 8.4.
The solution density is plotted against the measured insertion loss ∆IL in Figure 11 below.
As for the sample viscosity, the range 0 to 20dB was considered as it covers the range of
perturbations investigated throughout this work.
As with Figure 8.8, Figure 8.11 can be used as an operation characteristic of the SAW
biosensor, to either relate a measured insertion loss to a density perturbation, or to predict
the insertion loss caused by a given perturbation of the density within the sensing volume. It
is interesting to note that for any given change in solution density, the smallest and lightest
Chapter 8. Model to Characterise SAW Device Response, Sample and Target Protein
Properties 206
Protein
complex
Llama VHH +
HIV p24
Llama VHH +
HIV p24 + IgG
IgG + HIV p24
+ IgG
Radius
(nm)
6.8 15.3 21.5
Volume
(nm3)
1340 14973 41225
Molecular
weight
(kDa)
36.47 186.47 324
Table 8.4: Intrinsic properties of some proteins complexes used as examples.
Table to summarise the radius, volume and molecular weight of some of the protein com-
plexes used in the experiments presented in this section. Estimations based on the values
presented in Table 8.3.
protein (Llama VHH, blue trace) is predicted to give rise to a smaller insertion loss than any
other larger and/or heavier protein or protein complex. By contrast, the largest and heaviest
protein (two IgGs forming an immunosandwich around HIV p24, brown trace) gives rise
to the largest insertion loss for a given perturbation. Similarly, any protein complex gives
rise to a larger insertion loss than its individual protein components. However, the larger
protein does not always give rise to the larger insertion loss: the complex formed between
HIV p24 and the anti-p24 llama VHH (red trace) gives rise to a larger insertion loss than
the IgG (green trace) on its own, despite being 4 times lighter (36.47kDa vs 150kDa) and
about twice smaller (1340nm3 vs 2527nm3). In addition, proteins that are very different in
size can give a similar response: the traces representing HIV p24 (orange) and IgG (green)
are very close, despite the IgG protein being nearly 6 times heavier (150kDa vs 24kDa) and
about 6 times larger than HIV p24 (2527nm3 vs 389nm3). This shows that, in the context
of optimising the design of the SAW biosensor and aiming for the right protein target, the
combination of the structure of the protein and its molecular weight matter more than the
molecular weight or volume only. This is confirmed by the expression of the density in
Equation 8.8, which depends on the ratio of the molecular weight and the volume of the
particle.
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Figure 8.11: Solution density expressed as a function of the measured insertion
loss ∆IL. Plot to show the relationship between the insertion loss measured by the OJ15
SAW biochip and the corresponding solution density, for different proteins used throughout
this thesis. The measured insertion loss for a solution density of 999.97kg.m−3 (density of
water at 25◦C) is 0dB, as the sensor calibration was performed with water as the starting
reference point.
8.5 Characterisation of the proteins adsorbed on the surface
of the SAW device
In order to estimate the mass per surface area added onto the surface of the SAW device,
a model experiment was conducted. Solutions of anti-HSA at different concentrations in
buffer (PBS) were put in contact with the surface of OJ15 SAW devices. The measurement
protocol was the same as the one used for the SAW device calibration, except for the fact
the glycerol/water solutions were replaced by the antibody solutions, and the pure water
by a PBS running buffer in which the antibody was diluted. The insertion loss ∆IL was
recorded 15 minutes after sample injection.
In parallel, the theoretical maximum mass adsorbed per surface area was estimated. As
the antibodies adsorbed on the surface are modelled as spheres, the method developed by
Feder et al. could be used. They studied the coverage of a surface onto which discs of
constant diameter are disposed, and demonstrate that the theoretical maximum coverage
of the surface was 54.7%. [209] Based on this, and on the assumptions that the antibodies
form a monolayer at the point where the insertion loss is recorded, a theoretical maximum
Mnorm could be calculated, depending on rparticle.
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As mentioned earlier, in the calculations that led to the estimation of the mass per surface
area, the particle shape factor ν was set to 2.5, which corresponds to the antibody being
modelled as a spherical particle. However, an antibody is not likely to present itself to
the surface as a perfect sphere, but more as an ellipsoid. Jeffery [210] estimated the particle
shape factor theoretical values for different shapes of ellipsoids, depending on their ellipt-
icity. He showed that the average maximum values for ν were 3.3 and 6, for prolate and
oblate ellipsoids, respectively. This corresponds to ellispoids of ellipticity equal to 0.9, and
therefore represents extreme cases where the shape of the spheroid is the furthest away
from a perfect sphere (either a long thin prolate ellipsoid or a large flat oblate ellipsoid).
To investigate whether the model would still be valid with particles being modelled as el-
lipsoids instead of spheres, the calculations of Mnorm were run for these different values of
ν. Results are shown in Figure 8.12.
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Figure 8.12: Mass per surface area as a function of the antibody concentration.
Plot to show the mass adsorbed per surface area Mnorm as a function of the antibody
concentration, for three different shapes of particle. Each point represents the average
of 3 measurements. The black line represents the theoretical maximum Mnorm and was
estimated using the Feder method. [209]
Figure 8.12 shows that the surface coverage estimated using the method, was found to be
below the theoretical maximum surface coverage calculated by Buijs et al., for all concen-
trations tested. In this commonly cited study, they estimate the surface coverage when
IgG molecules adsorb on a surface based on crystal structure data, and find the maximum
values to be in the range 200 to 550ng/cm2, depending on the arrangement of the molecule
on the surface. [211] For each particle shape tested, the estimated Mnorm does not seem to
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plateau even at high concentrations, suggesting that higher antibody concentrations might
be needed to achieve a maximum surface coverage.
Note: the volume fraction of particle in the sensing volume does not depend on the volume
of the particle. However, it is important to note that within the range of antibody concen-
tration tested, it remained below the threshold of 0.2. Applying the Einstein relation for
solid particles therefore stands in this model for the range of concentration used.
8.6 Discussion
The Saha-Gizeli method was used to characterise the OJ15 SAW devices used throughout
this work. It was shown that the OJ SAW device has a slightly better sensitivity than
comparable SH-SAW devices used by Gizeli et al., in the viscosity region tested. Useful
calibration curves were obtained that indicate the relation between sample viscosity and
the measured insertion loss.
Using an estimation of the size of some of the proteins used to obtain the results presented
in Chapters 6 and 7, the solution density was plotted as function of the insertion loss,
for individual proteins as well as protein complexes. This highlighted the need for con-
sidering the combination of the structure of the protein and its molecular weight rather
than the molecular weight or volume only in the context of optimising the design of the
SAW biosensor and aiming for the right protein target. These results have to be nuanced,
however, by the fact they were obtained under the initial assumptions required to apply
the Saha-Gizeli method, which assimilates the proteins in solution as non-interacting solid
particles. At high concentrations especially for the protein used as a capture protein this
is unlikely to be exact. Further work will look into refining these results by applying the
model in two distinct steps to a surface/protein/protein system, instead of limiting it to the
surface/protein system studied to begin with. Target proteins binding to the functionalised
surface are more likely to act as non-interacting solid particles.
Similarly, the estimation of the acoustic wave penetration depth (see Figure 8.13) will have
to be refined to take into account the difference in density for each layer of proteins, rather
than assimilating the proteins in each layer as non-interaction solid particles.
Chapter 8. Model to Characterise SAW Device Response, Sample and Target Protein
Properties 210
5 10 15 20
Insertion loss (dB)30
40
50
60
70
80
Penetration depth (nm)
Llama VHH
HIV p24
IgG
Llama VHH + HIV p24
Llama VHH + HIV p24 + IgG
IgG + HIV p24 + IgG
Figure 8.13: Penetration depth expressed as a function of the measured inser-
tion loss ∆IL. Plot to show the relationship between the insertion loss measured by the
OJ15 SAW device and the corresponding acoustic wave penetration depth, for different
proteins used throughout this thesis. The penetration depth corresponding to an insertion
loss of 0dB is that of the running buffer, which in this case was PBS.
Using the Saha-Gizeli method, an estimation of the mass per surface area adsorbed on
the surface of the SAW device could also be achieved. One of the key parameters in
the model used is the volume of the particle. In Figure 8.12, the value of Vp was set to
2527nm3, which corresponds to the value estimated using Visual Molecular Dynamics under
the assumption that the protein was included in a sphere of water (see Table 8.3). Other
modern estimations or observations of single molecule IgG tend towards the representation
of IgG molecules as fitting within a sphere of radius 5 to 6nm. This is due to the fact the
long axis of the molecule, along which the Fc region is aligned, is approximately 10 to 12
nm. In addition, a study by Foster et al. [212] shows that IgG molecules do not undergo
important denaturation when adsorbing on bare gold surfaces. They used XPS to look at
the ratio between amino acids on the surface over amino acids buried inside the protein, in
order to estimate how much denaturation the protein had undergone after adsorbing to the
gold surface. As the value of Vp following this technique varies from the initial estimation
(about 900 nm3 compared to 2527nm3), calculations of the mass per surface area were run
again with the alternative value of Vp. However, if the absolute values of Mnorm increased
compared to the values observed in Figure 8.12 at similar concentrations, the general trend
was the same as the one observed in Figure 8.12. Even at high concentrations, Mnorm
did not plateau, and for every shape tested, the highest value of Mnorm did not reach the
theoretical maximum (which also increased, at it is dependent on the radius of the particle).
Future work will look into testing the model for particles of different sizes, with a better
knowledge of their size in order to minimise the uncertainty regarding the parameter of the
model corresponding to the particle volume. Similarly, studying the shape of the proteins
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with external methods would help with choosing the most appropriate value for the shape
factor when applying the Einstein relation, and therefore tend towards a more accurate
estimation of the surface coverage.
This powerful and simple method also has the potential to bring new insights into the
analysis of protein adsorption on surface, as well as protein protein interactions. Because
the SAW device operates at a frequency (251.5MHz) one to two orders of magnitude higher
than conventional quartz crystal microbalances (QCM), it probes mechanisms happening
within the typical relaxation time of proteins, whereas QCM can typically only give indic-
ations on the surface formed after relaxation. Future work will involve investigating this
aspect of the probing further.

Chapter 9
Conclusions and Future Work
New, higher performance and better connected PoCT for HIV can contribute to the fight
to stop the HIV/AIDS pandemic. Widening access to testing, making tests easier to use,
faster and more reliable, and building data sets with information that can be used to
monitor and fight the spread of the pandemic are all motivations that drive the design and
development of this new generation of PoCT. SAW devices are ideal candidates, as they are
low cost, disposable and can easily be integrated in a simple test performed in conjunction
with a smartphone. The aims of this thesis were to (i) explain the theoretical concept
of biosensing using SAW devices, (ii) contribute to the development of a simple to use,
reliable and sensitive SAW biosensor, (iii) show that it can be engineered to rapidly detect
key biomarkers of early HIV infection at clinically relevant levels, (iv) assess and optimise
its clinical performance indicators and (v) investigate the transduction mechanisms in the
hope to further improve its performance.
9.1 Summary of overall thesis conclusions
9.1.1 Chapter 2: HIV diagnostics needs
In 35 years, more than 60 million people have contracted HIV infection, causing nearly 30
million deaths. [1] As an alarming proportion of HIV infected persons (about a quarter in the
UK [2]) is unaware of their infection, the need for efficient diagnostics tools is crucial. The
recent court ruling in the UK specifying that the NHS has the legal power to commission
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pre-exposure prophylaxis (PrEP) is very good news. By blocking HIV from incorporating
its genetic material into the hosts genome and therefore preventing infection in healthy
individual, the treatment constitutes a welcomed additional tool to limit the spread of the
infection. [213] However, the need for effective diagnostic tools is still there, as PrEP is not
globally implemented yet, and has not been shown yet to be 100% efficient in the prevention
of HIV infection.
Traditional diagnostic tools are very efficient, but are associated with high costs, the need
for highly trained staff and modern equipment, and often patients experience delays between
their initial visit to the hospital or clinic, follow up appointments and eventually access to
care. [8–10] The interest shown in recent years by the WHO towards HIVST [14] has led to
reports of global acceptability towards this new form of testing [15] and its recent legalisation
in the UK [6]. The conclusions of various studies on the cost effectiveness of the implementa-
tion of HIVST at national level in the UK agree in saying that the costs associated with the
operation would largely be counterbalanced by the huge savings made by public healthcare
providers, and that this trend would carry on year on year. [11–13]
The target product profile set out by PATH to describe the ideal HIVST was presented in
Chapter 2. It constituted a point of reference throughout this work, along with the AS-
SURED criteria recommend by the WHO for PoCT. [18] In relation with the work presented
in this thesis, the following criteria were identified as crucial: (i) the test should be simple
to use, consisting of only 3 to 5 intuitive steps (ideally just one), (ii) the test should deliver
the result under 5 minutes, and (iii) the clinical sensitivity and specificity should be greater
than 99%.
A review of the currently available PoCT for HIV infection was conducted, which high-
lighted the current absence of a perfect test. Some tests were characterised by a limit of
detection to a certain biomarker of HIV infection that was too low (based on measurements
performed in the lab, which gave different results than the manufacturers claims). Some
tests required a time to result exceeding the 5 minute requirements. Most of the available
PoCT for HIV are based on lateral flow technology. These tests are notoriously difficult
to interpret [8] as they requires the test user to see the apparition of a coloured line on the
test, which can sometimes be quite faint if the concentration of the biomarker is low, or if
the light conditions are not ideal.
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It was also observed that very few current commercially available tests have the ability
to record and send the data to health care providers, and most of the ones who do are
laboratory-based tests. This feature is crucial to avoid loss of data, and represents a very
effective tool for global and local healthcare providers to monitor the spread of the infec-
tion, and occasional outbreaks. The connectivity is the key feature of the next generation
of PoCT, and their implementation may be facilitated by public healthcare providers who
could see in them an opportunity to access and record much needed data that could con-
tribute to stopping the spread of the infection. Some connected tests have been reported,
either using a smartphone to interpret existing current commercial lateral flow tests, [22] or
fully adapting an ELISA on a USB dongle. [23] However, the first conclusion of this work
is that there is still a gap in the field of high performance, simple to use, low cost and
connected PoCT for HIV infection.
9.1.2 Chapter 3: Potential of SAW devices for biosensing
One of the aims of this work was to justify the use of SAW sensors for biosensing, as
they have the potential to fulfil most of the ASSURED criteria of the ideal PoCT for HIV
described by the WHO. The objectives of this section were to understand the theory behind
the sensing mechanism of SAW devices, and explain the best options for monitoring the
events of interest detected by the sensor.
Acoustic wave based sensors consist of piezoelectric crystals through which an acoustic wave
is made to propagate. They make use of the piezoelectric effect to sense perturbations in
their surrounding medium. The effect of the perturbations on the acoustic wave, which
propagates much more slowly than its electromagnetic wave equivalent, can be monitored
via the piezoelectric effect. A well-known acoustic wave sensor, QCM, has been used in
laboratories since the 1980s to monitor the mass adsorbed on the surface of a gold coated
piezoelectric substrate. In 1959, Sauerbrey proposed a direct relationship between the mass
adsorbed and the shift in the resonant frequency of the acoustic wave propagating through
the crystal and reflected by the surface. [131]
A new form of acoustic wave based sensors emerged at the beginning of the 1980s, with
the emergence of the first SAW sensors. [145] Unlike the QCM whereby the acoustic wave
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propagates through the crystal twice before being monitored, the acoustic wave propaga-
tion is confined, as much as possible, to the surface of the crystal, making SAW sensors
theoretically more sensitive to surface perturbations. A necessary initial objective of this
work was to review the field of biosensing using SAW devices. Various applications have
been reported during the past 40 years or so, ranging from pH sensing [169] to the monit-
oring of phospholipids [153], antibody [155], or bacteria [157] adsorption on the surface of the
sensor. Little has been done, however, in the specific field of using SAW sensors for HIV
diagnostics. The proof of concept of detection of biomarkers of HIV infection, such as anti-
gp41 antibodies, has been reported by Thompson et al., [30] but with a limit of detection
(100µg/ml) too high to be used as a diagnostic test. It transpired that the potential for
using SAW devices for HIV diagnostic had yet to be fulfilled.
The particular case of SH-SAW devices was considered, as industrial partners OJ-Bio Ltd.
developed a SAW device based on a quartz crystal supporting a SH-SAW sensor, with the
capacity to handle liquid samples. IDTs deposited on the surface of the quartz crystal
make use of the piezoelectric effect to transduce an electromagnetic wave into an acous-
tic wave that propagates along the delay line in between the IDTs and back into an
electromagnetic wave. This system can be used to monitor the acoustic wave parameters
via the electromagnetic wave parameters. The perturbation theory applied to SH-SAW
predicts that perturbations occurring on the surface of the delay line of SH-SAW sensors
have a direct impact on the acoustic wave velocity and attenuation coefficient. Kondoh
et al. derived equations to define the impact of specific perturbations, namely a viscosity
change and a mass loading on the surface of the sensor, and analysed the implications of
viscoelastic perturbations on the same parameters. [173,174]
The perturbations of interest in the context of a biosensor for HIV consist of the binding of
target proteins to the functionalised surface of the sensor. They are most likely a combin-
ation of all the aforementioned basic perturbations. It was shown that the measurement
of two parameters - the electroacoustic wave phase shift and the insertion loss - gives a
direct indication of the changes occurring to the acoustic wave velocity and attenuation,
respectively. Therefore, monitoring the phase shift and insertion loss when submitting the
SAW device to a given sample is the ideal way to detect any perturbation cause by this
sample. In other words, when the target protein present in a positive sample binds to the
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functionalised surface, this can be detected by monitoring changes in the phase shift and
the insertion loss.
9.1.3 Chapter 5: SAW device characterisation
The first objective in relation to the usage of the SAW device developed by industrial
partners OJ-Bio Ltd. was to characterise its performance before it goes through the func-
tionalisation process to transform it into a SAW biochip. The performance of the device
was looked at from three different angles: the shear sensitivity, the simplicity of use, and the
reproducibility of measurements recorded using the laboratory control box. The objectives
and corresponding achievements are listed in Table 9.1.
The shear sensitivity of the SH-SAW device to given perturbations was studied and op-
timised. It was shown that two specific features characterising the device improved its
sensitivity, compared to other prototypes of SH-SAW devices. The length of the delay line
used (9mm) was shown to bring a higher sensitivity to the perturbations encountered in the
context of the use of the device as a biosensor than a shorter delay line of 5mm. Similarly,
the presence of a reflector on the lower delay line of the device a feature enabling the
monitoring of the surface component of the acoustic wave only, instead of a combination of
the bulk and surface components was shown to improve the devices sensitivity.
During the course of this work, it was noted that loading a sample onto the surface of
the sensor could easily result in the formation of a droplet, preventing the sample from
spreading across the whole area of the delay line. In the interest of developing a PoCT
that can be used easily by non-trained staff, a study was performed which showed that
the amplitude of the signal output by the control box phase shift and insertion loss was
dependent on the fraction of the surface of the delay line covered by liquid. As a smaller
signal was still output when the sample formed a droplet, the conclusion was that a correct
loading of the sample onto the surface of the sensor was crucial to the validity of the test
result.
The SH-SAW devices used throughout this work were considered disposable and were only
used for one measurement. The control box used to obtain the measurements featured 4
different SAW devices holders, enabling 4 measurements to be run in parallel. In order to
justify the comparison of measurements obtained on different devices, a statistical analysis
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Objective Achievements
Assess SAW device sensitivity
• Operational frequency used to drive the device
(f = 251.5Mhz) found to be very close to optimal
driving frequency (f = 251±0.16MHz).
• Length of the delay line used (9mm) generat-
ing higher sensitivity in perturbation region of
interest than other prototype available (5mm
delay line).
• Cancelling out the bulk component of the sig-
nal using reflector on lower delay line increases
overall device sensitivity in perturbation region
of interest.
Ensure ease of use of future
PoCT product
• Possible user mistake identified: liquid sample
forming a droplet on the surface of the delay
line instead of spreading across the sensing area.
• Signal readout found to be proportional to
fraction of surface area in contact with liquid
sample.
Measurements reproducibility
• 364 measurements recorded in parallel using
laboratory control box and 4 chip holders invest-
igated.
• Differences in similar measurements recorded on
different holders found to be low enough to con-
sider measurement reproducible (no more than
1.3%).
• Confirmation that laboratory control box allows
for 4 SAW devices to be used at the same time,
allowing for referencing or duplicate runs.
Table 9.1: Objectives and achievements of Chapter 5, in relation to assessing
the SAW device performance
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of a large number of measurements performed on the same sample were performed. The
construction of Bland-Altman plots and associated analysis applied to this specific sys-
tem concluded that the difference in measurements observed between the 4 different SAW
devices holders were small enough to justify intra-holders comparison.
9.1.4 Chapter 6: Detecting model proteins and HIV markers of infection
On the basis of this initial analysis of the SH-SAW device performance, an optimisation of
the functionalisation of the gold surface of the delay line was performed, with the aim of
turning the SAW device into a SAW biochip with the capacity to detect the presence of key
biomarkers of early HIV infection in a sample. The detailed objectives and corresponding
achievements are listed in Table 9.2.
It was shown that functionalising the surface with capture proteins via the chemical linker
DSP led to the optimal signal readout. Using different capture proteins, the detection of
various target proteins could be achieved. Anti-p24 was reproducibly detected down to
2nM (300ng/ml) within 5 minutes of sample injection, and down to the clinically relevant
concentration of 50nM (75µg/ml) within 10 seconds. This represents test results about 100
times faster than commercially available tests such as the Alere Determine lateral flow test
which requires about 20 minutes between sample injection and valid test result.
A series of experiments helped optimise the detection of HIV p24 antigen, an early marker
of HIV infection, using an immunosandwich consisting of novel anti-p24 llama VHH on
the surface and mouse anti-p24 antibody on top of the target protein. The use of an
immunosandwich was shown to increase the signal readout, enabling reproducible detection
of p24 down to 2nM (48ng/ml).
The use of gold nanoparticles to further improve the signal readout for this assay was
investigated using two layers of gold nanoparticles functionalised with anti-p24 and anti-
mouse antibodies. However, despite careful troubleshooting of the process, the initial results
could not be reproduced, and further work related to this assay optimisation is detailed in
the Future Work section further on.
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Objective Achievements
Optimise surface functional-
isation with model protein
complex HSA/anti-HSA
• DSP found to be ideal chemical linker to anchor
capture proteins on the gold surface of the delay
line.
• Assessment of optimised concentration to use
to functionalise surface with capture proteins
(100µg/ml)
• Titration curve of HSA detection using SAW
biochips yields kinetic constants comparable to
literature.
Rapid detection of anti-HIV
antibodies at clinically
relevant levels
(Anti-p24 82 - 1900µg/ml,
Anti-gp41 5.4 - 5194µg/ml)
• Proof-of-concept of detection of anti-p24 anti-
bodies using SAW biochips.
• Same measurement taken multiple times using
one SAW biochip found to be robust, highlight-
ing longevity and resistance of the capture pro-
teins layer.
• Titration curve of anti-p24 antibodies obtained.
• Reproducible detection down to 2nM
(300ng/ml) within 5 minutes of sample in-
jection.
• Ultrafast detection down to 50nM (7.5µg/ml),
below clinically relevant concentrations.
Rapid detection of HIV p24
antigen at clinically relevant
levels (0.1-1000pg/ml)
• Proof-of-concept of detection of HIV p24 antigen
using SAW biochips functionalised with anti-p24
llama VHH.
• Reproducible detection down to 2nM (48ng/ml).
• Benchmarking of detection assay using QCM.
Investigate signal amplifica-
tion strategies
• Initial results using gold nanoparticle as signal
enhancement inconclusive.
• Difficulties encountered in reproducing results.
• Troubleshooting not giving clear evidence of loss
of antibody affinity for its target protein.
Table 9.2: Objectives and achievements of Chapter 6, in relation to the detec-
tion of key biomarkers of HIV infection using SAW biochips.
Chapter 9. Conclusions and Future Work 221
9.1.5 Chapter 7: Clinical pilot studies: Testing real patient samples
After the biosensor was shown to be able to reliably detect biomarkers of HIV infection in
mock samples, it was decided to investigate its ability to do so in patient samples, then to
conduct a series of pilot studies to assess the clinical performance of the biosensor. In the
process of doing so, ensuring a smooth transition between the different generations of SAW
biochips became an additional objective. The objectives and achievements associated with
the testing of real patient samples are listed in Table 9.3.
Objective Achievements
Moving from detection in
mock samples to patient
samples
• Proof-of-concept of anti-HIV antibodies (anti-
p24 and anti-gp41) detection in human plasma
spiked with antibodies.
• Established the need for referencing to account
for non-specific binding of the many proteins
found in plasma.
Transition from single chan-
nel SAW biochips (OJ15)
to new generations of
SAW biochips featuring
two operational delay lines
(OJ24/OJ28/OJ31).
• Proof-of-concept of anti-HIV antibodies showing
similar results with manual functionalisation of
each delay line.
• Moving a step further towards automatization of
manufacturing process using liquid dispenser to
functionalise delay lines. delay lines. Increased
reproducibility of measurements.
• Using one of the two delay lines as an in-built
reference channel. Reference delay line function-
alised with NAP.
Achieving clinical perform-
ance in line with PATH target
product profile for HIVST
• Combined clinical sensitivity to anti-gp41 and
anti-p24 of 100% (target >99%)
• Combined clinical specificity to anti-gp41 and
anti-p24 of 100% (target >99%)
• Time to result <5min (target <5min)
Table 9.3: Objectives and achievements of Chapter 7, in relation to the assess-
ment of the PoCT clinical performance.
A proof-of-concept study established the need for a reference test to be run in parallel to
the sample test, due to the complexity and higher viscosity of plasma samples compared to
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aqueous buffer samples. It was shown that both anti-p24 and anti-gp41 antibodies could
be detected using SAW devices functionalised with the corresponding recombinant protein
(p24 or gp41, respectively). A series of pilot studies was therefore conducted, using a panel
of 31 HIV patient samples in addition to over 100 confirmed HIV negative patient samples.
An algorithm was developed herein to handle the large amount of data generated by testing
these numerous samples multiple times. The automation of the functionalisation process
of the SAW devices, conducted by industrial partners OJ-Bio Ltd., helped to perfect the
performance of the biosensor. A combined 100% sensitivity and 100% specificity to anti-
p24 and anti-gp41 was achieved, the test results being obtained under 5 minutes. The key
objectives set out by the PATH target product profile for HIVST were therefore achieved.
9.1.6 Chapter 8: Characterising SAW device response, sample and target
protein properties
The last aim of this work was to characterise the response of the SAW device to a known
perturbation, the liquid sample viscosity and density, and the mass loading when proteins
adsorb on the surface of the sensor. The objectives and corresponding achievements in
relation to this characterisation approach are listed in Table 9.4.
A method developed by Gizeli et al. was investigated and applied to the OJ15 SAW device.
The method relies on a calibration of the sample using solutions of known viscosities, and
the assimilation of proteins adsorbed on the surface of the delay line to non-interacting
solid particles. Gizeli et al. developed this method using SH-SAW devices very similar to
the OJ15 SAW device used throughout most of this work.
The calibration of the SAW device with solutions of different viscosities showed that the
OJ15 SAW device presented a higher sensitivity to viscosity changes, compared to the two
types of devices tested by Gizeli et al. The insertion loss response (0.24dB) and phase
shift response (1.47degrees) to a change in one percent glycerol weight fraction were both
found to be higher than the most sensitive device presented by Gizeli et al. (0.2dB and
0.91degrees, respectively).
Calibration curves were generated to describe the response of the SAW device to a given
change in sample viscosity and density. For the latter, specific examples were chosen to
reflect the properties of some key protein solutions used to obtain the results presented in
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Objective Achievements
Finding a new approach to
characterise the response of
the SAW device to given per-
turbation
• Literature review which highlighted the concept
of the Gizeli et al. method, applied to similar
SH-SAW devices.
Comparison of performance of
OJ15 devices to other SAW
devices
• Calibration of the SAW device using solutions of
glycerol/water.
• Estimated higher sensitivity to viscosity per-
turbation, compared to similar SH-SAW devices
used by Gizeli et al.
Characterise the response of
the SAW device to given per-
turbations
• Calibration curve generated to describe the re-
sponse of the SAW device to a given viscosity
perturbation.
• Calibration curve generated to describe the re-
sponse of the SAW device to specific solution
densities, corresponding to solutions of proteins
used throughout this thesis.
Characterise the mass per sur-
face area deposited on the sur-
face of the delay line
• Applied the model to a simple antibody adsorp-
tion on gold system.
• Estimation of the mass per surface area correctly
found to be below theoretical maximum cover-
age.
Table 9.4: Objectives and achievements of Chapter 8, in relation to character-
ising the SAW device response, sample and target protein properties.
previous chapters. More work is needed to make these calibration curves more accurate,
taking into account the specific characteristics of the proteins used. They could constitute
a potential useful tool to optimise the sensitivity of the biosensor in the future.
The mass per surface area of proteins loaded onto the surface of the delay line was estimated
by applying the model to a simple system whereby antibodies were adsorbed on the surface
of the delay line. Different values of the shape factor parameter were tested to reflect the
uncertainty about the shape of an antibody adsorbed on a surface. The values of mass per
surface area were found to be below the theoretical maximum coverage in every case tested,
even at high antibody concentrations. The model also opens up exciting opportunities to
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optimise crucial parameters of the assay, as will be discussed in the next section.
9.2 Future Work
This work presented in this thesis aimed at contributing to the development of a new,
better PoCT for HIV. As detailed throughout the thesis and above, it was shown that a
smartphone-connected biosensor could be developed using low cost SH-SAW devices optim-
ised for the rapid detection of key biomarkers of HIV infection in human samples. Building
on from this work, multiple aspects of the optimisation of the biosensor can be explored
and optimised further.
9.2.1 Further optimisation of the SAW biochip sensitivity
9.2.1.1 Novel capture ligands
In the process of designing the biosensor, one of the key aspects is the surface function-
alisation. The work in relation to the functionalisation of the delay line was detailed in
Chapter 6. One of the aspects of the functionalisation process that could be explored
further is the nature of the capture layer. Conventional antibodies, recombinant proteins
and llama VHH were used successfully to bind to key biomarkers of HIV infection in the
sample. Various other ligands binding to the target protein can be used, of which one stands
out, and could be used to functionalise the delay line of a SH-SAW device: aptamers.
Aptamers are synthetic peptides selected or engineered to bind to a specific target mo-
lecule. [214] Aptamers have attracted attention in recent years for their flexibility they can
theoretically be engineered to bind to any molecule depending on user requirements [215]
and thermal stability [216]. Like llama VHH, thermal stability would be a great asset in
the prospect of designing a biosensor able to endure important variations of temperature
during shipping or storage. Used in combination with recently developed portable PCR
systems, [217–219], aptamer-functionalised SAW biochips could be used as molecular probes
to detect the presence of viral RNA in a sample, further reducing the detection window for
new HIV infections.
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9.2.1.2 Multiplexed analysis
The choice of capture protein, and the way it is anchored to the surface directly impact on
the biosensors ability to detect the presence of the target protein in the sample. By chosing
the appropriate capture protein, it can be envisaged that the biosensor could theoretically
be used as a platform to detect any protein. A SH-SAW device featuring multiple delay
lines, each functionalised with a different capture protein, could be used as a biosensor to
diagnose multiple infections, or to detect multiple strains of the same infection. This could
be particularly useful in cases of testing groups of individuals who are at risk of multiple
infections, such as injection drug users (IDU). Another example of a benefit brought by a
multiplexed detection system would be to prevent the prescription of a particular drug in
the treatment of one infection, that would be contraindicated by the presence of infection
by a different pathogen. Some drugs used in the treatment of HIV also affect hepatitis B
virus (HBV), and can foster resistance if an ineffective HBV monotherapy is then effectively
used. This has to be avoided with patients presenting a HIV/HBV coinfection. [220]
9.2.1.3 Improved reference capture coatings
As mentioned in Chapter 7, testing plasma samples requires the use of a reference test, or
a reference channel on the same device. This reference test measures the signal generated
by the sample on a surface functionalised with proteins that are engineered to not resemble
human proteins, and therefore do not bind to the target protein. The ability of this reference
test to not bind to the target protein, while behaving as similarly as possible to the normal
test, is key to the accuracy of the test result. NAP was used for the reference tests performed
as part of the difference pilot studies. The average signal measured for negative samples
(both negative calibration samples and true negative samples) was not exactly zero, and
different for each biomarker tested (anti-p24 and anti-gp41). It is possible that other
proteins, or other strategies, would give a better reference and therefore increase the test
accuracy and overall performance.
Poly(L-lysine)-graft-PEG (PLL-g-PEG) has been widely reported as an efficient system to
prevent non-specific adsorption of serum proteins on a surface. [221,222]. However, in the case
of the SAW biosensor presented here, it is important that the two delay lines respond to
perturbations that are unrelated to the binding of the target protein (such as a change in
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viscosity for example), in a similar way, to ensure correct normalisation of the test signal.
As the structure and size of Poly(L-lysine)-graft-PEG (PLL-g-PEG)is quite different to
the characteristic of the capture protein used in this work, in is unlikely to be the ideal
solution. One way to enhance the effectiveness of the reference delay line is to functionalise
it with a protein that is almost identical to the capture protein used on the test delay
line, but engineered to not bind the target protein. This could be achieved by mutating
a small number of amino acids in the binding site region of the sequence of the capture
protein. Another approach would be to investigate multifunctional molecules. Synthetic
co-polymers have been engineered to bind to a substrate via their poly-(L-lysine) (PLL)
backbone, block non-specific adsorption of protein to a surface via poly(ethylene glycol)
(PEG) on the side chains, while promoting the binding of the cell target via incorporation
of a specific peptide to the side chains. [223,224] Using the appropriate backbone to bind to
gold, and the appropriate peptide engineered against the target protein, this strategy has
the potential to increase the sensitivity of the SAW biochips to biomarkers of HIV while
eliminating the need for a reference test.
9.2.1.4 New enhancement strategies
The thousand-fold improvement in the p24 detection assay, obtained using multiple layers
of gold nanoparticles and presented in Chapter 6, could not be reproduced and careful
troubleshooting did not give clear indications about the possible causes of the problem.
The significant improvement observed with the first successful assays, and the fact it takes
the level of detection of a key biomarker of early HIV infection down to clinically relevant
levels, calls for an in-depth investigation regarding the enhancement of the detection signal.
Other strategies to improve p24 detection assays can be envisaged, one of which being
the silver enhancement technique, whereby silver ions in solution nucleate around gold
nanoparticles and precipitate as silver metal. This technique is already used to increase the
size of small gold nanoparticles for better visualisation in scanning electron microscopy. [225]
It would be the natural step forward in the evolution of the signal amplification strategies
tested so far, as is schematised in Figure 9.1.
Following the perturbation theory applied to SH-SAW, mass loading on the surface of the
delay line of a SH-SAW device directly affects the acoustic wave velocity, which can be
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Figure 9.1: Silver enhancement as the next step signal amplification strategy.
Schematics to illustrate the different signal amplification strategies used throughout this
work in the context of the HIV p24 antigen detection assay. The arrow on the right-hand
side indicates the impact the amplification strategy is likely to have on the propagation
of the acoustic wave, and therefore on the sensitivity of the assay. The straightforward
detection of HIV p24 in solution (top) was improved with the formation of an immunosand-
wich using mouse anti-p24 antibodies. This strategy was further improved by replacing
the mouse antibody by a double layer of antibody-functionalised gold nanoparticles. A
potential improvement of this technique could be the nucleation of silver around the gold
nanoparticles, increasing the mass loading and therefore amplifying the signal. Drawings
not to scale.
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monitored via the phase shift . Using the silver enhancement strategy, an increase in
mass loading would be generated specifically where the target protein is present, therefore
improving the sensitivity of the assay.
Similarly, changes in viscoelasticity could be enhanced. The target proteins binding to the
surface of the delay line are isolated, as their concentration is usually low. Connecting them
using larger structures with an affinity for the target protein (and binding to a different
epitope than the capture protein on the surface) would create a net above the surface,
capturing more water molecules and generating a larger viscoelastic perturbation at the
surface proximity.
9.2.1.5 Maximising the perturbation of the SH-SAW
A method was presented in Chapter 8 to characterise the response of the SAW device
to given perturbation, and the potential for modelling certain physical parameters of the
samples, the target protein or the sensor itself was investigated. One of the outcomes was
the possibility to relate the penetration depth of the acoustic wave in the liquid sample to
the characteristics of the particles on the surface, i.e. the complex formed by the capture
protein, target protein, and signal amplification objects/proteins. The molecular weight,
shape and volume of the particle all contribute to the general effect on the penetration
depth. More work is needed to refine this model, notably in terms of characterising the
different proteins more accurately. There is a potential to create a very useful tool to
optimise the capture protein layer as well as validating the amplification strategy. Indeed,
the penetration depth was found to range in the order of a few tens of nanometres. The
strategy adopted to perform the assay would only be useful if the combined height of all
the elements (capture protein, target protein and any single amplification object) remains
below the penetration depth, otherwise perturbations would not be sensed by the acoustic
wave. As the capture proteins and target proteins usually range from a few nanometres to
a few tens of nanometres, investigating the acceptable boundaries of the penetration depth
would prove crucial. This is particularly relevant in the example of the signal amplification
strategy involving gold nanoparticles of 20nm diameter. This concept is schematised in
Figure 9.2.
Chapter 9. Conclusions and Future Work 229
Amplification strategy
Target protein
Capture protein
Chemical linker
H
ei
gh
t (
nm
)
P
en
et
ra
tio
n 
de
pt
h 
(n
m
)
0 0
D
C
B
A
Complex #1 Complex #2
A
MWA , VA
B
MWB , VB
C
MWC , VC
D
MWD , VD
Figure 9.2: Modelling penetration depth to validate the assay and signal amp-
lification strategy. Schematics to illustrate the effect of the choice of the assay elements
on the assays success. Two hypothetical complexes of different combined height are rep-
resented (Complex #1 and #2) and four different complex characteristics (combination of
the molecular weight, volume and shape) are considered (letters A to D). Each complex
can be characterised by any of these letters. The penetration depth corresponding to each
letter is indicated with a doted red line. For complex #1, B, C and D are efficient assay
strategies, while A would mean the signal amplification is useless. For complex #2, the
only efficient assay strategy corresponds to D. Drawings not to scale.
9.2.2 Next stage translational strategy
The SAW biosensor presented here already ticks some of the criteria of the ideal PoCT set
out by the WHO, and presents some characteristics of the ideal HIVST described by PATH.
It is potentially low cost as the disposable SAW devices are already on manufactured,
and the successful functionalisation of the delay line with an automated liquid spotter
performed by industrial partners OJ-Bio Ltd paves the way for a smooth transition to
mass manufacture the optimised SAW biochips. It has also been shown to deliver highly
accurate results under 5 minutes form sample injection. Other aspects of the design of the
biosensor as a connected PoCT can still be improved, and are detailed below.
Ultimately, the test should be able to work with whole blood samples, to avoid the centri-
fugation step necessary to extract plasma only from the sample. Ideally, the SAW device
would be able to handle the blood sample directly. However, blood being a non-Newtonian
fluid, this might complicate the analysis presented in Chapter 3 of the relation between the
perturbation and the corresponding output signal. Another potential idea to implement
this is the addition of a membrane filter above the surface, with pore size smaller than
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typical white and red blood cells. The sample could also be loaded on the membrane and
be carried while being filtered to the surface of the sensor using capillary action.
On the front of optimising the ease of use of the test, improvement could be made to
the way the sample is loaded onto the surface of the sensor. To avoid the formation of a
droplet, the surface could be made more hydrophilic by incorporating polylysine molecules
to the surface functionalisation, provided the resulting surface is still able to binding to
target proteins in the sample with the same efficiency. Ultimately, the step consisting in
the loading of the sample should be carried out by a panel of randomly selected participants
to confirm the test is easy enough to be used by non-trained staff. Any other potential user
mistakes should be identified and tested by the same panel as well.
As the test will ultimately be used in conjunction with a smartphone, there will be a need
to develop an app with the appropriate data processing algorithm. The app interface will
also constitute a future exciting challenge, as the simplicity of use of the test will largely
depend on it. Ideally, the instructions provided by the app should be clear enough that
the eventuality of mistakes by the test user will be very unlikely. In addition, the app will
provide a great opportunity to promote access to online patient pathways, which facilitate
counselling and linkage to care.
As mentioned earlier, the connectivity of the test is likely to bring the added benefit of
convincing public healthcare providers to fund and help with its implementation. The
added value of building datasets to monitor the spread of the infection and outbreaks would
be of great interest to these organisations. This will come with the absolute requirement
that the data is securely transmitted to relevant organisations only. Work will need to be
done towards convincing both the end users and public stakeholders they can trust the data
generated by the test will remain secure.
9.2.3 Engaging with end users and keeping up to date with their needs
A crucial aspect of the implementation of a new PoCT was not explored in this thesis. The
success of a new PoCT for HIV cannot happen without building patient trust, and making
sure the test, as well as the handling of the data it produces, is ethical and acceptable to the
patients themselves. Ensuring the patients will engage with the test is a key consideration
at every step of the design process. The biosensor presented here is designed to be used
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with a smartphone, not only for ease of use but also with the idea that any data it produces
could be stored and shared with health protection bodies. Work will need to be done to
assure patients their data are secured, and that it would only be shared with relevant health
protection organisations in order to contribute to the general fight to stop the pandemic.
It transpired during discussions with public healthcare workers that the end user needs may
differ from country to country. There is a case, in developed countries like the UK where
HIV prevalence is low, for targeting the groups at high risk of HIV infection and making
sure that healthy individuals are identified and linked to preventative measures. On the
other hand, in countries where HIV prevalence is still very high, such as South Africa,
correctly identifying individuals that have contracted the infection remains the priority,
focussing on the general population.
With the recent legalisation of self-testing in the UK, end user needs are likely to have to
be redefined depending on the context of the test usage. Target product profiles established
by and for health care workers may not be relevant to self-testers. Discussions have begun
about the concept of designing self-tests in a way that it would be impossible for the user
to interpret the test result. Instead, the result would be sent to an online healthcare system
that would have the capacity to interpret it and would provide the appropriate counselling
within a short time, thereby avoiding the difficult situation of an individual finding out
about the reactivity of their test on their own.
9.2.4 Testing the test refining clinical performance indicators by ex-
panding trials
Another aspect of the future work should look into refining the performance indicators of
the biosensor clinical sensitivity and specificity to a given biomarker of HIV infection by
testing larger panels of samples, ideally a few hundreds to a thousand of samples. The
key concept in the assessment of the clinical sensitivity and specificity of the test is the
combination between (i) a good knowledge of the amplitude of the signal recorded by the
sensor in response to both true positive and true negative samples, and (ii) the threshold
value used by the test to discriminate between positive and negative samples. Increasing
the number of samples tested, whether they are true positive, true negative, or negative
calibration samples, can only help in refining the value of the threshold value and therefore
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increases the accuracy of the test. In addition, the higher the number of samples tested,
the higher the confidence in the test performance indicators.
In terms of testing patient samples, the next step will be to obtain the authorisation to test
fresh samples (i.e. not stored samples). All the patient samples tested in the pilot studies
presented in Chapter 7 were at the stage of discard, after having been stored at 4◦C for
three weeks subsequent to collection. Testing fresh patient samples will provide the last
confirmation needed for the test to be ready for field trials, which will constitute one of the
most crucial and most exciting stages of development of this PoCT.
Trials should be implemented both in developed countries probably in the UK and low
and middle income countries. A current close collaboration with the Africa Centre, the
largest HIV diagnostic centre in South Africa, located in the province of KwaZulu-Natal,
should provide help in the process of implementing field test trials in a region with one of
the highest HIV prevalence in the world.
*
The work presented in this thesis was undertaken in the hope that it would bring a contribu-
tion to the development of a diagnostic system with the potential to bring major economic
and human benefits. If more work will be needed to perfect all aspects of the biosensor,
progress was made towards this exciting and challenging target.
Appendix A
Expression of VHH in E. coli TG1 cells
The following describes the principle and the protocol used to produce and purify the anti-
p24 llama VHH 59H10 from bacteria transformed with the original plasmid. The protocol
detailed below was optimised by Dr. Laura McCoy and colleagues. [226,227]
General principle
Plasmid and host cell
The general principle is to use a host bacteria to express the VHH sequence encoded by
a plasmid. The original plasmid used in this protocol, pCAD51-59H10, was a gift from
Professor Weiss. It encodes antibiotic resistance, and the 59H10 sequence inserted into a
multiple cloning site using restriction enzymes (SfiI and BstEII), adjacent to a promoter
under the control of the lac operon. The VHH sequence includes an N-teminal His-tag
that is used to purify the VHH during the production process, as well as a Myc-tag. The
host bacteria used in that process is a commercial E. coli called TG1, produced by several
suppliers. E. coli TG1 is a competent cell, which means it is primed for transformation.
Bug stock
The first step is transformation, that is forcing the plasmid into the host bacteria. This
is schematised in Figure 1. There are two main techniques to integrate a plasmid into a
cell, depending on the cell characteristics. A competent cell can either be electrocompetent
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or chemically competent. In both cases, the idea is to disturb the cell wall to make the
bacteria transiently permeable to plasmids. If the cell is electrocompetent - which is the
case of E. coli TG1 - this is done by submitting it to electric pulses in the presence of
the plasmid, a process called electroporation. If the cell is chemically competent, then a
simple temperature shock (typically 42◦C for 30 seconds) will make the cell walls transiently
permeable to the plasmid.
E. coli TG1
VHH plasmid
Electric pulses
Bug stock
VHH 
sequence
Antibiotic 
cassette
Figure 1: Electroporation process schematic. Electrocompetent E. coli TG1 cells
are submitted to electric pulses in the presence of a VHH plasmid, making the cell wall
transiently permeable to plasmids and therefore resulting in the incorporation of the plas-
mid into the bacteria.
After the host cell transformation, the cells are plated out on agar in a selective medium
containing an antibiotic called ampicillin. The plasmid sequence includes constitutive ex-
pression of an antibiotic resistance cassette, to produce a protein whose function is to make
the host cell resistant to ampicillin. Therefore, E. coli TG1 containing the plasmid are res-
istant to ampicillin, and they can use the rich medium to grow while all the other bacteria
are killed by the ampicillin. A colony is selected for growth in liquid media overnight. Once
prepared, the bug stock can be stored in 20-50% glycerol-LB broth at -80◦C. However, the
stock degrades with each freeze/thaw cycle, hence the need to prepare it fresh from time
to time.
First E. coli growing process
In order to isolate the transformed bacteria from any contamination (e.g. other bacteria
coming from the environment, pipette tips or the edges of the containers) before expressing
Appendix A 235
the VHH sequence, a toothpick of the bug stock is mixed with ampicilin, in a environment
suited for cell growing (rich medium consisting of LB broth and glucose). The cell growing
rate follows a well defined pattern illustrated in Figure 2. There are three main phases:
• a lag phase where cells start dividing slowly. The absolute number of cells increases
slowly..
• an exponential growth phase, where the number of cells is now high enough for the
cell number to increase quickly and significantly after each division process
• a stationary phase where the number of cells saturates, and cells stop dividing, partly
because of the lack of glucose, but also because of a phenomenon called quorum
sensing, where the cell population autoregulates its number to stay at equilibrium.
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Figure 2: E. coli typical growth rate E. coli typical growth curve featuring the lag,
exponential growth and stationary phases.
Cell growth follows this general pattern, making this plot a useful tool to control the
number of cells or to estimate the optimal time to start protein production. The growth
rate depends on different parameters, including the initial volume of bug stock and the
media.
During this first growth process, the growth rate and the number of cells does not need
to be thoroughly controlled, as the main objective is to grow a significant number of host
bacteria and to make sure that only these are grown, as schematised in Figure 3. The initial
volume added to the media is not measured exactly, and the cells are left growing for long
enough to reach the stationary phase. At this point, it is referred to as the starter culture.
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Ampicilin
Other bacteria/cells
E. coli TG1 containing 
VHH plasmid
Stationary phase
Figure 3: First E. coli TG1 growth process. The transformed cells are grown in a
selective rich medium until they reach stationary phase
Second E. coli growing process, VHH expression
Once the host bacteria has been isolated from other impurities, it can be grown with
more control. A defined volume of the starter culture (usually measured as a dilution, in
this case 1:100) is added to a second growth medium with ampicilin (in order to prevent
contamination). The new medium consists of a different broth (2xYT) and a smaller content
of glucose, making it an ideal media for protein production as well as cell growing. As the
important parameters are now under control, it is possible to estimate the start and finish
of the exponential growth phase. Triggering the protein production with a gene inducer
during the exponential growth phase is ideal, as the system is working at full speed and
the whole machinery for protein production is in place. There is also an ideal number
of bacteria without them having reached overpopulation. When cells are roughly in the
middle of this phase (OD600 0.6-0.8) a gene inducer (IPTG) is added to the culture. This
is schematised in Figure 4.
VHH extraction and purification
The next step is to extract the VHH from the bacteria and purify it. Extracting VHH from
the E. coli TG1 is simply done by lysing the bacteria walls using freeze/thaw cracking (see
schematics in Figure 5). The culture is centrifuged and the resulting pellet is left at -80◦C
for at least an hour. In order to get rid of the lysed bacteria debris, the pellet is then
resuspended in PBS and centrifuged again. As the lysed bacteria are much heavier than
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Ampicilin
Other bacteria/cells
E. coli TG1 containing 
VHH plasmid
Exponential growth 
phase
Gene inducer
Figure 4: Second E. coli TG1 growth process. The transformed cells are grown in
a selective rich medium until they reach the middle of the exponential growth phase, at
which point the gene inducer IPTG is added to the culture
single proteins, the supernatant contains the VHH and all the other bacterial proteins from
the lysed cells.
Lysing 
VHH 
Other proteins 
Figure 5: E. coli TG1 lysing process schematic. A freeze/thaw cracking breaks
open the bacterial membrane, releasing the bacterial proteins in the medium
Purifying the VHH from those proteins is done using an affinity resin, specific for His-
tagged proteins. This resin consists of cobalt-coated beads, to which the His6 tag binds. As
mentionned earlier, the VHH sequence contains an hexa His (HIS6)-tag, which means that
a series of six consecutive histidine amino acids are added at one end of the protein when it
is produced. This chain of six amino acids binds strongly to the cobalt, therefore allowing
for a selection of the VHH over the other proteins. Indeed, some of the other proteins may
have histidine amino acids in their sequence, but one or two histidine will bind much less
strongly to cobalt than the His-tagged VHH. Washing in a column helps getting rid of the
other weakly bound proteins.
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The VHH is then released from the resin in the column using an elution buffer containing
imidazole, which disturbs the His-Co bond. During this elution stage, a Bradford Colori-
metric Assay (BCA) is performed in order to assess whether a protein was released from
the resin. Fractions of eluate are collected after each addition of elution buffer, and a small
sample of each of those fractions is used in the BCA. The principle of the assay is based
on the absorbance shift of a dye (Coomassie Brilliant Blue G-250) which appears green or
purple under acidic conditions depending on the presence of the protein being assayed. The
dye is mixed with the different samples as well as a few controls.
The fractions of solution that exhibited the presence of protein in the BCA are dialysed
against PBS to get rid of the imidazole.
Finally, the concentration of the dialyzed proteins in solution is assessed using BCA.
Protocol
Culture media
1.6% (w/v) tryptone
2x Tryptone/yeast (YT) medium 1.0% (w/v) yeast extract
0.5% (w/v) NaCl
1.0% (w/v) tryptone
Lysogeny broth / Luria-Bertani (LB) medium 0.5% (w/v) yeast extract
0.5% (w/v) NaCl
VHH TALON purification
Materials required:
• Prepare buffers (see below)
• Plastic Bio-Rad columns
• TALON resins in solution: 50% TALON, 20% EtOH (+ 0.1% NaN3)
• Dialysis cassette: MWCO 3500Da
• PBS (10X PBS)
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Buffer composition (native buffers)
• 1x Equilibration buffer (pH 8.0): 50mM sodium phosphate, 300mM NaCl
• 1x Pre-elution buffer (pH 7.0): 50mM sodium phosphate, 300mM NaCl, 10mM im-
idazole
• 1x Elution buffer (pH 7.0): 50mM sodium phosphate, 300mM NaCl, 150mM imidazole
Buffer 1M NaH2PO4
(ml)
1M Na2HPO4
(ml)
3M NaCl (ml) Imidazole
(g)
Equilibration
(1l)
4.2 46.6 100 0
Pre-elution Dilute elution buffer 1 in 15 with equilibration buffer 0
Elution
(50ml)
Add imidazole to 50ml equilibration buffer 0.51
Components
• TALON resin Cat 635503 Takara Biotech (Clontech)
• Slide a Lyzer Cat 66330 Thermo Scientific
• Polyprep Columns Cat 731-1550 BioRad
Protocol (4 days)
Day 1
• 1. Prepare 2X YT medium, autoclave.
• 2. Inoculate 5ml (1/10th of expression volume) of LB medium containing 100 µg/ml
of ampicillin (or carbenicillin) and 2% (w/v) glucose with E. coli TG1 cells containing
the desired VHH/pCAD51 constructs (from a single colony).
• 3. Incubate overnight at 37◦C and 200-250rpm.
Day 2
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• 4. Use a 5-10ml aliquot to inoculate 500ml of 2X YT medium containing 100 µg/ml
of ampicillin and 0.1% (w/v) glucose. If expressing in a smaller volume of 2X YT
medium, inoculate with a smaller volume (corresponding to at least a 1:100 dilution
of the overnight culture).
• 5. Incubate at 37◦C and 250rpm until an OD600 of 0.6-0.8. under 3H
Collect pre-induced sample 500µl in eppendorf.
• 6. Induce VHH expression with 1 mM of IPTG (stock = 200mg/ml, = 839mM, =
596µl for 500ml)
• 7. Incubate overnight at 30◦C at 250rpm.
Day 3
PLACE EQUILBRATION BUFFER AT 56◦C, PRE-COOL CENTRIFUGE
• 8. Pellet bacteria in 2 x 250ml aliquots at 5000rpm in centrifuge for 10min
• 9. Freeze pelleted bacteria min 1h at -80◦C
• 10. Thaw pellets and resuspend in 2 x 25ml of STERILE 1x PBS with long pipette
and vortex.
• 11. Centrifuge at 5000rpm in centrifuge for 30min at 4◦C
• 12. Collect and pool supernatants (the VHH-containing E. coli lysate). Take pre-
purification sample (500µl into eppendorf)
• 13. Take 2ml 50% TALON suspension, bang to resuspend first. Use approximately
1ml of TALON resin (corresponding to 2ml of TALON suspension) for 3mg of anti-
cipated His-tagged protein per 50ml of supernatant.
– a. Centrifuge at 2000rpm for 2min at 4◦C. Remove and discard supernatant
– b. Resuspend TALON in 25-50ml equilibration buffer, pH 8.0
– c. Centrifuge at 2000rpm for 2min at 4◦C
– d. Repeat steps a-c (i.e. wash twice)
• 14. Add E. coli clarified lysate (supernatant only!) to the TALON resin.
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– a. Incubate for 20-60min on rotating wheel at room temperature.
– b. DO NOT LEAVE FOR >1h!
– c. Centrifuge at 2000rpm for 2min at 4◦C.
• 15. Remove and discard supernatant (= non-bound sample, collect 500µl in eppen-
dorf). Wash the TALON resin twice with 25-50ml of equilibration buffer, pH 8.0,
spin for 2min to repellet and wash again, then spin again.
• 16. Resuspend the TALON resin in equilibration buffer, pH 8.0, in a total volume of
approximately 10ml.
• 17. Pack the TALON resin into the column.
– a. Wash the column twice with equilibration buffer, pH 8.0, using a wash volume
equal to 1x the bed volume.
– b. Pre-elute with 1x the bed volume of pre-elution buffer. Keep the eluted
fraction for analysis COLLECT FRACTIONS
– c. Elute once with elution buffer, pH 7.0. Elution volume = 0.5x the bed volume.
– d. Elute further five times with elution buffer, pH 7.0. Elution volume = 0.5x
the bed volume - COLLECT FRACTIONS
• 18. Do quick BCA assay: 10µl of each fraction to flat 96 well plate, PBS ctl, 10µl
of standard 100ng and 250ng. Add 100µl of reagent A + B mixture (make up just
before 50:1) to each well, place at 37◦C for half an hour.
• 19. Dialyse the passed-through fractions which are positive for protein against 4l of
STERILE PBS overnight, change PBS first thing in morning, and again after 2h,
after another 2 hours collect fractions from dialysis cassettes
• 20. Run full BCA to assess protein concentration in including control samples (25µl
in triplicate plus 200µl of reagent A+B at 50:1 ratio)
• 21. Run SDS PAGE gel with pre-induction sample, pre-purification sample, unbound
sample, final purified sample and stain with Coomassie blue.
Steps 5.a, 12 and 15: include in full BCA to troubleshoot where protein may
have been lost.
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In[52]:= dir1 = SetDirectory[
"/Users/valerianturbe/Desktop/Work post backup/Analysis/Clinical
pilot study merge/Anti-p24/data/Calibration samples/"];
dir2 = SetDirectory["/Users/valerianturbe/Desktop/Work post
backup/Analysis/Clinical pilot study
merge/Anti-p24/data/Positive samples/"];
dir3 = SetDirectory["/Users/valerianturbe/Desktop/Work post
backup/Analysis/Clinical pilot study
merge/Anti-p24/data/Negative samples/"];
dir = {dir1, dir2, dir3};
In[56]:= cal = FileNames["*cal000_EDITED*.csv*", dir1];
c1 = Table[rawdat = Import[cal[[k]]];
c0 = Transpose[rawdat[[2 ;; -1]]]
, {k, 1, Length[cal]}];
c2 = Join[Table[c1[[i, 3]] - c1[[i, 2]], {i, 1, Length[c1]}],
Table[c1[[i, 5]] - c1[[i, 4]], {i, 1, Length[c1]}]];
limit = Table[Mean[Table[c2[[i, t]], {i, 1, Length[c2]}]] +
5 * StandardDeviation[Table[c2[[i, t]], {i, 1, Length[c2]}]], {t, 1, 229}];
In[60]:= values = Table[
files = FileNames["**_EDITED.csv", dir[[z]]];
d3 = Table[rawdat = Import[files[[k]]];
d1 = Transpose[rawdat[[2 ;; -1]]]
, {k, 1, Length[files]}];
d4 = Join[Table[d3[[i, 3]] - d3[[i, 2]], {i, 1, Length[d3]}],
Table[d3[[i, 5]] - d3[[i, 4]], {i, 1, Length[d3]}]];
d5 = Flatten[Table[{d4[[i]], d4[[i + Length[files]]]},{i, 1, Length[d4] - Length[files]}], 1]
, {z, 1, Length[dir]}];
In[61]:= start1 = {141, 142, 138};
start2 = {148, 149, 145};
samples = Table[
files = FileNames["**_EDITED.csv", dir[[z]]];
Flatten[Table[{StringTake[files[[i]], {start1[[z]], -19}],
StringTake[files[[i]], {start2[[z]], -12}]}, {i, 1, Length[files]}]]
, {z, 1, Length[dir]}];
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In[64]:= TP = Table[Count[values[[2, All, t]] - limit[[t]], _?Positive], {t, 1, 200}];
FN = Table[Length[values[[2]]] - TP[[t]], {t, 1, 200}];
TN = Table[Count[limit[[t]] - values[[3, All, t]], _?Positive], {t, 1, 200}];
FP = Table[Length[values[[3]]] - TN[[t]], {t, 1, 200}];
s1 = Table[100 * TP[[t]] / (TP[[t]] + FN[[t]]), {t, 1, 200}];
s2 = Table[100 * TN[[t]] / (TN[[t]] + FP[[t]]), {t, 1, 200}];
sensitivity = Table[{c1[[1, 1, i]] - c1[[1, 1, 19]], s1[[i]] // N}, {i, 19, 200}];
specificity = Table[{c1[[1, 1, i]] - c1[[1, 1, 19]], s2[[i]] // N}, {i, 19, 200}];
plot = ListLinePlot[{sensitivity, specificity},
PlotLegends → PointLegend[{"Sensitivity", "Specificity"}],
Frame → True, FrameLabel → {"Time (min)", "%"}, ImageSize → 500,
LabelStyle → Medium, PlotRange → {{0, 5.5}, {0, 105}}]
Out[72]=
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In[73]:= (*Export["/Users/valerianturbe/Desktop/Bim/Word/Chapter
4/Figures chapter 4/sensspechapt4.pdf",plot]*)
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In[74]:= Calibration = Manipulate
ShowBarChart
Table[values[[1, i, t]], {i, 1, Length[values[[1]]]}]
, ChartLabels → PlacedTable[samples[[1, i]],{i, 1, Length[samples[[1]]]}], Axis, Rotate#, Pi  2 &
, PlotRange → {-5, 50}
, AxesLabel → {" Sample ID", "Phase shift (degrees)"},
LabelStyle → Medium
, ColorFunction → Function[{height}, If[height > limit[[t]],
Green, Lighter[Black, 0.7]]], ColorFunctionScaling → False
, Graphics[{Red, Thick, Line[{{1, limit[[t]]},{Length[samples[[1]]], limit[[t]]}}]}]
, ImageSize → 500
, {t, 10, 229, 1}
Out[74]=
t
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In[75]:= PositiveS = Manipulate
ShowBarChart
Table[values[[2, i, t]], {i, 1, Length[values[[2]]]}]
, ChartLabels → PlacedTable[samples[[2, i]],{i, 1, Length[samples[[2]]]}], Axis, Rotate#, Pi  2 &
, PlotRange → {-5, 50}
, AxesLabel → {" Sample ID", "Phase shift (degrees)"},
LabelStyle → Medium
, ColorFunction → Function[{height}, If[height > limit[[t]],
Green, Lighter[Black, 0.7]]], ColorFunctionScaling → False
, Graphics[{Red, Thick, Line[{{1, limit[[t]]},{Length[samples[[2]]], limit[[t]]}}]}]
, ImageSize → 500
, {t, 10, 229, 1}
Out[75]=
t
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In[76]:= NegativeS = Manipulate
ShowBarChart
Table[values[[3, i, t]], {i, 1, Length[values[[3]]]}]
, ChartLabels → PlacedTable[samples[[3, i]],{i, 1, Length[samples[[3]]]}], Axis, Rotate#, Pi  2 &
, PlotRange → {-5, 50}
, AxesLabel → {" Sample ID", "Phase shift (degrees)"},
LabelStyle → Medium
, ColorFunction → Function[{height}, If[height > limit[[t]],
Green, Lighter[Black, 0.7]]], ColorFunctionScaling → False
, Graphics[{Red, Thick, Line[{{1, limit[[t]]},{Length[samples[[3]]], limit[[t]]}}]}]
, ImageSize → 500
, {t, 10, 229, 1}
Out[76]=
t
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